pmid,title,keywords,pubyear,jid
30518093,Modeling Parkinson's Disease and Atypical Parkinsonian Syndromes Using Induced Pluripotent Stem Cells.,CRISPR; FTDP-17; Parkinson’s disease; Perry syndrome; atypical parkinsonian syndromes; induced pluripotent stem cells; multiple system atrophy; proteinopathy,2018,1
30519012,A posturographic procedure assessing balance disorders in Parkinson's disease: a systematic review.,Parkinson’s disease; balance disorders; postural instability; posturography,2018,2
30519161,Divergent Effects of Metformin on an Inflammatory Model of Parkinson's Disease.,AMPK; Parkinson’s disease; animal model; metformin; microglia activation; neuroinflammation,2018,3
30519167,Disruption of Multiple Distinctive Neural Networks Associated With Impulse Control Disorder in Parkinson's Disease.,Go/No Go task; Parkinson's disease; delay discounting task; fMRI; functional connectivity; impulse control disorder,2018,4
30519184,Structural Brain Correlates of Attention Dysfunction in Lewy Body Dementias and Alzheimer's Disease.,Parkinson’s disease dementia; alerting; attention network test; dementia with Lewy bodies; executive conflict; orienting; reaction times; voxel-based morphometry,2018,5
30519212,White Matter Changes Along the Electrode Lead in Patients Treated With Deep Brain Stimulation.,Deep brain stimulation (DBS); MRI; Parkinson's disease (PD); electrode lead; white matter changes,2018,6
30522497,Generalizing remotely supervised transcranial direct current stimulation (tDCS): feasibility and benefit in Parkinson's disease.,Multiple sclerosis; Parkinson’s disease; Telerehabilitation; Transcranial direct current stimulation; tDCS,2018,7
30524223,Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson's Disease.,BDNF; MPTP parkinsonian model; Parkinson’s disease; behavior; orexin-A,2018,8
30524265,New Perspectives on Roles of Alpha-Synuclein in Parkinson's Disease.,Parkinson’s disease; alpha-synuclein; neurodegeneration; neurotherapy; prion-like,2018,5
30524270,"Quantifying Dynamic Balance in Young, Elderly and Parkinson's Individuals: A Systematic Review.",Parkinson's disease; dynamic balance; falls; perturbations; walking stability,2018,5
30524354,The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease.,Parkinson's disease; alpha-synuclein; cytokines; endotoxin; immune system,2018,6
30524579,A case of Type-C Wolff-Parkinson-White syndrome with severe left ventricular dysfunction: Efficacy of catheter ablation.,Left ventricular dyssynchrony; Radiofrequency catheter ablation; Severe left ventricular dysfunction; Wolff–Parkinson–White syndrome,2017,9
30524706,GM604 regulates developmental neurogenesis pathways and the expression of genes associated with amyotrophic lateral sclerosis.,Alzheimer’s disease; Amyotrophic lateral sclerosis; Extracellular matrix; Hedgehog; Huntington’s disease; Neurodegenerative disease; Notch; Parkinson’s disease; RNA-seq; Transcriptome,2018,10
30344007,Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy.,MSA;autophagy;dopaminergic neurons;induced pluripotent stem cells;mitochondria;multiple system atrophy;neurodegeneration,2018,11
30344006,T-type Calcium Channels Determine the Vulnerability of Dopaminergic Neurons to Mitochondrial Stress in Familial Parkinson Disease.,PARK2;Parkinson disease;T-type calcium channels;disease modeling;induced pluripotent stem cells,2018,11
30057263,Genetically Engineered iPSC-Derived FTDP-17 MAPT Neurons Display Mutation-Specific Neurodegenerative and Neurodevelopmental Phenotypes.,FTDP-17;MAPT;ZFN;disease modelling;iPSC,2018,11
29511098,Murine knockin model for progranulin-deficient frontotemporal dementia with nonsense-mediated mRNA decay.,"D000818:Animals;D004195:Disease Models, Animal;D005347:Fibroblasts;D057180:Frontotemporal Dementia;D055879:Gene Knock-In Techniques;D006801:Humans;D036341:Intercellular Signaling Peptides and Proteins;D008247:Lysosomes;D008810:Mice, Inbred C57BL;D009154:Mutation;D059365:Nonsense Mediated mRNA Decay;D016376:Oligonucleotides, Antisense;D000077153:Progranulins;D012333:RNA, Messenger",2018,12
29364288,The rise of three-dimensional human brain cultures.,"D005075:Biological Evolution;D001921:Brain;D002454:Cell Differentiation;D006801:Humans;D008954:Models, Biological;D009474:Neurons;D009924:Organ Culture Techniques;D038081:Organogenesis;D039904:Pluripotent Stem Cells;D011786:Quality Control",2018,13
29273399,Behavioral defects in a DCTN1,"D000818:Animals;D003863:Depression;D004195:Disease Models, Animal;D000072159:Dynactin Complex;D055106:Genome-Wide Association Study;D007040:Hypoventilation;D051379:Mice;D008822:Mice, Transgenic;D008869:Microtubule-Associated Proteins;D009154:Mutation;D020734:Parkinsonian Disorders",2018,14
29151169,Parkinson's disease: experimental models and reality.,,2017,15
29112121,The Potential of iPSCs for the Treatment of Premature Aging Disorders.,"D019588:Aging, Premature;D000818:Animals;D064113:CRISPR-Cas Systems;D016922:Cellular Senescence;D044127:Epigenesis, Genetic;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D034882:Lamins;D008928:Mitochondria;D011371:Progeria",2018,1
29089398,Establishing diagnostic criteria for Perry syndrome.,,2017,16
28892059,A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci.,D000978:Antiparkinson Agents;D001343:Autophagy;D016022:Case-Control Studies;D020022:Genetic Predisposition to Disease;D055106:Genome-Wide Association Study;D006801:Humans;D015810:Linkage Disequilibrium;D008247:Lysosomes;D058990:Molecular Targeted Therapy;D010300:Parkinson Disease;D012306:Risk;D014157:Transcription Factors,2017,17
28882997,Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.,"D000818:Animals;D000975:Antioxidants;D065095:Calcineurin Inhibitors;D002460:Cell Line;D004195:Disease Models, Animal;D004298:Dopamine;D059290:Dopaminergic Neurons;D005962:Glucosylceramidase;D006801:Humans;D008247:Lysosomes;D008543:Melanins;D008636:Mesencephalon;D051379:Mice;D018345:Mice, Knockout;D008928:Mitochondria;D010084:Oxidation-Reduction;D018384:Oxidative Stress;D010300:Parkinson Disease;D000071617:Protein Deglycase DJ-1;D013378:Substantia Nigra;D016559:Tacrolimus;D051844:alpha-Synuclein",2018,18
28858313,Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model.,"D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine;D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000818:Animals;D049109:Cell Proliferation;D002470:Cell Survival;D004195:Disease Models, Animal;D059290:Dopaminergic Neurons;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D008252:Macaca fascicularis;D008279:Magnetic Resonance Imaging;D008297:Male;D008636:Mesencephalon;D009068:Movement;D017072:Neostriatum;D016501:Neurites;D010300:Parkinson Disease;D049268:Positron-Emission Tomography;D044968:Regenerative Medicine;D012697:Serine Endopeptidases",2018,13
28789478,Perry Syndrome: A Distinctive Type of TDP-43 Proteinopathy.,"D000368:Aged;D000369:Aged, 80 and over;D000690:Amyotrophic Lateral Sclerosis;D001933:Brain Stem;D004268:DNA-Binding Proteins;D003863:Depression;D000072159:Dynactin Complex;D005192:Family Health;D005260:Female;D006801:Humans;D007040:Hypoventilation;D008297:Male;D016253:Microscopy, Immunoelectron;D008875:Middle Aged;D020734:Parkinsonian Disorders;D057177:TDP-43 Proteinopathies",2017,19
28780180,Neuropathology of Parkinson disease.,D001921:Brain;D006801:Humans;D000069338:Neuropathology;D010300:Parkinson Disease,2018,20
28725696,Creation of a library of induced pluripotent stem cells from Parkinsonian patients.,,2017,21
28625517,Reduced TDP-43 Expression Improves Neuronal Activities in a Drosophila Model of Perry Syndrome.,"D000200:Action Potentials;D000818:Animals;D001370:Axonal Transport;D004268:DNA-Binding Proteins;D003863:Depression;D004195:Disease Models, Animal;D004298:Dopamine;D004330:Drosophila;D029721:Drosophila Proteins;D005786:Gene Expression Regulation;D007040:Hypoventilation;D007150:Immunohistochemistry;D008297:Male;D009043:Motor Activity;D009046:Motor Neurons;D009154:Mutation;D009474:Neurons;D020734:Parkinsonian Disorders;D013572:Synaptic Vesicles",2018,22
28579476,Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges.,"D018929:Cell Culture Techniques;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D008954:Models, Biological;D019636:Neurodegenerative Diseases;D009474:Neurons",2018,23
28416701,Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson's disease.,"D019943:Amino Acid Substitution;D001369:Axons;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D008954:Models, Biological;D020125:Mutation, Missense;D010300:Parkinson Disease;D011115:Polyneuropathies;D009435:Synaptic Transmission;D051844:alpha-Synuclein",2018,12
28256506,Astrocyte pathology in a human neural stem cell model of frontotemporal dementia caused by mutant TAU protein.,"D017306:Annexin A2;D001253:Astrocytes;D002454:Cell Differentiation;D018920:Coculture Techniques;D057180:Frontotemporal Dementia;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D008954:Models, Biological;D058953:Neural Stem Cells;D009474:Neurons;D018384:Oxidative Stress;D020641:Polymorphism, Single Nucleotide;D020033:Protein Isoforms;D059467:Transcriptome;D054875:Ubiquitination;D016875:tau Proteins",2018,24
28235153,Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells.,D000328:Adult;D002454:Cell Differentiation;D005260:Female;D015870:Gene Expression;D063990:Gene Ontology;D016678:Genome;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D007413:Intestinal Mucosa;D007422:Intestines;D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2;D008297:Male;D008875:Middle Aged;D009154:Mutation;D009474:Neurons;D009940:Organoids;D010300:Parkinson Disease,2018,25
28157108,The Prevalence of Constipation and Irritable Bowel Syndrome in Parkinson's Disease Patients According to Rome III Diagnostic Criteria.,D000368:Aged;D003248:Constipation;D003430:Cross-Sectional Studies;D005260:Female;D006801:Humans;D043183:Irritable Bowel Syndrome;D008297:Male;D010300:Parkinson Disease;D015995:Prevalence;D011795:Surveys and Questionnaires,2018,26
28057485,Efficient induction of dopaminergic neuron differentiation from induced pluripotent stem cells reveals impaired mitophagy in PARK2 neurons.,"D017209:Apoptosis;D002454:Cell Differentiation;D002460:Cell Line;D059290:Dopaminergic Neurons;D006801:Humans;D018960:Hyaluronan Receptors;D057026:Induced Pluripotent Stem Cells;D063306:Mitochondrial Degradation;D008959:Models, Neurological;D058953:Neural Stem Cells;D010300:Parkinson Disease;D017382:Reactive Oxygen Species;D044767:Ubiquitin-Protein Ligases",2017,27
28009087,Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy.,"D000368:Aged;D000369:Aged, 80 and over;D000679:Amygdala;D015897:Comorbidity;D004268:DNA-Binding Proteins;D005260:Female;D006624:Hippocampus;D006801:Humans;D008297:Male;D013494:Supranuclear Palsy, Progressive;D057177:TDP-43 Proteinopathies",2017,28
27980341,Induced pluripotent stem cell technology: a decade of progress.,"D055808:Drug Discovery;D004358:Drug Therapy;D057166:High-Throughput Screening Assays;D049674:History, 21st Century;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D044968:Regenerative Medicine;D033581:Stem Cell Transplantation",2017,29
27739432,Purification of functional human ES and iPSC-derived midbrain dopaminergic progenitors using LRTM1.,"D000818:Animals;D002454:Cell Differentiation;D002469:Cell Separation;D002478:Cells, Cultured;D059290:Dopaminergic Neurons;D005260:Female;D000066449:Human Embryonic Stem Cells;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D008252:Macaca fascicularis;D008297:Male;D008636:Mesencephalon;D008810:Mice, Inbred C57BL;D010300:Parkinson Disease;D011506:Proteins;D017207:Rats, Sprague-Dawley;D012697:Serine Endopeptidases;D033581:Stem Cell Transplantation;D014183:Transplantation, Heterologous",2018,30
27721502,Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons.,"D002118:Calcium;D002470:Cell Survival;D002478:Cells, Cultured;D057174:Frontotemporal Lobar Degeneration;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D008954:Models, Biological;D009474:Neurons;D017510:Protein Folding;D016875:tau Proteins",2018,24
27499201,A Cas9 Variant for Efficient Generation of Indel-Free Knockin or Gene-Corrected Human Pluripotent Stem Cells.,"D001483:Base Sequence;D064113:CRISPR-Cas Systems;D002460:Cell Line;D065150:Cellular Reprogramming;D059766:DNA End-Joining Repair;D005347:Fibroblasts;D064248:Geminin;D015870:Gene Expression;D055879:Gene Knock-In Techniques;D017930:Genes, Reporter;D006801:Humans;D054643:INDEL Mutation;D039904:Pluripotent Stem Cells;D017422:Sequence Analysis, DNA;D052416:Targeted Gene Repair;D014162:Transfection",2017,11
27476966,Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons.,"D002454:Cell Differentiation;D002460:Cell Line;D059290:Dopaminergic Neurons;D006801:Humans;D008543:Melanins;D008636:Mesencephalon;D009940:Organoids;D039904:Pluripotent Stem Cells;D014158:Transcription, Genetic",2017,31
27346608,Cytoplasmic aggregates of dynactin in iPSC-derived tyrosine hydroxylase-positive neurons from a patient with Perry syndrome.,D003593:Cytoplasm;D003863:Depression;D000072159:Dynactin Complex;D006801:Humans;D007040:Hypoventilation;D057026:Induced Pluripotent Stem Cells;D008297:Male;D008869:Microtubule-Associated Proteins;D008875:Middle Aged;D009154:Mutation;D009474:Neurons;D020734:Parkinsonian Disorders;D014446:Tyrosine 3-Monooxygenase,2018,20
27120160,Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.,"D000293:Adolescent;D017668:Age of Onset;D000483:Alleles;D000544:Alzheimer Disease;D016564:Amyloid beta-Protein Precursor;D000818:Animals;D001483:Base Sequence;D064113:CRISPR-Cas Systems;D053903:DNA Breaks, Double-Stranded;D053837:DNA Cleavage;D004260:DNA Repair;D005260:Female;D005799:Genes, Dominant;D056726:Genetic Association Studies;D005818:Genetic Engineering;D006579:Heterozygote;D006720:Homozygote;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D008297:Male;D051379:Mice;D016296:Mutagenesis;D009154:Mutation;D053763:Presenilins;D017394:RNA, Guide;D017385:Sequence Homology;D013379:Substrate Specificity;D013698:Templates, Genetic",2016,13
26628643,Rationally engineered Cas9 nucleases with improved specificity.,"D001426:Bacterial Proteins;D053837:DNA Cleavage;D004720:Endonucleases;D006801:Humans;D016296:Mutagenesis;D017354:Point Mutation;D011487:Protein Conformation;D015202:Protein Engineering;D017394:RNA, Guide;D013297:Streptococcus pyogenes",2016,18
26618722,Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes.,"D000368:Aged;D000369:Aged, 80 and over;D000818:Animals;D015153:Blotting, Western;D045744:Cell Line, Tumor;D034281:Dynamins;D005260:Female;D036681:Fluorescence Recovery After Photobleaching;D005455:Fluorescent Antibody Technique;D020558:GTP Phosphohydrolases;D055785:Gene Knockdown Techniques;D006801:Humans;D066298:In Vitro Techniques;D008297:Male;D051379:Mice;D046529:Microscopy, Electron, Transmission;D016253:Microscopy, Immunoelectron;D008869:Microtubule-Associated Proteins;D008928:Mitochondria;D063154:Mitochondrial Dynamics;D024101:Mitochondrial Proteins;D009474:Neurons;D018384:Oxidative Stress;D010300:Parkinson Disease;D051381:Rats;D013378:Substantia Nigra;D059008:Time-Lapse Imaging;D033921:Vesicular Transport Proteins",2016,32
26499757,Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence.,"D000818:Animals;D002766:Cholecystokinin;D004525:Efferent Pathways;D017615:Enteric Nervous System;D005746:Gastric Emptying;D005769:Gastrointestinal Motility;D018589:Gastroparesis;D006801:Humans;D051379:Mice;D008822:Mice, Transgenic;D008959:Models, Neurological;D009469:Neuromuscular Junction;D016627:Oxidopamine;D010300:Parkinson Disease;D020734:Parkinsonian Disorders;D066329:Protein Aggregates;D051381:Rats;D012402:Rotenone;D057170:Translational Medical Research;D014630:Vagus Nerve;D051844:alpha-Synuclein",2016,20
26373282,Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells.,"D001665:Binding Sites;D002478:Cells, Cultured;D058732:Embryoid Bodies;D011992:Endosomes;D005091:Exons;D055354:Exosomes;D005260:Female;D005625:Frontal Lobe;D057180:Frontotemporal Dementia;D005786:Gene Expression Regulation;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D008247:Lysosomes;D008565:Membrane Proteins;D008875:Middle Aged;D020125:Mutation, Missense;D009419:Nerve Tissue Proteins;D009778:Occipital Lobe;D017354:Point Mutation;D021381:Protein Transport;D012333:RNA, Messenger;D013702:Temporal Lobe;D022161:Transport Vesicles;D016875:tau Proteins",2016,33
26240036,Cell-based therapies for Parkinson disease—past insights and future potential.,D000818:Animals;D064987:Cell- and Tissue-Based Therapy;D002986:Clinical Trials as Topic;D006801:Humans;D010300:Parkinson Disease,2016,34
26237226,"Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells.","D061249:Batch Cell Culture Techniques;D002454:Cell Differentiation;D002469:Cell Separation;D002478:Cells, Cultured;D004867:Equipment Design;D019544:Equipment Failure Analysis;D005347:Fibroblasts;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D046210:Microfluidic Analytical Techniques;D012371:Robotics",2015,35
26235891,Alpha-Synuclein Expression in the Oligodendrocyte Lineage: an In Vitro and In Vivo Study Using Rodent and Human Models.,"D000818:Animals;D002454:Cell Differentiation;D019070:Cell Lineage;D002478:Cells, Cultured;D053595:Embryonic Stem Cells;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D051379:Mice;D058953:Neural Stem Cells;D009836:Oligodendroglia;D013045:Species Specificity;D051844:alpha-Synuclein",2016,11
26220942,Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations.,"D000328:Adult;D000368:Aged;D016022:Case-Control Studies;D002460:Cell Line;D002478:Cells, Cultured;D005260:Female;D018507:Gene Expression Regulation, Developmental;D006801:Humans;D007150:Immunohistochemistry;D057026:Induced Pluripotent Stem Cells;D007231:Infant, Newborn;D008297:Male;D018613:Microscopy, Confocal;D008870:Microtubules;D008875:Middle Aged;D009474:Neurons;D018408:Patch-Clamp Techniques;D020033:Protein Isoforms;D012333:RNA, Messenger;D020133:Reverse Transcriptase Polymerase Chain Reaction;D024801:Tauopathies;D051844:alpha-Synuclein;D016875:tau Proteins",2016,36
26143746,Distinct Neurodegenerative Changes in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia Linked to Mutant TAU Protein.,D002454:Cell Differentiation;D057180:Frontotemporal Dementia;D020869:Gene Expression Profiling;D005786:Gene Expression Regulation;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D008928:Mitochondria;D009154:Mutation;D016501:Neurites;D018384:Oxidative Stress;D056811:Unfolded Protein Response;D016875:tau Proteins,2016,11
26056228,I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway.,D000818:Animals;D017209:Apoptosis;D001343:Autophagy;D053148:Caspase 3;D002460:Cell Line;D004298:Dopamine;D038362:Glycogen Synthase Kinase 3;D000071679:Glycogen Synthase Kinase 3 beta;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2;D051379:Mice;D009154:Mutation;D009474:Neurons;D018384:Oxidative Stress;D010766:Phosphorylation;D017346:Protein-Serine-Threonine Kinases;D051057:Proto-Oncogene Proteins c-akt;D015398:Signal Transduction;D016875:tau Proteins,2016,37
26046759,Programming and Reprogramming Cellular Age in the Era of Induced Pluripotency.,"D000818:Animals;D065150:Cellular Reprogramming;D016922:Cellular Senescence;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D008136:Longevity;D023421:Models, Animal;D008954:Models, Biological",2016,31
26005811,Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture.,"D001253:Astrocytes;D002478:Cells, Cultured;D002540:Cerebral Cortex;D006801:Humans;D039904:Pluripotent Stem Cells;D018874:Spheroids, Cellular;D013569:Synapses",2015,35
25904081,Parkinson's disease.,D001921:Brain;D018450:Disease Progression;D015259:Dopamine Agents;D020022:Genetic Predisposition to Disease;D006801:Humans;D010300:Parkinson Disease;D012307:Risk Factors,2016,38
25775569,Transcriptome analysis reveals transmembrane targets on transplantable midbrain dopamine progenitors.,"D020410:Activated-Leukocyte Cell Adhesion Molecule;D000818:Animals;D051792:Basic Helix-Loop-Helix Transcription Factors;D002352:Carrier Proteins;D015815:Cell Adhesion Molecules;D002478:Cells, Cultured;D059290:Dopaminergic Neurons;D005260:Female;D005434:Flow Cytometry;D020869:Gene Expression Profiling;D018507:Gene Expression Regulation, Developmental;D051097:Glial Cell Line-Derived Neurotrophic Factor Receptors;D049452:Green Fluorescent Proteins;D060850:LIM-Homeodomain Proteins;D008297:Male;D008565:Membrane Proteins;D008636:Mesencephalon;D008815:Mice, Inbred Strains;D008822:Mice, Transgenic;D018613:Microscopy, Confocal;D009419:Nerve Tissue Proteins;D058953:Neural Stem Cells;D010300:Parkinson Disease;D017207:Rats, Sprague-Dawley;D033581:Stem Cell Transplantation;D014157:Transcription Factors",2015,12
25621111,Methods of induced pluripotent stem cells for clinical application.,Cell reprogramming;Induced pluripotent stem cells,2015,39
25556567,Restoration of progranulin expression rescues cortical neuron generation in an induced pluripotent stem cell model of frontotemporal dementia.,"D015415:Biomarkers;D002454:Cell Differentiation;D002460:Cell Line;D057180:Frontotemporal Dementia;D015870:Gene Expression;D020869:Gene Expression Profiling;D057895:Haploinsufficiency;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D036341:Intercellular Signaling Peptides and Proteins;D009154:Mutation;D058953:Neural Stem Cells;D055495:Neurogenesis;D009474:Neurons;D010641:Phenotype;D000077153:Progranulins;D013997:Time Factors;D014158:Transcription, Genetic;D059467:Transcriptome;D060449:Wnt Signaling Pathway",2015,11
25383599,Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes.,D002454:Cell Differentiation;D020650:Combinatorial Chemistry Techniques;D006801:Humans;D009474:Neurons;D039904:Pluripotent Stem Cells,2015,40
25064009,Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.,"D016022:Case-Control Studies;D056426:Genetic Loci;D020022:Genetic Predisposition to Disease;D055106:Genome-Wide Association Study;D005838:Genotype;D006801:Humans;D010300:Parkinson Disease;D020641:Polymorphism, Single Nucleotide;D012307:Risk Factors",2015,17
24998994,Parkinsonian syndrome in familial frontotemporal dementia.,D000818:Animals;D057180:Frontotemporal Dementia;D020022:Genetic Predisposition to Disease;D006801:Humans;D008869:Microtubule-Associated Proteins;D009154:Mutation;D020734:Parkinsonian Disorders;D016875:tau Proteins,2015,20
24906146,Development and applications of CRISPR-Cas9 for genome engineering.,D000818:Animals;D001419:Bacteria;D064113:CRISPR-Cas Systems;D005057:Eukaryotic Cells;D018390:Gene Targeting;D005818:Genetic Engineering;D016678:Genome;D006801:Humans;D013297:Streptococcus pyogenes,2014,41
24672756,Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation.,"D000818:Animals;D001522:Behavior, Animal;D018929:Cell Culture Techniques;D002454:Cell Differentiation;D049109:Cell Proliferation;D002470:Cell Survival;D002478:Cells, Cultured;D059290:Dopaminergic Neurons;D005260:Female;D005434:Flow Cytometry;D020869:Gene Expression Profiling;D064593:Heterografts;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D008636:Mesencephalon;D058953:Neural Stem Cells;D051381:Rats;D012697:Serine Endopeptidases;D013997:Time Factors",2014,11
24507191,Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations.,"D000690:Amyotrophic Lateral Sclerosis;D000818:Animals;D030801:Animals, Genetically Modified;D001370:Axonal Transport;D002478:Cells, Cultured;D002540:Cerebral Cortex;D004268:DNA-Binding Proteins;D004330:Drosophila;D029721:Drosophila Proteins;D006801:Humans;D051741:Kruppel-Like Transcription Factors;D008164:Luminescent Proteins;D051379:Mice;D008928:Mitochondria;D009046:Motor Neurons;D009154:Mutation;D050814:Octamer Transcription Factor-3;D012333:RNA, Messenger;D016601:RNA-Binding Proteins;D055748:SOXB1 Transcription Factors",2014,42
24315443,Human iPSC-based modeling of late-onset disease via progerin-induced aging.,"D000328:Adult;D017668:Age of Onset;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D000818:Animals;D015415:Biomarkers;D002454:Cell Differentiation;D065150:Cellular Reprogramming;D016922:Cellular Senescence;D002648:Child;D059290:Dopaminergic Neurons;D005347:Fibroblasts;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D034904:Lamin Type A;D008636:Mesencephalon;D051379:Mice;D008875:Middle Aged;D008954:Models, Biological;D009687:Nuclear Proteins;D010300:Parkinson Disease;D010641:Phenotype;D011498:Protein Precursors;D014019:Tissue Donors",2014,31
24262191,α-Synucleinopathy phenotypes.,D006801:Humans;D020961:Lewy Body Disease;D019578:Multiple System Atrophy;D010300:Parkinson Disease;D010641:Phenotype;D051844:alpha-Synuclein,2014,20
24239350,"The presenilin-1 ΔE9 mutation results in reduced γ-secretase activity, but not total loss of PS1 function, in isogenic human stem cells.","D000544:Alzheimer Disease;D053829:Amyloid Precursor Protein Secretases;D016229:Amyloid beta-Peptides;D016564:Amyloid beta-Protein Precursor;D001483:Base Sequence;D002460:Cell Line;D002478:Cells, Cultured;D049452:Green Fluorescent Proteins;D006801:Humans;D009154:Mutation;D055495:Neurogenesis;D009474:Neurons;D010446:Peptide Fragments;D039904:Pluripotent Stem Cells;D053764:Presenilin-1;D011499:Protein Processing, Post-Translational;D017422:Sequence Analysis, DNA",2014,43
23472874,Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.,"D001549:Benzamides;D002454:Cell Differentiation;D002478:Cells, Cultured;D004159:Diphenylamine;D004298:Dopamine;D048049:Extracellular Signal-Regulated MAP Kinases;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2;D009154:Mutation;D009474:Neurons;D016627:Oxidopamine;D010300:Parkinson Disease;D017346:Protein-Serine-Threonine Kinases;D020133:Reverse Transcriptase Polymerase Chain Reaction;D012402:Rotenone",2013,31
23467164,Biotechnology: Rewriting a genome.,"D000818:Animals;D001419:Bacteria;D001709:Biotechnology;D004247:DNA;D053837:DNA Cleavage;D004720:Endonucleases;D005818:Genetic Engineering;D006801:Humans;D055029:Inverted Repeat Sequences;D012329:RNA, Bacterial;D017394:RNA, Guide",2013,13
23371366,Corticobasal degeneration with olivopontocerebellar atrophy and TDP-43 pathology: an unusual clinicopathologic variant of CBD.,"D000368:Aged;D002524:Cerebellar Ataxia;D004268:DNA-Binding Proteins;D005260:Female;D006801:Humans;D008297:Male;D009410:Nerve Degeneration;D009849:Olivopontocerebellar Atrophies;D013494:Supranuclear Palsy, Progressive",2013,15
23237903,Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease.,D000818:Animals;D016380:Brain Tissue Transplantation;D002986:Clinical Trials as Topic;D004298:Dopamine;D016332:Fetal Tissue Transplantation;D006801:Humans;D009474:Neurons;D010300:Parkinson Disease,2013,44
23063362,Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects.,"D002460:Cell Line;D015536:Down-Regulation;D057180:Frontotemporal Dementia;D057895:Haploinsufficiency;D006579:Heterozygote;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D036341:Intercellular Signaling Peptides and Proteins;D017628:Microglia;D020928:Mitogen-Activated Protein Kinases;D009154:Mutation;D009474:Neurons;D058539:Phosphatidylinositol 3-Kinase;D000077153:Progranulins;D047428:Protein Kinase Inhibitors;D038762:Ribosomal Protein S6 Kinases, 70-kDa;D019311:Staurosporine",2013,43
23039195,Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue.,"D000328:Adult;D000368:Aged;D000818:Animals;D001921:Brain;D002258:Carbonyl Cyanide m-Chlorophenyl Hydrazone;D005260:Female;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D016631:Lewy Bodies;D008297:Male;D053078:Membrane Potential, Mitochondrial;D051379:Mice;D008875:Middle Aged;D008928:Mitochondria;D063269:Mitochondrial Turnover;D051267:NF-E2-Related Factor 2;D009474:Neurons;D018384:Oxidative Stress;D010300:Parkinson Disease;D011180:Postmortem Changes;D015398:Signal Transduction;D051844:alpha-Synuclein",2013,45
22764206,Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.,D006801:Humans;D007211:Indoles;D057026:Induced Pluripotent Stem Cells;D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2;D008928:Mitochondria;D009474:Neurons;D010300:Parkinson Disease;D010636:Phenols;D017346:Protein-Serine-Threonine Kinases;D020123:Sirolimus;D014451:Ubiquinone,2012,46
22407749,Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease.,"D001343:Autophagy;D002478:Cells, Cultured;D004298:Dopamine;D006801:Humans;D009474:Neurons;D010300:Parkinson Disease;D039904:Pluripotent Stem Cells;D011954:Receptors, Dopamine;D014617:Vacuoles",2012,47
22328536,Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease.,"D000818:Animals;D018929:Cell Culture Techniques;D002471:Cell Transformation, Neoplastic;D002478:Cells, Cultured;D004195:Disease Models, Animal;D059290:Dopaminergic Neurons;D000882:Haplorhini;D006801:Humans;D020267:MPTP Poisoning;D008297:Male;D051379:Mice;D016513:Mice, SCID;D058953:Neural Stem Cells;D033581:Stem Cell Transplantation;D014183:Transplantation, Heterologous",2012,48
22314364,Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells.,"D000818:Animals;D001665:Binding Sites;D001921:Brain;D004298:Dopamine;D059290:Dopaminergic Neurons;D005347:Fibroblasts;D005786:Gene Expression Regulation;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D051379:Mice;D008928:Mitochondria;D008954:Models, Biological;D008995:Monoamine Oxidase;D009154:Mutation;D009474:Neurons;D018384:Oxidative Stress;D010100:Oxygen;D010300:Parkinson Disease;D010641:Phenotype;D012867:Skin;D013997:Time Factors;D044767:Ubiquitin-Protein Ligases",2012,30
21993621,Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells.,"D000818:Animals;D002460:Cell Line;D004251:DNA Transposable Elements;D022781:Hepatocytes;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D008099:Liver;D051379:Mice;D012709:Serum Albumin;D000075462:Serum Albumin, Human;D052416:Targeted Gene Repair;D013997:Time Factors;D000515:alpha 1-Antitrypsin;D019896:alpha 1-Antitrypsin Deficiency",2011,13
21863007,Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus.,"D002454:Cell Differentiation;D002478:Cells, Cultured;D018628:Gene Dosage;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D009474:Neurons;D010300:Parkinson Disease;D051844:alpha-Synuclein",2011,30
21700325,Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.,"D000818:Animals;D001921:Brain;D002478:Cells, Cultured;D004195:Disease Models, Animal;D025461:Feedback, Physiological;D005776:Gaucher Disease;D005962:Glucosylceramidase;D005963:Glucosylceramides;D006801:Humans;D008247:Lysosomes;D051379:Mice;D009474:Neurons;D051844:alpha-Synuclein",2011,41
21508222,Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells.,"D000818:Animals;D015153:Blotting, Western;D002452:Cell Count;D002478:Cells, Cultured;D005455:Fluorescent Antibody Technique;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D051379:Mice;D018613:Microscopy, Confocal;D008928:Mitochondria;D009474:Neurons;D011494:Protein Kinases;D044767:Ubiquitin-Protein Ligases",2011,49
21430656,The use of induced pluripotent stem cells in drug development.,"D000818:Animals;D002454:Cell Differentiation;D065150:Cellular Reprogramming;D055808:Drug Discovery;D004353:Drug Evaluation, Preclinical;D006801:Humans;D057026:Induced Pluripotent Stem Cells",2011,50
21362567,LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.,D000577:Amides;D019943:Amino Acid Substitution;D000818:Animals;D016923:Cell Death;D002454:Cell Differentiation;D004298:Dopamine;D005260:Female;D006801:Humans;D006861:Hydrogen Peroxide;D057026:Induced Pluripotent Stem Cells;D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2;D007976:Leupeptins;D008636:Mesencephalon;D051379:Mice;D008875:Middle Aged;D009154:Mutation;D009474:Neurons;D018384:Oxidative Stress;D016627:Oxidopamine;D010300:Parkinson Disease;D010641:Phenotype;D017346:Protein-Serine-Threonine Kinases;D011725:Pyridines;D054460:rho-Associated Kinases,2011,31
20942898,TDP-43 pathology occurs infrequently in multiple system atrophy.,D000368:Aged;D001921:Brain;D004268:DNA-Binding Proteins;D005260:Female;D006801:Humans;D007150:Immunohistochemistry;D002479:Inclusion Bodies;D008297:Male;D008875:Middle Aged;D019578:Multiple System Atrophy;D034702:RNA-Binding Protein FUS;D057177:TDP-43 Proteinopathies,2011,25
20581816,What can pluripotent stem cells teach us about neurodegenerative diseases?,"D000818:Animals;D016923:Cell Death;D002454:Cell Differentiation;D002478:Cells, Cultured;D053595:Embryonic Stem Cells;D006801:Humans;D057026:Induced Pluripotent Stem Cells;D009410:Nerve Degeneration;D019636:Neurodegenerative Diseases;D009474:Neurons;D014157:Transcription Factors",2010,51
20547124,Genetic animal models of Parkinson's disease.,"D000818:Animals;D016923:Cell Death;D004195:Disease Models, Animal;D006801:Humans;D051379:Mice;D008822:Mice, Transgenic;D019636:Neurodegenerative Diseases;D010300:Parkinson Disease",2010,42
20512649,Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy.,"D000368:Aged;D000369:Aged, 80 and over;D016022:Case-Control Studies;D004268:DNA-Binding Proteins;D003704:Dementia;D005260:Female;D006624:Hippocampus;D006801:Humans;D008032:Limbic System;D019636:Neurodegenerative Diseases;D010766:Phosphorylation;D012598:Sclerosis;D013494:Supranuclear Palsy, Progressive;D057177:TDP-43 Proteinopathies;D016875:tau Proteins",2010,15
19846850,Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.,D000368:Aged;D016022:Case-Control Studies;D005838:Genotype;D005962:Glucosylceramidase;D006801:Humans;D007585:Jews;D016015:Logistic Models;D008875:Middle Aged;D015999:Multivariate Analysis;D009154:Mutation;D016017:Odds Ratio;D010300:Parkinson Disease,2009,52
19297401,Parkinson's disease: from monogenic forms to genetic susceptibility factors.,D000818:Animals;D020022:Genetic Predisposition to Disease;D006801:Humans;D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2;D009419:Nerve Tissue Proteins;D010300:Parkinson Disease;D017346:Protein-Serine-Threonine Kinases;D051844:alpha-Synuclein,2009,37
19269371,Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors.,D002454:Cell Differentiation;D065150:Cellular Reprogramming;D004298:Dopamine;D005347:Fibroblasts;D006801:Humans;D009474:Neurons;D010300:Parkinson Disease;D039904:Pluripotent Stem Cells,2009,41
19136952,DCTN1 mutations in Perry syndrome.,D001921:Brain;D004268:DNA-Binding Proteins;D003863:Depression;D000072159:Dynactin Complex;D005190:Family;D005260:Female;D020022:Genetic Predisposition to Disease;D055106:Genome-Wide Association Study;D006801:Humans;D007040:Hypoventilation;D008297:Male;D008869:Microtubule-Associated Proteins;D009154:Mutation;D020734:Parkinsonian Disorders;D010375:Pedigree;D013577:Syndrome;D015431:Weight Loss,2009,17
19098894,Induced pluripotent stem cells from a spinal muscular atrophy patient.,"D002454:Cell Differentiation;D019070:Cell Lineage;D002469:Cell Separation;D002478:Cells, Cultured;D065150:Cellular Reprogramming;D002648:Child;D005260:Female;D005347:Fibroblasts;D005786:Gene Expression Regulation;D006801:Humans;D008297:Male;D008954:Models, Biological;D009046:Motor Neurons;D009134:Muscular Atrophy, Spinal;D039904:Pluripotent Stem Cells;D012867:Skin;D055533:Survival of Motor Neuron 1 Protein",2009,13
18691744,Disease-specific induced pluripotent stem cells.,"D001854:Bone Marrow Cells;D002460:Cell Line;D005347:Fibroblasts;D030342:Genetic Diseases, Inborn;D006801:Humans;D007621:Karyotyping;D059630:Mesenchymal Stem Cells;D009154:Mutation;D039904:Pluripotent Stem Cells",2008,41
18669821,Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons.,"D000369:Aged, 80 and over;D000690:Amyotrophic Lateral Sclerosis;D002454:Cell Differentiation;D002460:Cell Line;D065150:Cellular Reprogramming;D053595:Embryonic Stem Cells;D005260:Female;D005347:Fibroblasts;D015870:Gene Expression;D006801:Humans;D009046:Motor Neurons;D009457:Neuroglia;D039904:Pluripotent Stem Cells;D012190:Retroviridae;D013116:Spinal Cord;D013482:Superoxide Dismutase;D000072105:Superoxide Dismutase-1;D014157:Transcription Factors;D014161:Transduction, Genetic",2008,18
18520774,Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.,D000368:Aged;D000544:Alzheimer Disease;D001921:Brain;D004268:DNA-Binding Proteins;D005260:Female;D006801:Humans;D015151:Immunoblotting;D007150:Immunohistochemistry;D002479:Inclusion Bodies;D008297:Male;D009474:Neurons;D024801:Tauopathies,2008,19
18035408,Induction of pluripotent stem cells from adult human fibroblasts by defined factors.,"D000328:Adult;D000368:Aged;D000818:Animals;D015415:Biomarkers;D002454:Cell Differentiation;D002478:Cells, Cultured;D065150:Cellular Reprogramming;D004268:DNA-Binding Proteins;D004622:Embryo, Mammalian;D005260:Female;D005347:Fibroblasts;D016259:Genes, myc;D024002:HMGB Proteins;D006801:Humans;D051741:Kruppel-Like Transcription Factors;D008297:Male;D051379:Mice;D008813:Mice, Inbred ICR;D032383:Myocytes, Cardiac;D009474:Neurons;D050814:Octamer Transcription Factor-3;D039904:Pluripotent Stem Cells;D055748:SOXB1 Transcription Factors;D019098:Telomerase;D013724:Teratoma;D014157:Transcription Factors;D014161:Transduction, Genetic",2008,41
17898702,Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy.,D001921:Brain;D018450:Disease Progression;D005240:Feasibility Studies;D005260:Female;D019788:Fluorodeoxyglucose F18;D006801:Humans;D008297:Male;D045164:Mesenchymal Stem Cell Transplantation;D008875:Middle Aged;D019578:Multiple System Atrophy;D049268:Positron-Emission Tomography;D011446:Prospective Studies,2008,50
17653732,Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases.,D000368:Aged;D015897:Comorbidity;D004268:DNA-Binding Proteins;D005260:Female;D006624:Hippocampus;D006801:Humans;D007150:Immunohistochemistry;D002479:Inclusion Bodies;D020961:Lewy Body Disease;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D025801:Ubiquitin;D051844:alpha-Synuclein;D016875:tau Proteins,2007,15
17568013,Mixed brain pathologies account for most dementia cases in community-dwelling older persons.,"D000369:Aged, 80 and over;D001921:Brain;D015331:Cohort Studies;D003704:Dementia;D005260:Female;D016852:Housing for the Elderly;D006801:Humans;D008134:Long-Term Care;D008137:Longitudinal Studies;D008297:Male",2008,53
16904174,Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.,"D000328:Adult;D000818:Animals;D002454:Cell Differentiation;D017690:Cell Transplantation;D002478:Cells, Cultured;D004268:DNA-Binding Proteins;D004622:Embryo, Mammalian;D005347:Fibroblasts;D020869:Gene Expression Profiling;D018398:Homeodomain Proteins;D006801:Humans;D051741:Kruppel-Like Transcription Factors;D051379:Mice;D008819:Mice, Nude;D008822:Mice, Transgenic;D000071317:Nanog Homeobox Protein;D050814:Octamer Transcription Factor-3;D020411:Oligonucleotide Array Sequence Analysis;D039904:Pluripotent Stem Cells;D016271:Proto-Oncogene Proteins c-myc;D055748:SOXB1 Transcription Factors;D015534:Trans-Activators",2006,41
16899117,Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).,"D001921:Brain;D002886:Chromosomes, Human, Pair 17;D003704:Dementia;D008040:Genetic Linkage;D006801:Humans;D009154:Mutation;D020734:Parkinsonian Disorders;D016875:tau Proteins",2007,54
16556709,Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation.,"D000818:Animals;D002454:Cell Differentiation;D049109:Cell Proliferation;D002470:Cell Survival;D005260:Female;D006801:Humans;D066298:In Vitro Techniques;D009474:Neurons;D020734:Parkinsonian Disorders;D051381:Rats;D017207:Rats, Sprague-Dawley;D033581:Stem Cell Transplantation;D013724:Teratoma;D014183:Transplantation, Heterologous",2006,48
14735124,Using human neural stem cells to model neurological disease.,"D004622:Embryo, Mammalian;D005333:Fetus;D006801:Humans;D008954:Models, Biological;D009154:Mutation;D009419:Nerve Tissue Proteins;D009422:Nervous System Diseases;D019636:Neurodegenerative Diseases;D009474:Neurons;D013234:Stem Cells",2004,55
9770561,Parkinson's disease. Second of two parts.,"D000978:Antiparkinson Agents;D006801:Humans;D007980:Levodopa;D008954:Models, Biological;D010300:Parkinson Disease",1998,52
8096623,Neurobiology. Better cells for brain repair.,D001921:Brain;D016380:Brain Tissue Transplantation;D004295:Dihydroxyphenylalanine;D006801:Humans;D009474:Neurons;D009928:Organ Specificity;D010300:Parkinson Disease;D014446:Tyrosine 3-Monooxygenase,1993,13
29737198,Does Tai Chi improve balance and reduce falls incidence in neurological disorders? A systematic review and meta-analysis.,Nervous system diseases;Tai Chi;Tai Ji;accidental falls;meta-analysis,2018,56
28954481,Motor assessment in Parkinson`s disease.,D000818:Animals;D018450:Disease Progression;D006801:Humans;D009043:Motor Activity;D010300:Parkinson Disease;D004856:Postural Balance;D016138:Walking,2017,57
27348819,Assessing stability in mild and moderate Parkinson's disease: Can clinical measures provide insight?,D000368:Aged;D003430:Cross-Sectional Studies;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D004856:Postural Balance;D012678:Sensation Disorders;D012720:Severity of Illness Index;D011795:Surveys and Questionnaires;D016138:Walking,2018,58
26741255,Effects of disease severity and medication state on postural control asymmetry during challenging postural tasks in individuals with Parkinson's disease.,D000368:Aged;D000978:Antiparkinson Agents;D004185:Disability Evaluation;D005260:Female;D006801:Humans;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D012720:Severity of Illness Index;D016474:Weight-Bearing,2016,59
26582134,Changes in postural control in patients with Parkinson's disease: a posturographic study.,"D000058:Accidental Falls;D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D003430:Cross-Sectional Studies;D004185:Disability Evaluation;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D012720:Severity of Illness Index",2017,60
26517212,The competition with a concurrent cognitive task affects posturographic measures in patients with Parkinson disease.,D000368:Aged;D000704:Analysis of Variance;D016022:Case-Control Studies;D003071:Cognition;D005260:Female;D006801:Humans;D008297:Male;D008609:Mental Status Schedule;D008875:Middle Aged;D009460:Neurologic Examination;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D013647:Task Performance and Analysis;D014796:Visual Perception,2016,61
26504611,Balance Dysfunction in Parkinson's Disease: The Role of Posturography in Developing a Rehabilitation Program.,,2015,62
26316998,Obstacle Avoidance amongst Parkinson Disease Patients Is Challenged in a Threatening Context.,,2013,63
26149283,Standing balance in individuals with Parkinson's disease during single and dual-task conditions.,"D000368:Aged;D000369:Aged, 80 and over;D016022:Case-Control Studies;D003430:Cross-Sectional Studies;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D004856:Postural Balance;D013647:Task Performance and Analysis",2016,58
25457071,Postural control in Parkinson's disease.,D016022:Case-Control Studies;D005260:Female;D005583:Fourier Analysis;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D004856:Postural Balance;D012678:Sensation Disorders;D012720:Severity of Illness Index,2015,64
25143549,Interest of active posturography to detect age-related and early Parkinson's disease-related impairments in mediolateral postural control.,D061725:Accelerometry;D000375:Aging;D001415:Back;D005260:Female;D006257:Head;D006801:Humans;D008297:Male;D008875:Middle Aged;D009333:Neck;D010300:Parkinson Disease;D004856:Postural Balance;D014741:Video Recording;D055815:Young Adult,2015,65
25031483,The effects of whole body vibration on mobility and balance in Parkinson disease: a systematic review.,Balance;Parkinson disease;Vibration,2014,66
24691816,Age-related changes in cognitive function and postural control in Parkinson's disease.,"D000328:Adult;D000367:Age Factors;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D003071:Cognition;D003072:Cognition Disorders;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D004856:Postural Balance",2015,67
24671005,Disease severity affects obstacle crossing in people with Parkinson's disease.,D000368:Aged;D000704:Analysis of Variance;D001696:Biomechanical Phenomena;D001827:Body Height;D005260:Female;D005684:Gait;D006801:Humans;D018476:Hypokinesia;D008124:Locomotion;D008297:Male;D009460:Neurologic Examination;D010300:Parkinson Disease;D012720:Severity of Illness Index;D062211:Spatio-Temporal Analysis;D016138:Walking,2015,58
24466187,Influence of perturbation velocity on balance control in Parkinson's disease.,D000842:Ankle;D019540:Area Under Curve;D001696:Biomechanical Phenomena;D005260:Female;D006801:Humans;D007596:Joints;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D012399:Rotation,2014,68
23936729,Which Aspects of Postural Control Differentiate between Patients with Parkinson's Disease with and without Freezing of Gait?,,2013,62
23647655,Obstacle crossing in Parkinson's disease: mediolateral sway of the centre of mass during level-ground walking and obstacle crossing.,"D000368:Aged;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D004856:Postural Balance",2014,58
23609352,Clinical and posturographic correlates of falling in Parkinson's disease.,"D000058:Accidental Falls;D000368:Aged;D000704:Analysis of Variance;D016022:Case-Control Studies;D005260:Female;D020233:Gait Disorders, Neurologic;D006801:Humans;D008297:Male;D008875:Middle Aged;D009460:Neurologic Examination;D010300:Parkinson Disease;D010808:Physical Examination;D004856:Postural Balance;D012044:Regression Analysis;D012720:Severity of Illness Index",2014,28
22888319,Static posturography in aging and Parkinson's disease.,Parkinson's disease;Romberg-test;aging;balance testing;posturography,2012,5
22877844,The reliability of a rambling-trembling analysis of center of pressure measures.,"D000704:Analysis of Variance;D006801:Humans;D008297:Male;D015233:Models, Statistical;D004856:Postural Balance;D011312:Pressure;D015203:Reproducibility of Results;D055815:Young Adult",2013,58
22030976,Balance in Parkinson's disease patients changing the visual input.,D000368:Aged;D016022:Case-Control Studies;D006801:Humans;D010300:Parkinson Disease;D010775:Photic Stimulation;D004856:Postural Balance;D014796:Visual Perception,2012,64
21740307,Postural sway in patients with mild to moderate Parkinson's disease.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D004185:Disability Evaluation;D006801:Humans;D008875:Middle Aged;D009460:Neurologic Examination;D010300:Parkinson Disease;D004856:Postural Balance;D020886:Somatosensory Disorders;D055815:Young Adult",2012,69
21412830,Posturography reflects clinical imbalance in Parkinson's disease.,D000368:Aged;D000704:Analysis of Variance;D005080:Exercise Test;D005684:Gait;D006801:Humans;D008875:Middle Aged;D009460:Neurologic Examination;D010300:Parkinson Disease;D011187:Posture,2011,28
21153725,Perturbations of ground support alter posture and locomotion coupling during step initiation in Parkinson's disease.,"D000368:Aged;D000369:Aged, 80 and over;D000978:Antiparkinson Agents;D001696:Biomechanical Phenomena;D003627:Data Interpretation, Statistical;D005121:Extremities;D005260:Female;D006801:Humans;D008124:Locomotion;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011187:Posture;D016138:Walking",2011,70
21126990,Gait-related cerebral alterations in patients with Parkinson's disease with freezing of gait.,"D000368:Aged;D000704:Analysis of Variance;D001921:Brain;D001931:Brain Mapping;D005260:Female;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D007091:Image Processing, Computer-Assisted;D007092:Imagination;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011795:Surveys and Questionnaires",2011,36
20832347,Dynamic posturography in evaluation of balance in patients of Parkinson's disease with normal pull test: concept of a diagonal pull test.,"D000368:Aged;D000704:Analysis of Variance;D001696:Biomechanical Phenomena;D005069:Evaluation Studies as Topic;D005260:Female;D020233:Gait Disorders, Neurologic;D006801:Humans;D008297:Male;D008875:Middle Aged;D026201:Musculoskeletal Manipulations;D009460:Neurologic Examination;D010300:Parkinson Disease;D004856:Postural Balance;D012720:Severity of Illness Index;D013223:Statistics as Topic;D016896:Treatment Outcome",2011,20
20800915,Assessment of postural control in patients with Parkinson's disease: sway ratio analysis.,"D000058:Accidental Falls;D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D004185:Disability Evaluation;D018450:Disease Progression;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009127:Muscle Rigidity;D009949:Orientation;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D012016:Reference Values;D012683:Sensory Deprivation;D012815:Signal Processing, Computer-Assisted;D013223:Statistics as Topic;D014202:Tremor;D016474:Weight-Bearing",2011,59
20665348,Obstacle crossing among people with Parkinson disease is influenced by concurrent music.,D000368:Aged;D001288:Attention;D016022:Case-Control Studies;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008875:Middle Aged;D009048:Motor Skills;D009147:Music Therapy;D010300:Parkinson Disease;D011597:Psychomotor Performance;D013647:Task Performance and Analysis;D016138:Walking,2010,71
20388604,"iTUG, a sensitive and reliable measure of mobility.","D001696:Biomechanical Phenomena;D003627:Data Interpretation, Statistical;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008875:Middle Aged;D009068:Movement;D010300:Parkinson Disease;D004856:Postural Balance",2010,72
19945285,Arm swing magnitude and asymmetry during gait in the early stages of Parkinson's disease.,"D000368:Aged;D001132:Arm;D001696:Biomechanical Phenomena;D016022:Case-Control Studies;D018450:Disease Progression;D005260:Female;D020233:Gait Disorders, Neurologic;D006801:Humans;D021621:Imaging, Three-Dimensional;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease",2010,58
19854057,Effects of obstacle height on obstacle crossing in mild Parkinson's disease.,"D000368:Aged;D000704:Analysis of Variance;D000886:Anthropometry;D016022:Case-Control Studies;D005260:Female;D020233:Gait Disorders, Neurologic;D006801:Humans;D021621:Imaging, Three-Dimensional;D008124:Locomotion;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011597:Psychomotor Performance",2010,58
19026965,Postural disorders in Parkinson's disease.,D001696:Biomechanical Phenomena;D006801:Humans;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D012678:Sensation Disorders,2009,73
18789756,The clinical utility of posturography.,"D001696:Biomechanical Phenomena;D003937:Diagnosis, Differential;D006801:Humans;D009460:Neurologic Examination;D004856:Postural Balance;D011187:Posture;D011237:Predictive Value of Tests;D012306:Risk;D012678:Sensation Disorders",2009,74
18591014,Postural stability in Parkinson's disease: the effects of disease severity and acute levodopa dosing.,,1996,20
18380279,Postural sway and effect of levodopa in early Parkinson's disease.,D000368:Aged;D000978:Antiparkinson Agents;D004298:Dopamine;D005260:Female;D006801:Humans;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D004856:Postural Balance,2008,75
18155331,Effects of Parkinson's disease and levodopa on functional limits of stability.,D000368:Aged;D001696:Biomechanical Phenomena;D016022:Case-Control Studies;D006112:Gravitation;D006801:Humans;D007699:Kinesthesis;D007980:Levodopa;D008875:Middle Aged;D009048:Motor Skills;D009068:Movement;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D011312:Pressure,2008,76
18093549,Parkinson's disease and movement disorders: moving forward.,D018491:Dopamine Agonists;D006801:Humans;D008750:Methyldopa;D009069:Movement Disorders;D010300:Parkinson Disease;D013764:Tetrahydronaphthalenes;D013876:Thiophenes,2008,44
18044726,Discordance between measured postural instability and absence of clinical symptoms in Parkinson's disease patients in the early stages of the disease.,"D000368:Aged;D000369:Aged, 80 and over;D016022:Case-Control Studies;D005123:Eye;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009068:Movement;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D011312:Pressure;D011434:Proprioception;D014724:Vestibular Function Tests",2008,28
17644337,"The control of upright stance in young, elderly and persons with Parkinson's disease.","D000328:Adult;D000368:Aged;D000375:Aging;D000704:Analysis of Variance;D001696:Biomechanical Phenomena;D005260:Female;D005528:Foot;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D008297:Male;D008875:Middle Aged;D018482:Muscle, Skeletal;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D011312:Pressure;D012815:Signal Processing, Computer-Assisted",2008,58
17609881,Assessment of postural instability in patients with Parkinson's disease.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000704:Analysis of Variance;D016022:Case-Control Studies;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D012678:Sensation Disorders",2008,70
17595043,Postural sway and falls in Parkinson's disease: a regression approach.,"D000058:Accidental Falls;D000203:Activities of Daily Living;D000368:Aged;D000369:Aged, 80 and over;D000978:Antiparkinson Agents;D004359:Drug Therapy, Combination;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009460:Neurologic Examination;D010300:Parkinson Disease;D004856:Postural Balance;D012008:Recurrence;D012044:Regression Analysis;D012307:Risk Factors;D012815:Signal Processing, Computer-Assisted;D011795:Surveys and Questionnaires",2008,28
16944355,Scales in Parkinson's disease.,D004185:Disability Evaluation;D006304:Health Status;D006801:Humans;D010300:Parkinson Disease;D011788:Quality of Life;D012720:Severity of Illness Index,2009,77
16926210,Postural orientation and equilibrium: what do we need to know about neural control of balance to prevent falls?,D000058:Accidental Falls;D000368:Aged;D000375:Aging;D001696:Biomechanical Phenomena;D003071:Cognition;D006801:Humans;D009068:Movement;D004856:Postural Balance;D011187:Posture;D011597:Psychomotor Performance,2007,78
16901637,Step initiation in Parkinson's disease: influence of initial stance conditions.,"D000368:Aged;D000978:Antiparkinson Agents;D001479:Basal Ganglia;D005260:Female;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D007866:Leg;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D009434:Neural Pathways;D010300:Parkinson Disease;D004856:Postural Balance",2006,14
16817196,Balance in Parkinson's disease under static and dynamic conditions.,"D000058:Accidental Falls;D000368:Aged;D000978:Antiparkinson Agents;D004305:Dose-Response Relationship, Drug;D004359:Drug Therapy, Combination;D005260:Female;D019416:Head Movements;D006801:Humans;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D009460:Neurologic Examination;D010300:Parkinson Disease;D004856:Postural Balance",2007,28
16530203,The equations of motion for a standing human reveal three mechanisms for balance.,"D001696:Biomechanical Phenomena;D003198:Computer Simulation;D006801:Humans;D008954:Models, Biological;D009068:Movement;D004856:Postural Balance",2007,79
16487527,Evidence-based medicine: what it is and what it is not.,"D003625:Data Collection;D003627:Data Interpretation, Statistical;D019317:Evidence-Based Medicine;D006801:Humans;D016247:Information Storage and Retrieval;D015201:Meta-Analysis as Topic;D016032:Randomized Controlled Trials as Topic;D012196:Review Literature as Topic",2006,80
16269212,Identification of distinct characteristics of postural sway in Parkinson's disease: a feature selection procedure based on principal component analysis.,D000368:Aged;D005260:Female;D006801:Humans;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D009068:Movement;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D011312:Pressure;D025341:Principal Component Analysis;D011434:Proprioception;D011597:Psychomotor Performance,2006,14
16047175,Deterministic center of pressure patterns characterize postural instability in Parkinson's disease.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D016022:Case-Control Studies;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D017711:Nonlinear Dynamics;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D011312:Pressure;D011930:Reaction Time;D012677:Sensation;D013997:Time Factors",2006,70
15869953,Direction-specific postural instability in subjects with Parkinson's disease.,D000368:Aged;D000704:Analysis of Variance;D001696:Biomechanical Phenomena;D016022:Case-Control Studies;D020820:Dyskinesias;D006801:Humans;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D011312:Pressure;D011930:Reaction Time,2005,81
12784268,Effect of cognitive and motor tasks on postural stability in Parkinson's disease: a posturographic study.,D000058:Accidental Falls;D000368:Aged;D001288:Attention;D016022:Case-Control Studies;D003071:Cognition;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009043:Motor Activity;D009069:Movement Disorders;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D013647:Task Performance and Analysis,2003,28
12722162,Fear of falling and postural control in Parkinson's disease.,D000058:Accidental Falls;D000368:Aged;D005239:Fear;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D010300:Parkinson Disease;D010698:Phobic Disorders;D004856:Postural Balance;D011187:Posture;D011601:Psychophysics;D011795:Surveys and Questionnaires,2003,28
11500575,Rambling and trembling in quiet standing.,"D000328:Adult;D055592:Biophysical Phenomena;D001703:Biophysics;D005260:Female;D006801:Humans;D008297:Male;D008838:Microcomputers;D004856:Postural Balance;D011187:Posture;D012815:Signal Processing, Computer-Assisted;D016474:Weight-Bearing",2001,82
11427288,The biomechanics and motor control of gait in Parkinson disease.,D001696:Biomechanical Phenomena;D001921:Brain;D003463:Cues;D005684:Gait;D006801:Humans;D010300:Parkinson Disease,2001,76
9776467,Clinimetrics of postural instability in Parkinson's disease.,D000328:Adult;D000368:Aged;D005069:Evaluation Studies as Topic;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D004856:Postural Balance;D011187:Posture;D015203:Reproducibility of Results,1998,77
8793751,"Effects of dopamine on postural control in parkinsonian subjects: scaling, set, and tone.","D000978:Antiparkinson Agents;D004298:Dopamine;D004576:Electromyography;D005260:Female;D006801:Humans;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D009129:Muscle Tonus;D018482:Muscle, Skeletal;D010300:Parkinson Disease;D011187:Posture;D011597:Psychomotor Performance",1996,65
8139608,Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group.,"D000203:Activities of Daily Living;D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D005163:Factor Analysis, Statistical;D005260:Female;D006801:Humans;D008297:Male;D008609:Mental Status Schedule;D008875:Middle Aged;D009460:Neurologic Examination;D015588:Observer Variation;D010300:Parkinson Disease;D010555:Personality Inventory;D015203:Reproducibility of Results",1994,28
6067254,"Parkinsonism: onset, progression and mortality.",D000293:Adolescent;D000328:Adult;D000368:Aged;D000375:Aging;D001996:Bronchopneumonia;D005260:Female;D005500:Follow-Up Studies;D006801:Humans;D008297:Male;D008875:Middle Aged;D009026:Mortality;D009135:Muscular Diseases;D009369:Neoplasms;D010300:Parkinson Disease;D012723:Sex;D014202:Tremor;D014552:Urinary Tract Infections,1967,53
2138696,Assessment of balance control in humans.,D001696:Biomechanical Phenomena;D005684:Gait;D006801:Humans;D007596:Joints;D007866:Leg;D008124:Locomotion;D009068:Movement;D004856:Postural Balance;D011187:Posture,1990,83
1736324,"Movement, posture and equilibrium: interaction and coordination.","D000222:Adaptation, Physiological;D001132:Arm;D001696:Biomechanical Phenomena;D001921:Brain;D006706:Homeostasis;D006801:Humans;D007858:Learning;D007866:Leg;D008954:Models, Biological;D009068:Movement;D004856:Postural Balance;D011187:Posture",1992,84
30258234,Microglia in neurodegeneration.,,2018,51
30206330,Inflammasome signalling in brain function and neurodegenerative disease.,,2018,85
30107806,Corylin inhibits LPS-induced inflammatory response and attenuates the activation of NLRP3 inflammasome in microglia.,"D000818:Animals;D002470:Cell Survival;D005419:Flavonoids;D058847:Inflammasomes;D007249:Inflammation;D008070:Lipopolysaccharides;D051379:Mice;D017628:Microglia;D020928:Mitogen-Activated Protein Kinases;D000071199:NLR Family, Pyrin Domain-Containing 3 Protein;D010766:Phosphorylation;D015398:Signal Transduction",2018,86
29942040,Author Correction: Microglial immune checkpoint mechanisms.,,2018,51
29778803,Age affects reinforcement learning through dopamine-based learning imbalance and high decision noise-not through Parkinsonian mechanisms.,"D000293:Adolescent;D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D001519:Behavior;D000066492:Cognitive Aging;D003657:Decision Making;D004298:Dopamine;D051937:Dopamine and cAMP-Regulated Phosphoprotein 32;D025461:Feedback, Physiological;D005260:Female;D006801:Humans;D007858:Learning;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011110:Polymorphism, Genetic;D012054:Reinforcement (Psychology);D055815:Young Adult",2018,87
29761156,Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease.,,2018,21
29743866,Dexmedetomidine inhibits inflammation in microglia cells under stimulation of LPS and ATP by c-Fos/NLRP3/caspase-1 cascades.,NLRP3;dexmedetomidine;inflammatory;microglia,2018,88
29719505,Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease.,Parkinson disease;gene mutation;mechanism;neurodegeneration;neuronal death,2018,5
29718367,Increased Oxidative Stress Exacerbates α-Synuclein Aggregation In Vivo.,,2018,19
29699914,Risk factors for non-motor symptoms in Parkinson's disease.,,2018,44
29649621,Astrocyte-specific DJ-1 overexpression protects against rotenone-induced neurotoxicity in a rat model of Parkinson's disease.,Astrocyte;Chaperone-mediated autophagy;DJ-1;Gene therapy;Neuroinflammation;Oxidative stress;Parkinson's disease;Rotenone,2018,89
29611482,Potential Use of Nanomedicine for the Anti-inflammatory Treatment of Neurodegenerative Diseases.,Alzheimer´s disease;PLGA;Parkinson´s disease;anti-inflammatory drugs;nanoparticles;neuroinflammation;nose-to-brain.,2018,90
29174171,Helicobacter pylori infection is associated with an increased risk of Parkinson's disease: A population-based retrospective cohort study.,Cohort study;Helicobacter pylori;Parkinson's disease,2017,20
29132391,NADPH oxidases in Parkinson's disease: a systematic review.,D000818:Animals;D006801:Humans;D019255:NADPH Oxidases;D010300:Parkinson Disease,2018,33
29111328,3-(Naphthalen-2-yl(propoxy)methyl)azetidine hydrochloride attenuates NLRP3 inflammasome-mediated signaling pathway in lipopolysaccharide-stimulated BV2 microglial cells.,"D000818:Animals;D000893:Anti-Inflammatory Agents;D001384:Azetidines;D002460:Cell Line;D058847:Inflammasomes;D053583:Interleukin-1beta;D015850:Interleukin-6;D008070:Lipopolysaccharides;D051379:Mice;D017628:Microglia;D000071199:NLR Family, Pyrin Domain-Containing 3 Protein;D009281:Naphthalenes;D017382:Reactive Oxygen Species;D015398:Signal Transduction;D014409:Tumor Necrosis Factor-alpha",2018,27
28930663,The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.,"D000544:Alzheimer Disease;D016229:Amyloid beta-Peptides;D016564:Amyloid beta-Protein Precursor;D000818:Animals;D001057:Apolipoproteins E;D017209:Apoptosis;D002540:Cerebral Cortex;D016000:Cluster Analysis;D004195:Disease Models, Animal;D004681:Encephalomyelitis, Autoimmune, Experimental;D005260:Female;D020869:Gene Expression Profiling;D005786:Gene Expression Regulation;D018390:Gene Targeting;D006801:Humans;D007108:Immune Tolerance;D008562:Membrane Glycoproteins;D051379:Mice;D018345:Mice, Knockout;D008822:Mice, Transgenic;D017628:Microglia;D009000:Monocytes;D019636:Neurodegenerative Diseases;D009474:Neurons;D010587:Phagocytosis;D010641:Phenotype;D058225:Plaque, Amyloid;D011971:Receptors, Immunologic;D015398:Signal Transduction;D000072105:Superoxide Dismutase-1;D059467:Transcriptome;D016212:Transforming Growth Factor beta",2017,91
28807678,Metformin lowers α-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease.,"D000818:Animals;D000978:Antiparkinson Agents;D001253:Astrocytes;D019208:Brain-Derived Neurotrophic Factor;D045744:Cell Line, Tumor;D002470:Cell Survival;D004298:Dopamine;D059290:Dopaminergic Neurons;D006801:Humans;D020267:MPTP Poisoning;D008297:Male;D008562:Membrane Glycoproteins;D008687:Metformin;D008810:Mice, Inbred C57BL;D018696:Neuroprotective Agents;D010766:Phosphorylation;D000075082:Proof of Concept Study;D054648:Protein Phosphatase 2;D020813:Receptor, trkB;D013378:Substantia Nigra;D014446:Tyrosine 3-Monooxygenase;D051844:alpha-Synuclein",2018,92
28602351,A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.,"D000544:Alzheimer Disease;D000818:Animals;D006801:Humans;D051379:Mice;D008822:Mice, Transgenic;D017628:Microglia;D019636:Neurodegenerative Diseases;D010586:Phagocytes;D011971:Receptors, Immunologic;D017423:Sequence Analysis, RNA;D059010:Single-Cell Analysis",2017,41
28583443,Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.,"D000368:Aged;D015897:Comorbidity;D003924:Diabetes Mellitus, Type 2;D004305:Dose-Response Relationship, Drug;D005260:Female;D005500:Follow-Up Studies;D006801:Humans;D007004:Hypoglycemic Agents;D015994:Incidence;D008137:Longitudinal Studies;D008297:Male;D008687:Metformin;D008875:Middle Aged;D015999:Multivariate Analysis;D019636:Neurodegenerative Diseases;D016016:Proportional Hazards Models;D012189:Retrospective Studies;D012307:Risk Factors;D013624:Taiwan;D013997:Time Factors",2018,93
28203479,Metformin Impairs Spatial Memory and Visual Acuity in Old Male Mice.,aging;antidiabetic;antioxidant enzymes;cognition;metformin;redox stress;visual function,2017,94
28018360,ATP-Induced Inflammasome Activation and Pyroptosis Is Regulated by AMP-Activated Protein Kinase in Macrophages.,AMP-activated protein kinase;bacterial sepsis;inflammasome;metformin;pyroptosis,2016,95
27669650,Mechanism and Regulation of NLRP3 Inflammasome Activation.,"D000818:Animals;D020170:Caspase 1;D005786:Gene Expression Regulation;D006801:Humans;D058847:Inflammasomes;D020382:Interleukin-18;D053583:Interleukin-1beta;D017136:Ion Transport;D008070:Lipopolysaccharides;D008264:Macrophages;D051379:Mice;D009000:Monocytes;D000072379:NIMA-Related Kinases;D000071199:NLR Family, Pyrin Domain-Containing 3 Protein;D011188:Potassium;D000069292:Pyroptosis;D015398:Signal Transduction",2017,96
27467571,Metformin Prevents Nigrostriatal Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons.,"D055372:AMP-Activated Protein Kinases;D000818:Animals;D003342:Corpus Striatum;D004298:Dopamine;D004789:Enzyme Activation;D007004:Hypoglycemic Agents;D008687:Metformin;D051379:Mice;D018345:Mice, Knockout;D009474:Neurons;D013378:Substantia Nigra",2017,68
27276511,Metformin and resveratrol inhibit Drp1-mediated mitochondrial fission and prevent ER stress-associated NLRP3 inflammasome activation in the adipose tissue of diabetic mice.,"D041721:3T3-L1 Cells;D000273:Adipose Tissue;D000818:Animals;D017209:Apoptosis;D002454:Cell Differentiation;D003921:Diabetes Mellitus, Experimental;D034281:Dynamins;D059865:Endoplasmic Reticulum Stress;D005786:Gene Expression Regulation;D058847:Inflammasomes;D008687:Metformin;D051379:Mice;D008928:Mitochondria;D063154:Mitochondrial Dynamics;D000071199:NLR Family, Pyrin Domain-Containing 3 Protein;D010766:Phosphorylation;D017382:Reactive Oxygen Species;D000077185:Resveratrol;D013267:Stilbenes",2017,97
27207919,Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance.,AMPK;Parkinson’s disease;autophagy;metformin;mitochondrial ROS,2016,98
26971375,"Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system.","D000818:Animals;D000893:Anti-Inflammatory Agents;D017209:Apoptosis;D018929:Cell Culture Techniques;D002460:Cell Line;D003342:Corpus Striatum;D004298:Dopamine;D059290:Dopaminergic Neurons;D007150:Immunohistochemistry;D008297:Male;D008687:Metformin;D008810:Mice, Inbred C57BL;D017628:Microglia;D018384:Oxidative Stress;D020734:Parkinsonian Disorders;D017382:Reactive Oxygen Species;D060888:Real-Time Polymerase Chain Reaction;D013378:Substantia Nigra",2016,99
26821015,Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice.,"D000818:Animals;D004195:Disease Models, Animal;D006801:Humans;D020267:MPTP Poisoning;D051379:Mice;D008822:Mice, Transgenic;D017628:Microglia;D009414:Nerve Growth Factors;D010300:Parkinson Disease;D017475:Receptors, Nerve Growth Factor",2016,1
26211973,Antidiabetic drugs restore abnormal transport of amyloid-β across the blood-brain barrier and memory impairment in db/db mice.,"D016229:Amyloid beta-Peptides;D000818:Animals;D017209:Apoptosis;D001812:Blood-Brain Barrier;D003924:Diabetes Mellitus, Type 2;D004195:Disease Models, Animal;D005106:Exploratory Behavior;D005215:Fasting;D006624:Hippocampus;D007004:Hypoglycemic Agents;D007328:Insulin;D007456:Iodine Isotopes;D017774:Long-Term Potentiation;D008297:Male;D018782:Maze Learning;D008569:Memory Disorders;D051379:Mice;D008817:Mice, Mutant Strains;D000067759:Receptor for Advanced Glycation End Products;D054411:Receptors, Leptin",2016,92
26152715,Metformin Inhibits the Production of Reactive Oxygen Species from NADH:Ubiquinone Oxidoreductase to Limit Induction of Interleukin-1β (IL-1β) and Boosts Interleukin-10 (IL-10) in Lipopolysaccharide (LPS)-activated Macrophages.,"D000263:Adenylate Kinase;D000818:Animals;D042967:Electron Transport Complex I;D016753:Interleukin-10;D053583:Interleukin-1beta;D008070:Lipopolysaccharides;D008262:Macrophage Activation;D008264:Macrophages;D008687:Metformin;D051379:Mice;D008810:Mice, Inbred C57BL;D017382:Reactive Oxygen Species;D012402:Rotenone",2015,100
26132721,AMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome.,"D055372:AMP-Activated Protein Kinases;D000328:Adult;D000818:Animals;D002352:Carrier Proteins;D005260:Female;D005356:Fibromyalgia;D006801:Humans;D007211:Indoles;D058847:Inflammasomes;D020382:Interleukin-18;D053583:Interleukin-1beta;D008297:Male;D008687:Metformin;D051379:Mice;D008875:Middle Aged;D000071199:NLR Family, Pyrin Domain-Containing 3 Protein;D010146:Pain;D058748:Pain Perception;D010766:Phosphorylation;D011758:Pyrroles;D000077210:Sunitinib",2016,101
26059357,Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases.,D000544:Alzheimer Disease;D000818:Animals;D002908:Chronic Disease;D019587:Dietary Supplements;D004660:Encephalitis;D005767:Gastrointestinal Diseases;D006801:Humans;D007249:Inflammation;D015212:Inflammatory Bowel Diseases;D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2;D017628:Microglia;D019636:Neurodegenerative Diseases;D010300:Parkinson Disease;D017346:Protein-Serine-Threonine Kinases,2016,102
25639775,Impaired intracellular trafficking defines early Parkinson's disease.,D000818:Animals;D001692:Biological Transport;D006801:Humans;D009474:Neurons;D010300:Parkinson Disease,2015,103
25315906,Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion.,"D055372:AMP-Activated Protein Kinases;D000818:Animals;D001812:Blood-Brain Barrier;D020520:Brain Infarction;D002478:Cells, Cultured;D016207:Cytokines;D004195:Disease Models, Animal;D005786:Gene Expression Regulation;D005947:Glucose;D007004:Hypoglycemic Agents;D000860:Hypoxia;D020244:Infarction, Middle Cerebral Artery;D018799:Intercellular Adhesion Molecule-1;D008297:Male;D008687:Metformin;D051379:Mice;D020556:Neutrophil Infiltration;D019408:Platelet Endothelial Cell Adhesion Molecule-1;D015398:Signal Transduction;D013997:Time Factors;D062826:Zonula Occludens-1 Protein",2015,104
25172433,Chronic Metformin Preconditioning Provides Neuroprotection via Suppression of NF-κB-Mediated Inflammatory Pathway in Rats with Permanent Cerebral Ischemia.,"D000208:Acute Disease;D000818:Animals;D001253:Astrocytes;D001921:Brain;D002545:Brain Ischemia;D002135:Calcium-Binding Proteins;D016207:Cytokines;D005904:Glial Fibrillary Acidic Protein;D020244:Infarction, Middle Cerebral Artery;D007249:Inflammation;D018836:Inflammation Mediators;D008297:Male;D008687:Metformin;D008840:Microfilament Proteins;D017628:Microglia;D016328:NF-kappa B;D000066829:Neuroprotection;D012333:RNA, Messenger;D017207:Rats, Sprague-Dawley;D020521:Stroke",2016,105
25108167,Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice.,"D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine;D000818:Animals;D000975:Antioxidants;D019208:Brain-Derived Neurotrophic Factor;D002374:Catalase;D005978:Glutathione;D015227:Lipid Peroxidation;D020267:MPTP Poisoning;D008297:Male;D008687:Metformin;D051379:Mice;D009043:Motor Activity;D018696:Neuroprotective Agents;D018384:Oxidative Stress;D011897:Random Allocation;D045442:Rotarod Performance Test;D013378:Substantia Nigra;D013482:Superoxide Dismutase;D014446:Tyrosine 3-Monooxygenase",2015,106
24791887,Metformin inhibits nuclear factor-κB activation and inflammatory cytokines expression induced by high glucose via adenosine monophosphate-activated protein kinase activation in rat glomerular mesangial cells in vitro.,"D055372:AMP-Activated Protein Kinases;D000818:Animals;D002478:Cells, Cultured;D005920:Glomerular Mesangium;D005947:Glucose;D050527:Mesangial Cells;D008687:Metformin;D016328:NF-kappa B;D051381:Rats",2015,107
24424382,NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke.,"D000818:Animals;D001253:Astrocytes;D001812:Blood-Brain Barrier;D002352:Carrier Proteins;D002478:Cells, Cultured;D018920:Coculture Techniques;D004195:Disease Models, Animal;D042783:Endothelial Cells;D005947:Glucose;D002546:Ischemic Attack, Transient;D008279:Magnetic Resonance Imaging;D008562:Membrane Glycoproteins;D051379:Mice;D008810:Mice, Inbred C57BL;D018345:Mice, Knockout;D017628:Microglia;D000074662:NADPH Oxidase 2;D019255:NADPH Oxidases;D000071199:NLR Family, Pyrin Domain-Containing 3 Protein;D009474:Neurons;D018384:Oxidative Stress;D010100:Oxygen;D015398:Signal Transduction;D020521:Stroke",2014,108
23800361,TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease.,"D000368:Aged;D005260:Female;D057180:Frontotemporal Dementia;D005787:Gene Frequency;D020022:Genetic Predisposition to Disease;D005838:Genotype;D006801:Humans;D008297:Male;D008562:Membrane Glycoproteins;D008875:Middle Aged;D019636:Neurodegenerative Diseases;D010300:Parkinson Disease;D020641:Polymorphism, Single Nucleotide;D060888:Real-Time Polymerase Chain Reaction;D011971:Receptors, Immunologic",2013,33
23515615,The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease.,Parkinson's disease;axons;dopamine;energy metabolism;neurodegeneration;nigrostriatal pathway;unmyelinated,2013,109
23086037,Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes.,"D055372:AMP-Activated Protein Kinases;D000328:Adult;D000368:Aged;D053468:CARD Signaling Adaptor Proteins;D002352:Carrier Proteins;D003598:Cytoskeletal Proteins;D003924:Diabetes Mellitus, Type 2;D005260:Female;D006801:Humans;D058847:Inflammasomes;D020382:Interleukin-18;D053583:Interleukin-1beta;D008297:Male;D008687:Metformin;D008875:Middle Aged;D000071199:NLR Family, Pyrin Domain-Containing 3 Protein;D012333:RNA, Messenger;D017382:Reactive Oxygen Species",2013,110
22503440,NADPH oxidases: novel therapeutic targets for neurodegenerative diseases.,D000544:Alzheimer Disease;D000818:Animals;D000975:Antioxidants;D001253:Astrocytes;D055808:Drug Discovery;D004791:Enzyme Inhibitors;D006801:Humans;D008562:Membrane Glycoproteins;D051379:Mice;D000074662:NADPH Oxidase 2;D019255:NADPH Oxidases;D009474:Neurons;D018696:Neuroprotective Agents;D018384:Oxidative Stress;D010300:Parkinson Disease;D010586:Phagocytes;D017382:Reactive Oxygen Species;D013481:Superoxides,2012,111
22108613,Neurotoxin-based models of Parkinson's disease.,"D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine;D000818:Animals;D001522:Behavior, Animal;D016923:Cell Death;D004195:Disease Models, Animal;D009498:Neurotoxins;D016627:Oxidopamine;D010269:Paraquat;D010302:Parkinson Disease, Secondary;D012402:Rotenone",2012,106
21628463,The rate of interleukin-1beta secretion in different myeloid cells varies with the extent of redox response to Toll-like receptor triggering.,"D000818:Animals;D001483:Base Sequence;D015153:Blotting, Western;D002352:Carrier Proteins;D002460:Cell Line;D003470:Culture Media;D017931:DNA Primers;D004797:Enzyme-Linked Immunosorbent Assay;D020868:Gene Silencing;D006801:Humans;D053583:Interleukin-1beta;D017737:Macrophages, Peritoneal;D051379:Mice;D009000:Monocytes;D000071199:NLR Family, Pyrin Domain-Containing 3 Protein;D010084:Oxidation-Reduction;D016133:Polymerase Chain Reaction;D017382:Reactive Oxygen Species;D051193:Toll-Like Receptors",2011,100
21626550,Etiology and pathogenesis of Parkinson's disease.,D006801:Humans;D016631:Lewy Bodies;D017628:Microglia;D010300:Parkinson Disease,2011,28
21411503,Diabetes and the risk of developing Parkinson's disease in Denmark.,"D000368:Aged;D000369:Aged, 80 and over;D003718:Denmark;D003920:Diabetes Mellitus;D005260:Female;D006801:Humans;D016015:Logistic Models;D008297:Male;D008875:Middle Aged;D016017:Odds Ratio;D010300:Parkinson Disease;D012307:Risk Factors",2011,112
21378214,Diabetes and risk of Parkinson's disease.,"D000368:Aged;D016001:Confidence Intervals;D003924:Diabetes Mellitus, Type 2;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D015999:Multivariate Analysis;D016017:Odds Ratio;D010300:Parkinson Disease;D011446:Prospective Studies;D012307:Risk Factors",2011,112
21124315,A role for mitochondria in NLRP3 inflammasome activation.,"D000818:Animals;D051017:Apoptosis Regulatory Proteins;D001343:Autophagy;D053468:CARD Signaling Adaptor Proteins;D002352:Carrier Proteins;D002460:Cell Line;D003598:Cytoskeletal Proteins;D004721:Endoplasmic Reticulum;D006801:Humans;D007113:Immunity, Innate;D058847:Inflammasomes;D007249:Inflammation;D053583:Interleukin-1beta;D008264:Macrophages;D051379:Mice;D008807:Mice, Inbred BALB C;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D008928:Mitochondria;D000071199:NLR Family, Pyrin Domain-Containing 3 Protein;D017382:Reactive Oxygen Species;D013879:Thioredoxins;D050994:Voltage-Dependent Anion Channels",2011,13
20659322,Gp91phox (NOX2) in classically activated microglia exacerbates traumatic brain injury.,"D000818:Animals;D001921:Brain;D001930:Brain Injuries;D002460:Cell Line;D003573:Cytochrome b Group;D017353:Gene Deletion;D006801:Humans;D007371:Interferon-gamma;D016753:Interleukin-10;D015847:Interleukin-4;D008562:Membrane Glycoproteins;D051379:Mice;D008810:Mice, Inbred C57BL;D017628:Microglia;D000074662:NADPH Oxidase 2;D019255:NADPH Oxidases;D010641:Phenotype;D017382:Reactive Oxygen Species;D013481:Superoxides",2010,104
20347450,"Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan.","D000367:Age Factors;D000368:Aged;D016022:Case-Control Studies;D003924:Diabetes Mellitus, Type 2;D004032:Diet;D005260:Female;D006801:Humans;D006937:Hypercholesterolemia;D006973:Hypertension;D007564:Japan;D008297:Male;D008875:Middle Aged;D016017:Odds Ratio;D010300:Parkinson Disease;D012307:Risk Factors;D012680:Sensitivity and Specificity;D012737:Sex Factors;D011795:Surveys and Questionnaires",2010,113
20079433,Pathological roles of MAPK signaling pathways in human diseases.,D016207:Cytokines;D006801:Humans;D036341:Intercellular Signaling Peptides and Proteins;D020935:MAP Kinase Signaling System;D020928:Mitogen-Activated Protein Kinases;D009369:Neoplasms;D019636:Neurodegenerative Diseases;D018384:Oxidative Stress;D056811:Unfolded Protein Response,2010,114
20012266,Metformin increases phagocytosis and acidifies lysosomal/endosomal compartments in AMPK-dependent manner in rat primary microglia.,"D055372:AMP-Activated Protein Kinases;D000620:Aminoimidazole Carboxamide;D016229:Amyloid beta-Peptides;D000818:Animals;D002478:Cells, Cultured;D011992:Endosomes;D004789:Enzyme Activation;D006863:Hydrogen-Ion Concentration;D007004:Hypoglycemic Agents;D008070:Lipopolysaccharides;D008247:Lysosomes;D008687:Metformin;D017628:Microglia;D010446:Peptide Fragments;D010587:Phagocytosis;D010750:Phosphoproteins;D011720:Pyrazoles;D011743:Pyrimidines;D051381:Rats;D017208:Rats, Wistar;D012265:Ribonucleotides",2010,115
19442825,"The intranigral injection of tissue plasminogen activator induced blood-brain barrier disruption, inflammatory process and degeneration of the dopaminergic system of the rat.","D000818:Animals;D001253:Astrocytes;D001812:Blood-Brain Barrier;D019208:Brain-Derived Neurotrophic Factor;D004298:Dopamine;D018836:Inflammation Mediators;D020935:MAP Kinase Signaling System;D008297:Male;D017628:Microglia;D008845:Microinjections;D009474:Neurons;D052248:Nitric Oxide Synthase Type I;D052247:Nitric Oxide Synthase Type II;D051381:Rats;D017208:Rats, Wistar;D013378:Substantia Nigra;D010959:Tissue Plasminogen Activator;D051844:alpha-Synuclein;D005680:gamma-Aminobutyric Acid",2009,116
19356970,Diabetes preceding Parkinson's disease onset. A case-control study.,D016022:Case-Control Studies;D015897:Comorbidity;D003920:Diabetes Mellitus;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D012307:Risk Factors,2010,20
19296921,Neuroinflammation in Parkinson's disease: a target for neuroprotection?,D000818:Animals;D000893:Anti-Inflammatory Agents;D016923:Cell Death;D004298:Dopamine;D006801:Humans;D007114:Immunization;D007155:Immunologic Factors;D007249:Inflammation;D009410:Nerve Degeneration;D015213:Neuroimmunomodulation;D009474:Neurons;D018696:Neuroprotective Agents;D010300:Parkinson Disease,2009,44
19286276,Stress is critical for LPS-induced activation of microglia and damage in the rat hippocampus.,"D000818:Animals;D001095:Arachidonic Acids;D001835:Body Weight;D019208:Brain-Derived Neurotrophic Factor;D002452:Cell Count;D003345:Corticosterone;D004195:Disease Models, Animal;D048049:Extracellular Signal-Regulated MAP Kinases;D005452:Fluoresceins;D005786:Gene Expression Regulation;D005904:Glial Fibrillary Acidic Protein;D005968:Glutamate Decarboxylase;D006624:Hippocampus;D008070:Lipopolysaccharides;D008297:Male;D017628:Microglia;D052248:Nitric Oxide Synthase Type I;D052247:Nitric Oxide Synthase Type II;D009930:Organic Chemicals;D010751:Phosphopyruvate Hydratase;D011374:Progesterone;D012333:RNA, Messenger;D051381:Rats;D017208:Rats, Wistar;D013315:Stress, Psychological;D013997:Time Factors;D014409:Tumor Necrosis Factor-alpha",2011,87
19090996,NADPH oxidase as a therapeutic target in Alzheimer's disease.,"D000544:Alzheimer Disease;D016229:Amyloid beta-Peptides;D000818:Animals;D016207:Cytokines;D006801:Humans;D017628:Microglia;D008954:Models, Biological;D019255:NADPH Oxidases;D009474:Neurons;D017382:Reactive Oxygen Species",2009,117
18710400,The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery.,"D000818:Animals;D000978:Antiparkinson Agents;D004195:Disease Models, Animal;D055808:Drug Discovery;D006801:Humans;D008070:Lipopolysaccharides;D010300:Parkinson Disease",2009,118
18599528,Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease.,"D000328:Adult;D000368:Aged;D001241:Aspirin;D015992:Body Mass Index;D002318:Cardiovascular Diseases;D015331:Cohort Studies;D003924:Diabetes Mellitus, Type 2;D003925:Diabetic Angiopathies;D006801:Humans;D008297:Male;D008875:Middle Aged;D015999:Multivariate Analysis;D009369:Neoplasms;D010300:Parkinson Disease;D018579:Patient Selection;D010820:Physicians;D011446:Prospective Studies;D016032:Randomized Controlled Trials as Topic;D012307:Risk Factors;D019207:beta Carotene",2008,112
18504291,Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease.,"D000818:Animals;D002478:Cells, Cultured;D003907:Dexamethasone;D004195:Disease Models, Animal;D018450:Disease Progression;D004797:Enzyme-Linked Immunosorbent Assay;D005938:Glucocorticoids;D007375:Interleukin-1;D008070:Lipopolysaccharides;D008297:Male;D017628:Microglia;D009410:Nerve Degeneration;D009569:Nitric Oxide;D016627:Oxidopamine;D010300:Parkinson Disease;D011597:Psychomotor Performance;D051381:Rats;D017208:Rats, Wistar;D020133:Reverse Transcriptase Polymerase Chain Reaction;D013378:Substantia Nigra",2008,36
18044695,Glial reactions in Parkinson's disease.,"D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine;D000818:Animals;D000894:Anti-Inflammatory Agents, Non-Steroidal;D001253:Astrocytes;D001921:Brain;D004298:Dopamine;D005260:Female;D006684:HLA-DR Antigens;D000882:Haplorhini;D006801:Humans;D007150:Immunohistochemistry;D007249:Inflammation;D018799:Intercellular Adhesion Molecule-1;D008297:Male;D017628:Microglia;D009474:Neurons;D009498:Neurotoxins;D018384:Oxidative Stress;D010300:Parkinson Disease;D013378:Substantia Nigra;D051844:alpha-Synuclein",2008,28
17950926,Neuronal 'On' and 'Off' signals control microglia.,"D000818:Animals;D002450:Cell Communication;D018925:Chemokines;D017628:Microglia;D008959:Models, Neurological;D009474:Neurons;D015398:Signal Transduction",2008,103
17947670,Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microglia.,"D000107:Acetylation;D000818:Animals;D002460:Cell Line;D005786:Gene Expression Regulation;D006657:Histones;D050832:Interferon-Stimulated Gene Factor 3;D016753:Interleukin-10;D008070:Lipopolysaccharides;D020935:MAP Kinase Signaling System;D008264:Macrophages;D051379:Mice;D017628:Microglia;D020928:Mitogen-Activated Protein Kinases;D011401:Promoter Regions, Genetic;D050796:STAT3 Transcription Factor;D000071223:Suppressor of Cytokine Signaling 3 Protein;D050826:Suppressor of Cytokine Signaling Proteins;D018808:Transcription Factor AP-1",2007,119
17761552,"Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease.",D000328:Adult;D000367:Age Factors;D000368:Aged;D003920:Diabetes Mellitus;D005260:Female;D006801:Humans;D006937:Hypercholesterolemia;D006973:Hypertension;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D012307:Risk Factors;D012907:Smoking,2007,53
17720159,"Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.","D000818:Animals;D000893:Anti-Inflammatory Agents;D002470:Cell Survival;D003342:Corpus Striatum;D004298:Dopamine;D004777:Environment;D044127:Epigenesis, Genetic;D006801:Humans;D007249:Inflammation;D009422:Nervous System Diseases;D009474:Neurons;D010300:Parkinson Disease;D013378:Substantia Nigra",2008,81
17495632,Therapeutic approaches to inflammation in neurodegenerative disease.,"D001921:Brain;D004660:Encephalitis;D005911:Gliosis;D006801:Humans;D007155:Immunologic Factors;D007167:Immunotherapy;D017628:Microglia;D010300:Parkinson Disease;D018121:Receptors, Cytokine;D051844:alpha-Synuclein",2007,120
17433296,Non-steroidal anti-inflammatory drugs in Parkinson's disease.,"D000368:Aged;D000894:Anti-Inflammatory Agents, Non-Steroidal;D006801:Humans;D007249:Inflammation;D008875:Middle Aged;D018696:Neuroprotective Agents;D010300:Parkinson Disease",2007,81
17251276,Type 2 diabetes and the risk of Parkinson's disease.,"D000328:Adult;D000368:Aged;D015992:Body Mass Index;D003924:Diabetes Mellitus, Type 2;D005260:Female;D005387:Finland;D006306:Health Surveys;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D016016:Proportional Hazards Models;D011446:Prospective Studies;D012307:Risk Factors;D012727:Sex Characteristics;D012959:Socioeconomic Factors;D011795:Surveys and Questionnaires",2007,112
16732273,Control of microglial neurotoxicity by the fractalkine receptor.,"D000704:Analysis of Variance;D000818:Animals;D000073883:CX3C Chemokine Receptor 1;D002135:Calcium-Binding Proteins;D016923:Cell Death;D002478:Cells, Cultured;D002490:Central Nervous System;D016207:Cytokines;D004195:Disease Models, Animal;D005434:Flow Cytometry;D049452:Green Fluorescent Proteins;D007150:Immunohistochemistry;D008070:Lipopolysaccharides;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D008840:Microfilament Proteins;D017628:Microglia;D016472:Motor Neuron Disease;D009419:Nerve Tissue Proteins;D009474:Neurons;D020258:Neurotoxicity Syndromes;D010300:Parkinson Disease;D019707:Receptors, Chemokine",2006,51
16385087,Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.,"D000893:Anti-Inflammatory Agents;D050197:Atherosclerosis;D002470:Cell Survival;D002478:Cells, Cultured;D003924:Diabetes Mellitus, Type 2;D003925:Diabetic Angiopathies;D004730:Endothelium, Vascular;D005947:Glucose;D006801:Humans;D007004:Hypoglycemic Agents;D007375:Interleukin-1;D015850:Interleukin-6;D016209:Interleukin-8;D008264:Macrophages;D008687:Metformin;D009131:Muscle, Smooth, Vascular;D016328:NF-kappa B;D019869:Phosphatidylinositol 3-Kinases;D051057:Proto-Oncogene Proteins c-akt;D012501:Saphenous Vein",2006,121
16240369,Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease.,"D000082:Acetaminophen;D000368:Aged;D000894:Anti-Inflammatory Agents, Non-Steroidal;D001241:Aspirin;D015331:Cohort Studies;D005260:Female;D006801:Humans;D007052:Ibuprofen;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D012307:Risk Factors",2006,122
15983226,Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin.,"D001011:Aorta;D002455:Cell Division;D002478:Cells, Cultured;D004789:Enzyme Activation;D006801:Humans;D020738:Leptin;D020778:Matrix Metalloproteinase 2;D008687:Metformin;D009131:Muscle, Smooth, Vascular;D019255:NADPH Oxidases;D011493:Protein Kinase C",2005,110
15599609,Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons.,D000818:Animals;D004298:Dopamine;D006801:Humans;D007249:Inflammation;D009410:Nerve Degeneration;D009474:Neurons;D013378:Substantia Nigra,2005,123
14502103,Antiatherogenic properties of metformin: the experimental evidence.,"D000818:Animals;D001018:Aortic Diseases;D001158:Arteries;D001161:Arteriosclerosis;D003924:Diabetes Mellitus, Type 2;D004195:Disease Models, Animal;D006801:Humans;D007004:Hypoglycemic Agents;D007333:Insulin Resistance;D008687:Metformin;D009765:Obesity",2003,124
12925360,Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease.,"D000082:Acetaminophen;D000328:Adult;D000368:Aged;D018712:Analgesics, Non-Narcotic;D000894:Anti-Inflammatory Agents, Non-Steroidal;D001241:Aspirin;D015331:Cohort Studies;D016001:Confidence Intervals;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D015999:Multivariate Analysis;D010300:Parkinson Disease;D011446:Prospective Studies;D012307:Risk Factors",2003,125
12603843,Thrombin induces in vivo degeneration of nigral dopaminergic neurones along with the activation of microglia.,"D000818:Animals;D000991:Antithrombins;D003342:Corpus Striatum;D004151:Dipeptides;D004298:Dopamine;D004305:Dose-Response Relationship, Drug;D004790:Enzyme Induction;D005260:Female;D017403:In Situ Hybridization;D007375:Interleukin-1;D017628:Microglia;D008845:Microinjections;D019636:Neurodegenerative Diseases;D009474:Neurons;D019001:Nitric Oxide Synthase;D052247:Nitric Oxide Synthase Type II;D010880:Piperidines;D012333:RNA, Messenger;D051381:Rats;D017208:Rats, Wistar;D013378:Substantia Nigra;D013917:Thrombin;D014409:Tumor Necrosis Factor-alpha;D014446:Tyrosine 3-Monooxygenase",2003,126
12191486,The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.,"D048868:Adaptor Proteins, Signal Transducing;D051017:Apoptosis Regulatory Proteins;D015153:Blotting, Western;D053468:CARD Signaling Adaptor Proteins;D020170:Caspase 1;D020169:Caspases;D002460:Cell Line;D002474:Cell-Free System;D003598:Cytoskeletal Proteins;D004789:Enzyme Activation;D006367:HeLa Cells;D006801:Humans;D007249:Inflammation;D007375:Interleukin-1;D008070:Lipopolysaccharides;D046911:Macromolecular Substances;D011498:Protein Precursors;D011499:Protein Processing, Post-Translational;D011506:Proteins",2002,127
12072366,CD200 and membrane protein interactions in the control of myeloid cells.,"D000818:Animals;D015703:Antigens, CD;D000943:Antigens, Differentiation;D000954:Antigens, Surface;D051928:CD47 Antigen;D002352:Carrier Proteins;D002462:Cell Membrane;D005260:Female;D006801:Humans;D007107:Immune System;D007153:Immunologic Deficiency Syndromes;D008024:Ligands;D008262:Macrophage Activation;D008297:Male;D008562:Membrane Glycoproteins;D051379:Mice;D008810:Mice, Inbred C57BL;D018345:Mice, Knockout;D008954:Models, Biological;D018716:Molecular Mimicry;D022423:Myeloid Cells;D019006:Neural Cell Adhesion Molecules;D009474:Neurons;D064446:Orexin Receptors;D010053:Ovary;D011487:Protein Conformation;D051381:Rats;D043562:Receptors, G-Protein-Coupled;D011971:Receptors, Immunologic;D018013:Receptors, Neuropeptide;D015398:Signal Transduction;D014780:Viruses",2002,128
12067227,"The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma.","D000818:Animals;D015306:Biogenic Monoamines;D002395:Catecholamines;D002470:Cell Survival;D003342:Corpus Striatum;D003907:Dexamethasone;D004195:Disease Models, Animal;D004298:Dopamine;D005260:Female;D007371:Interferon-gamma;D007375:Interleukin-1;D008070:Lipopolysaccharides;D008262:Macrophage Activation;D017628:Microglia;D008845:Microinjections;D019636:Neurodegenerative Diseases;D009474:Neurons;D010302:Parkinson Disease, Secondary;D051381:Rats;D011994:Recombinant Proteins;D013378:Substantia Nigra;D014409:Tumor Necrosis Factor-alpha;D014446:Tyrosine 3-Monooxygenase",2002,126
11717581,Identification of Toll-like receptor 4 (Tlr4) as the sole conduit for LPS signal transduction: genetic and evolutionary studies.,"D000818:Animals;D029721:Drosophila Proteins;D019143:Evolution, Molecular;D006801:Humans;D008070:Lipopolysaccharides;D008562:Membrane Glycoproteins;D011956:Receptors, Cell Surface;D015398:Signal Transduction;D051197:Toll-Like Receptor 4;D051193:Toll-Like Receptors",2002,129
11099416,Down-regulation of the macrophage lineage through interaction with OX2 (CD200).,"D000818:Animals;D015703:Antigens, CD;D000954:Antigens, Surface;D001169:Arthritis, Experimental;D019070:Cell Lineage;D002490:Central Nervous System;D003714:Denervation;D015536:Down-Regulation;D004681:Encephalomyelitis, Autoimmune, Experimental;D005154:Facial Nerve;D018390:Gene Targeting;D007596:Joints;D008198:Lymph Nodes;D008262:Macrophage Activation;D008264:Macrophages;D051379:Mice;D008810:Mice, Inbred C57BL;D017628:Microglia;D009474:Neurons;D051381:Rats;D011971:Receptors, Immunologic;D013154:Spleen",2001,18
10964613,The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system.,"D000818:Animals;D003342:Corpus Striatum;D004195:Disease Models, Animal;D004298:Dopamine;D005260:Female;D007249:Inflammation;D008070:Lipopolysaccharides;D009457:Neuroglia;D010300:Parkinson Disease;D051381:Rats;D017208:Rats, Wistar;D012701:Serotonin;D013378:Substantia Nigra;D014446:Tyrosine 3-Monooxygenase",2000,89
10839993,Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.,"D000818:Animals;D004579:Electron Transport;D042967:Electron Transport Complex I;D005943:Gluconeogenesis;D007004:Hypoglycemic Agents;D008099:Liver;D008297:Male;D008687:Metformin;D008928:Mitochondria;D009247:NADH, NADPH Oxidoreductases;D051381:Rats;D017208:Rats, Wistar;D015398:Signal Transduction;D013367:Submitochondrial Particles;D014407:Tumor Cells, Cultured",2000,130
10617608,Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.,"D000818:Animals;D002463:Cell Membrane Permeability;D019069:Cell Respiration;D042967:Electron Transport Complex I;D005971:Glutamates;D007004:Hypoglycemic Agents;D008293:Malates;D008564:Membrane Potentials;D008687:Metformin;D008930:Mitochondria, Liver;D009247:NADH, NADPH Oxidoreductases;D010085:Oxidative Phosphorylation;D010101:Oxygen Consumption;D051381:Rats;D015398:Signal Transduction;D019802:Succinic Acid;D013696:Temperature;D013772:Tetramethylphenylenediamine",2000,100
9580157,Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system.,"D000818:Animals;D003342:Corpus Striatum;D004298:Dopamine;D004660:Encephalitis;D005260:Female;D006897:Hydroxyindoleacetic Acid;D007150:Immunohistochemistry;D007267:Injections;D008070:Lipopolysaccharides;D019335:Nitroarginine;D051381:Rats;D017208:Rats, Wistar;D012701:Serotonin;D013378:Substantia Nigra;D014446:Tyrosine 3-Monooxygenase",1998,126
8988390,Biochemistry and cell biology of bacterial endotoxins.,D000818:Animals;D004731:Endotoxins;D006801:Humans;D007962:Leukocytes;D008050:Lipid A;D018950:Lipopolysaccharide Receptors;D008070:Lipopolysaccharides;D008264:Macrophages,1996,131
7542643,CD14 and other recognition molecules for lipopolysaccharide: a review.,"D000209:Acute-Phase Proteins;D015703:Antigens, CD;D015214:Antigens, Differentiation, Myelomonocytic;D018821:CD18 Antigens;D002352:Carrier Proteins;D016207:Cytokines;D018950:Lipopolysaccharide Receptors;D008070:Lipopolysaccharides;D008262:Macrophage Activation;D008562:Membrane Glycoproteins;D018448:Models, Immunological;D009000:Monocytes;D011971:Receptors, Immunologic",1995,132
3399080,Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains.,"D000368:Aged;D000369:Aged, 80 and over;D000544:Alzheimer Disease;D001923:Brain Chemistry;D003704:Dementia;D005260:Female;D006681:HLA-D Antigens;D006684:HLA-DR Antigens;D006801:Humans;D008297:Male;D008543:Melanins;D008875:Middle Aged;D009457:Neuroglia;D010300:Parkinson Disease;D013378:Substantia Nigra",1988,53
3056461,"The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis.",D000818:Animals;D003584:Cytological Techniques;D006801:Humans;D008853:Microscopy;D010336:Pathology;D013238:Stereotaxic Techniques,1988,133
29383446,The neurobiology of impulse control disorders in Parkinson's disease: from neurotransmitters to neural networks.,"D001921:Brain;D007174:Disruptive, Impulse Control, and Conduct Disorders;D004298:Dopamine;D006801:Humans;D009415:Nerve Net;D009446:Neurobiology;D018377:Neurotransmitter Agents;D010300:Parkinson Disease",2019,134
28315845,ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease.,"D000328:Adult;D017668:Age of Onset;D000368:Aged;D000369:Aged, 80 and over;D003430:Cross-Sectional Studies;D007174:Disruptive, Impulse Control, and Conduct Disorders;D005260:Female;D005500:Follow-Up Studies;D006801:Humans;D007558:Italy;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011446:Prospective Studies;D011788:Quality of Life",2017,16
28108021,"Phenomenology and epidemiology of impulsive-compulsive behaviours in Parkinson's disease, atypical Parkinsonian disorders and non-Parkinsonian populations.",D003192:Compulsive Behavior;D006801:Humans;D007175:Impulsive Behavior;D010300:Parkinson Disease,2017,113
27215393,Profiling cognitive and neuropsychiatric heterogeneity in Parkinson's disease.,"D000342:Affective Symptoms;D000368:Aged;D000369:Aged, 80 and over;D016000:Cluster Analysis;D060825:Cognitive Dysfunction;D056344:Executive Function;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D010641:Phenotype;D012720:Severity of Illness Index",2018,20
27048443,Neuropsychiatric Issues in Parkinson's Disease.,"D000818:Animals;D001007:Anxiety;D057565:Apathy;D003072:Cognition Disorders;D003863:Depression;D007174:Disruptive, Impulse Control, and Conduct Disorders;D006801:Humans;D010300:Parkinson Disease;D011618:Psychotic Disorders",2016,135
26798982,Opioid antagonists in broadly defined behavioral addictions: a narrative review.,"D000437:Alcoholism;D002032:Bulimia;D003192:Compulsive Behavior;D007174:Disruptive, Impulse Control, and Conduct Disorders;D005715:Gambling;D006801:Humans;D009271:Naltrexone;D009292:Narcotic Antagonists;D009771:Obsessive-Compulsive Disorder;D016032:Randomized Controlled Trials as Topic;D014256:Trichotillomania",2016,136
25925985,Impaired corticostriatal connectivity in impulse control disorders in Parkinson disease.,"D000368:Aged;D001284:Atrophy;D001931:Brain Mapping;D002540:Cerebral Cortex;D007174:Disruptive, Impulse Control, and Conduct Disorders;D006801:Humans;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D017072:Neostriatum;D010300:Parkinson Disease",2015,53
25649923,Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease.,"D000328:Adult;D000368:Aged;D002540:Cerebral Cortex;D007174:Disruptive, Impulse Control, and Conduct Disorders;D005260:Female;D005500:Follow-Up Studies;D006801:Humans;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D011569:Psychiatric Status Rating Scales;D012720:Severity of Illness Index",2015,28
25476402,Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease.,"D000818:Animals;D001921:Brain;D004195:Disease Models, Animal;D007174:Disruptive, Impulse Control, and Conduct Disorders;D018491:Dopamine Agonists;D006801:Humans;D007175:Impulsive Behavior;D010300:Parkinson Disease",2015,28
25406711,Salience processing and insular cortical function and dysfunction.,D001931:Brain Mapping;D002540:Cerebral Cortex;D006801:Humans;D001523:Mental Disorders;D009415:Nerve Net;D009434:Neural Pathways,2015,85
25370355,Clinical spectrum of impulse control disorders in Parkinson's disease.,"D000818:Animals;D001921:Brain;D003192:Compulsive Behavior;D007174:Disruptive, Impulse Control, and Conduct Disorders;D004298:Dopamine;D018491:Dopamine Agonists;D006801:Humans;D010300:Parkinson Disease",2015,28
25037206,Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.,"D000368:Aged;D007174:Disruptive, Impulse Control, and Conduct Disorders;D004311:Double-Blind Method;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009271:Naltrexone;D009292:Narcotic Antagonists;D010300:Parkinson Disease",2014,53
24893708,Targeting impulsivity in Parkinson's disease using atomoxetine.,"D018759:Adrenergic Uptake Inhibitors;D000368:Aged;D000069445:Atomoxetine Hydrochloride;D001288:Attention;D003657:Decision Making;D004311:Double-Blind Method;D005260:Female;D005717:Games, Experimental;D006801:Humans;D007175:Impulsive Behavior;D007266:Inhibition (Psychology);D008297:Male;D008570:Memory, Short-Term;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D011437:Propylamines;D011930:Reaction Time;D014706:Verbal Learning",2014,36
24832846,Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D007174:Disruptive, Impulse Control, and Conduct Disorders;D004298:Dopamine;D050483:Dopamine Plasma Membrane Transport Proteins;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D012189:Retrospective Studies;D015899:Tomography, Emission-Computed, Single-Photon",2015,28
24578545,Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease.,D000368:Aged;D001921:Brain;D015283:Citalopram;D018592:Cross-Over Studies;D056324:Diffusion Tensor Imaging;D004311:Double-Blind Method;D005260:Female;D006801:Humans;D007175:Impulsive Behavior;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011930:Reaction Time;D017367:Serotonin Uptake Inhibitors,2014,36
24465678,Multiple modes of impulsivity in Parkinson's disease.,"D000328:Adult;D000368:Aged;D016022:Case-Control Studies;D003710:Demography;D005260:Female;D006801:Humans;D007175:Impulsive Behavior;D016014:Linear Models;D008297:Male;D008875:Middle Aged;D008959:Models, Neurological;D018377:Neurotransmitter Agents;D010300:Parkinson Disease;D025341:Principal Component Analysis;D013647:Task Performance and Analysis",2014,68
24434037,Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.,"D000279:Administration, Cutaneous;D000284:Administration, Oral;D000367:Age Factors;D000368:Aged;D000978:Antiparkinson Agents;D052160:Benzothiazoles;D007174:Disruptive, Impulse Control, and Conduct Disorders;D018491:Dopamine Agonists;D005260:Female;D006801:Humans;D007211:Indoles;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D000077487:Pramipexole;D012737:Sex Factors;D013764:Tetrahydronaphthalenes;D013876:Thiophenes",2014,16
24038587,Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions.,"D052160:Benzothiazoles;D001921:Brain;D001931:Brain Mapping;D002755:Choice Behavior;D018491:Dopamine Agonists;D005260:Female;D006801:Humans;D007175:Impulsive Behavior;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D049268:Positron-Emission Tomography;D000077487:Pramipexole;D012201:Reward;D012815:Signal Processing, Computer-Assisted;D013647:Task Performance and Analysis",2014,137
23833269,Beyond and below the cortex: the contribution of striatal dysfunction to cognition and behaviour in neurodegeneration.,D002540:Cerebral Cortex;D003072:Cognition Disorders;D003342:Corpus Striatum;D006801:Humans;D009410:Nerve Degeneration;D009434:Neural Pathways;D019636:Neurodegenerative Diseases,2014,16
23565936,Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's disease.,"D000328:Adult;D000368:Aged;D016739:Behavior, Addictive;D005260:Female;D006801:Humans;D007175:Impulsive Behavior;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D012201:Reward;D035501:Uncertainty",2013,138
23490464,Pathological gambling in Parkinson's disease. A comprehensive review.,D003072:Cognition Disorders;D046690:Deep Brain Stimulation;D015259:Dopamine Agents;D005715:Gambling;D006801:Humans;D010300:Parkinson Disease,2014,20
23378222,Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease.,"D000328:Adult;D000368:Aged;D002540:Cerebral Cortex;D018592:Cross-Over Studies;D003463:Cues;D007174:Disruptive, Impulse Control, and Conduct Disorders;D018491:Dopamine Agonists;D005260:Female;D006801:Humans;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D010775:Photic Stimulation;D012725:Sexual Behavior;D016896:Treatment Outcome",2013,36
23296128,Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study.,"D000368:Aged;D015415:Biomarkers;D018450:Disease Progression;D007174:Disruptive, Impulse Control, and Conduct Disorders;D005260:Female;D005715:Gambling;D006801:Humans;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D011569:Psychiatric Status Rating Scales;D012107:Research Design;D012306:Risk;D011795:Surveys and Questionnaires",2013,53
23123689,Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.,"D000368:Aged;D007174:Disruptive, Impulse Control, and Conduct Disorders;D018491:Dopamine Agonists;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D015995:Prevalence;D012307:Risk Factors;D011795:Surveys and Questionnaires",2013,139
22986077,Disentangling common and specific neural subprocesses of response inhibition.,D000328:Adult;D002540:Cerebral Cortex;D003657:Decision Making;D005260:Female;D006801:Humans;D007266:Inhibition (Psychology);D008279:Magnetic Resonance Imaging;D008297:Male;D009415:Nerve Net;D009433:Neural Inhibition;D055815:Young Adult,2013,140
22766031,Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study.,D004298:Dopamine;D018491:Dopamine Agonists;D005715:Gambling;D006706:Homeostasis;D006801:Humans;D008636:Mesencephalon;D008875:Middle Aged;D010300:Parkinson Disease;D049268:Positron-Emission Tomography;D011759:Pyrrolidines;D019275:Radiopharmaceuticals;D012457:Salicylamides,2013,89
22713671,White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function.,"D000368:Aged;D016880:Anisotropy;D001921:Brain;D001931:Brain Mapping;D038524:Diffusion Magnetic Resonance Imaging;D056344:Executive Function;D005260:Female;D006801:Humans;D008297:Male;D009413:Nerve Fibers, Myelinated;D010300:Parkinson Disease",2012,140
22526761,Iowa Gambling Task in patients with early-onset Parkinson's disease: strategy analysis.,D000328:Adult;D017668:Age of Onset;D003657:Decision Making;D056344:Executive Function;D005260:Female;D005715:Gambling;D006801:Humans;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D011597:Psychomotor Performance,2013,141
22134476,Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats.,"D018759:Adrenergic Uptake Inhibitors;D000661:Amphetamine;D000818:Animals;D021461:Animals, Outbred Strains;D000069445:Atomoxetine Hydrochloride;D002755:Choice Behavior;D015283:Citalopram;D018765:Dopamine Uptake Inhibitors;D004305:Dose-Response Relationship, Drug;D007175:Impulsive Behavior;D008297:Male;D010879:Piperazines;D011437:Propylamines;D051381:Rats;D011930:Reaction Time;D012691:Serial Learning;D017367:Serotonin Uptake Inhibitors;D013997:Time Factors",2012,142
21983019,Impulse control disorders and depression in Finnish patients with Parkinson's disease.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D003430:Cross-Sectional Studies;D003863:Depression;D007174:Disruptive, Impulse Control, and Conduct Disorders;D005260:Female;D005387:Finland;D005715:Gambling;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011569:Psychiatric Status Rating Scales;D012042:Registries;D012307:Risk Factors",2012,20
21725242,Impulse control disorders in Parkinson's disease: recent advances.,"D007174:Disruptive, Impulse Control, and Conduct Disorders;D004298:Dopamine;D006801:Humans;D015337:Multicenter Studies as Topic;D010300:Parkinson Disease;D011954:Receptors, Dopamine;D012201:Reward",2011,120
21596771,Dopamine agonists and risk: impulse control disorders in Parkinson's disease.,"D000328:Adult;D000368:Aged;D000704:Analysis of Variance;D001931:Brain Mapping;D007174:Disruptive, Impulse Control, and Conduct Disorders;D018491:Dopamine Agonists;D005260:Female;D006801:Humans;D007091:Image Processing, Computer-Assisted;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D010100:Oxygen;D010300:Parkinson Disease;D012307:Risk Factors;D012309:Risk-Taking",2011,36
21543619,Effective connectivity reveals important roles for both the hyperdirect (fronto-subthalamic) and the indirect (fronto-striatal-pallidal) fronto-basal ganglia pathways during response inhibition.,"D000293:Adolescent;D000328:Adult;D000704:Analysis of Variance;D001931:Brain Mapping;D003342:Corpus Striatum;D005260:Female;D005625:Frontal Lobe;D005917:Globus Pallidus;D006801:Humans;D007091:Image Processing, Computer-Assisted;D007266:Inhibition (Psychology);D008279:Magnetic Resonance Imaging;D008297:Male;D009434:Neural Pathways;D009483:Neuropsychological Tests;D011930:Reaction Time;D020531:Subthalamic Nucleus",2011,49
21486295,"Cognitive control and right ventrolateral prefrontal cortex: reflexive reorienting, motor inhibition, and action updating.","D003071:Cognition;D003463:Cues;D006801:Humans;D008954:Models, Biological;D009046:Motor Neurons;D009433:Neural Inhibition;D009949:Orientation;D017397:Prefrontal Cortex;D011859:Radiography;D012018:Reflex;D013037:Spatial Behavior",2011,143
21389298,Upregulation of D2-class signaling in dopamine-denervated striatum is in part mediated by D3 receptors acting on Ca V 2.1 channels via PIP2 depletion.,"D000818:Animals;D020864:Calcium Channels, N-Type;D003342:Corpus Striatum;D004298:Dopamine;D008297:Male;D051379:Mice;D008822:Mice, Transgenic;D054801:Phosphoinositide Phospholipase C;D051381:Rats;D017208:Rats, Wistar;D017448:Receptors, Dopamine D2;D050637:Receptors, Dopamine D3;D015398:Signal Transduction;D013562:Sympathectomy;D015854:Up-Regulation",2012,65
21284039,Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis.,"D000368:Aged;D000704:Analysis of Variance;D001931:Brain Mapping;D003342:Corpus Striatum;D005260:Female;D005715:Gambling;D006801:Humans;D007091:Image Processing, Computer-Assisted;D008297:Male;D008875:Middle Aged;D009434:Neural Pathways;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D017397:Prefrontal Cortex;D015899:Tomography, Emission-Computed, Single-Photon",2011,28
21247790,Stroop test performance in impulsive and non impulsive patients with Parkinson's disease.,D000368:Aged;D000704:Analysis of Variance;D001288:Attention;D005260:Female;D006801:Humans;D007175:Impulsive Behavior;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011930:Reaction Time;D057190:Stroop Test;D014796:Visual Perception,2011,20
21069833,Systematic review of levodopa dose equivalency reporting in Parkinson's disease.,D000978:Antiparkinson Agents;D006801:Humans;D007980:Levodopa;D010300:Parkinson Disease,2011,28
20976739,Parkinson's disease and pathological gambling: results from a functional MRI study.,"D000368:Aged;D001921:Brain;D001931:Brain Mapping;D003463:Cues;D005260:Female;D005715:Gambling;D006801:Humans;D007091:Image Processing, Computer-Assisted;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010100:Oxygen;D010300:Parkinson Disease;D010775:Photic Stimulation",2011,28
20671181,Dopaminergic network differences in human impulsivity.,"D000293:Adolescent;D000328:Adult;D019969:Amphetamine-Related Disorders;D017660:Autoreceptors;D001549:Benzamides;D003342:Corpus Striatum;D003913:Dextroamphetamine;D004298:Dopamine;D005260:Female;D006801:Humans;D007175:Impulsive Behavior;D008024:Ligands;D008297:Male;D049268:Positron-Emission Tomography;D011759:Pyrrolidines;D017448:Receptors, Dopamine D2;D050637:Receptors, Dopamine D3;D015398:Signal Transduction;D013378:Substantia Nigra;D013681:Tegmentum Mesencephali;D017557:Ventral Tegmental Area;D055815:Young Adult",2010,18
20589879,Decreased ventral striatal activity with impulse control disorders in Parkinson's disease.,"D000328:Adult;D000368:Aged;D001479:Basal Ganglia;D007174:Disruptive, Impulse Control, and Conduct Disorders;D005260:Female;D006801:Humans;D007091:Image Processing, Computer-Assisted;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D010100:Oxygen;D010300:Parkinson Disease;D012146:Rest;D013647:Task Performance and Analysis",2010,28
20152119,Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors.,D015982:Bias;D002755:Choice Behavior;D003192:Compulsive Behavior;D003342:Corpus Striatum;D004298:Dopamine;D005715:Gambling;D006801:Humans;D007858:Learning;D008279:Magnetic Resonance Imaging;D010300:Parkinson Disease;D012054:Reinforcement (Psychology);D012201:Reward,2010,42
20138482,Neurobiological correlates of problem gambling in a quasi-realistic blackjack scenario as revealed by fMRI.,"D000328:Adult;D001921:Brain;D001931:Brain Mapping;D005715:Gambling;D006801:Humans;D007091:Image Processing, Computer-Assisted;D007175:Impulsive Behavior;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D010100:Oxygen;D011930:Reaction Time;D012201:Reward;D018570:Risk Assessment;D013997:Time Factors",2010,144
20123548,"Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management.","D000818:Animals;D019468:Disease Management;D007174:Disruptive, Impulse Control, and Conduct Disorders;D006801:Humans;D010300:Parkinson Disease;D012307:Risk Factors",2010,20
19404616,"Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats.","D000704:Analysis of Variance;D000818:Animals;D000069445:Atomoxetine Hydrochloride;D001522:Behavior, Animal;D015283:Citalopram;D003216:Conditioning, Operant;D004298:Dopamine;D004305:Dose-Response Relationship, Drug;D016316:Guanfacine;D007266:Inhibition (Psychology);D008297:Male;D014179:Neurotransmitter Uptake Inhibitors;D009638:Norepinephrine;D010879:Piperazines;D011437:Propylamines;D051381:Rats;D011930:Reaction Time;D012701:Serotonin;D017367:Serotonin Uptake Inhibitors;D013647:Task Performance and Analysis;D013997:Time Factors",2009,142
19346328,Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.,D000368:Aged;D000704:Analysis of Variance;D002250:Carbon Radioisotopes;D016022:Case-Control Studies;D003342:Corpus Striatum;D004298:Dopamine;D018492:Dopamine Antagonists;D005260:Female;D005715:Gambling;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D049268:Positron-Emission Tomography;D011485:Protein Binding;D020891:Raclopride,2009,36
18384246,"A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges.","D000293:Adolescent;D000328:Adult;D000368:Aged;D039721:Diagnostic and Statistical Manual of Mental Disorders;D007174:Disruptive, Impulse Control, and Conduct Disorders;D004311:Double-Blind Method;D004334:Drug Administration Schedule;D005260:Female;D005715:Gambling;D006801:Humans;D008297:Male;D008875:Middle Aged;D009271:Naltrexone;D009292:Narcotic Antagonists",2008,145
17897403,Serotonin transporter deficiency in rats improves inhibitory control but not behavioural flexibility.,"D000374:Aggression;D000704:Analysis of Variance;D000818:Animals;D030801:Animals, Genetically Modified;D001362:Avoidance Learning;D001522:Behavior, Animal;D002540:Cerebral Cortex;D002755:Choice Behavior;D006897:Hydroxyindoleacetic Acid;D007266:Inhibition (Psychology);D051381:Rats;D017208:Rats, Wistar;D011930:Reaction Time;D012701:Serotonin;D050486:Serotonin Plasma Membrane Transport Proteins",2008,146
17850833,Meta-analysis of Go/No-go tasks demonstrating that fMRI activation associated with response inhibition is task-dependent.,"D001931:Brain Mapping;D003657:Decision Making;D005260:Female;D005625:Frontal Lobe;D006801:Humans;D007091:Image Processing, Computer-Assisted;D007266:Inhibition (Psychology);D008279:Magnetic Resonance Imaging;D008297:Male;D015201:Meta-Analysis as Topic;D010100:Oxygen;D011930:Reaction Time",2008,147
17121746,Cortical activity in Parkinson's disease during executive processing depends on striatal involvement.,D000368:Aged;D016022:Case-Control Studies;D002421:Caudate Nucleus;D002540:Cerebral Cortex;D003071:Cognition;D006801:Humans;D008279:Magnetic Resonance Imaging;D008875:Middle Aged;D009044:Motor Cortex;D009778:Occipital Lobe;D010296:Parietal Lobe;D010300:Parkinson Disease;D017397:Prefrontal Cortex;D011581:Psychological Tests;D011930:Reaction Time,2007,36
16543934,Genetics of Parkinson disease: paradigm shifts and future prospects.,"D004777:Environment;D005799:Genes, Dominant;D005808:Genes, Recessive;D008040:Genetic Linkage;D006801:Humans;D009154:Mutation;D010300:Parkinson Disease;D015398:Signal Transduction",2006,55
15716523,Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.,"D017668:Age of Onset;D000368:Aged;D003072:Cognition Disorders;D015331:Cohort Studies;D003863:Depression;D003937:Diagnosis, Differential;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D012016:Reference Values;D014202:Tremor",2005,16
15528409,By carrot or by stick: cognitive reinforcement learning in parkinsonism.,"D000368:Aged;D000978:Antiparkinson Agents;D001479:Basal Ganglia;D003071:Cognition;D003198:Computer Simulation;D004298:Dopamine;D030141:Feedback, Psychological;D005260:Female;D005625:Frontal Lobe;D006801:Humans;D007858:Learning;D008297:Male;D016555:Matched-Pair Analysis;D008875:Middle Aged;D008959:Models, Neurological;D010300:Parkinson Disease;D011336:Probability;D012054:Reinforcement (Psychology)",2005,18
12880848,An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets.,"D001921:Brain;D003627:Data Interpretation, Statistical;D001330:Electronic Data Processing;D006801:Humans;D007091:Image Processing, Computer-Assisted;D008279:Magnetic Resonance Imaging;D008959:Models, Neurological;D015203:Reproducibility of Results;D012984:Software",2003,140
12498954,Staging of brain pathology related to sporadic Parkinson's disease.,"D000368:Aged;D000369:Aged, 80 and over;D001921:Brain;D005260:Female;D006801:Humans;D016631:Lewy Bodies;D020961:Lewy Body Disease;D008297:Male;D008526:Medulla Oblongata;D019579:Neocortex;D010300:Parkinson Disease;D013702:Temporal Lobe",2003,87
11771995,Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.,"D001921:Brain;D001931:Brain Mapping;D003196:Computer Graphics;D004292:Dominance, Cerebral;D006801:Humans;D007091:Image Processing, Computer-Assisted;D021621:Imaging, Three-Dimensional;D008279:Magnetic Resonance Imaging;D012016:Reference Values",2002,140
9344826,Psychophysiological and modulatory interactions in neuroimaging.,"D001288:Attention;D001921:Brain;D003952:Diagnostic Imaging;D005145:Face;D006801:Humans;D008279:Magnetic Resonance Imaging;D008959:Models, Neurological;D009039:Motion Perception;D009434:Neural Pathways;D010364:Pattern Recognition, Visual;D011601:Psychophysics;D014055:Tomography, Emission-Computed",1997,140
8778124,Factor structure of the Barratt impulsiveness scale.,"D000704:Analysis of Variance;D016022:Case-Control Studies;D007174:Disruptive, Impulse Control, and Conduct Disorders;D005163:Factor Analysis, Statistical;D005260:Female;D006801:Humans;D007175:Impulsive Behavior;D008297:Male;D001523:Mental Disorders;D010555:Personality Inventory;D011329:Prisoners;D011594:Psychometrics;D019966:Substance-Related Disorders",1995,148
8401595,The neural basis of drug craving: an incentive-sensitization theory of addiction.,"D000222:Adaptation, Physiological;D000818:Animals;D001921:Brain;D003213:Conditioning (Psychology);D003342:Corpus Striatum;D004298:Dopamine;D006801:Humans;D008959:Models, Neurological;D009042:Motivation;D009714:Nucleus Accumbens;D012008:Recurrence;D012054:Reinforcement (Psychology);D019966:Substance-Related Disorders",1993,149
3450848,A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.,"D001682:Biological Availability;D008954:Models, Biological;D010599:Pharmacokinetics;D013223:Statistics as Topic",1987,150
1564476,Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D001921:Brain;D005260:Female;D006801:Humans;D016631:Lewy Bodies;D008131:London;D008297:Male;D008875:Middle Aged;D009460:Neurologic Examination;D010300:Parkinson Disease;D011446:Prospective Studies;D014015:Tissue Banks",1992,16
1202204,"""Mini-mental state"". A practical method for grading the cognitive state of patients for the clinician.","D000328:Adult;D000342:Affective Symptoms;D000368:Aged;D001714:Bipolar Disorder;D003071:Cognition;D003072:Cognition Disorders;D006259:Craniocerebral Trauma;D003704:Dementia;D003863:Depression;D003937:Diagnosis, Differential;D005260:Female;D006801:Humans;D008297:Male;D001523:Mental Disorders;D008609:Mental Status Schedule;D008659:Metabolic Diseases;D008875:Middle Aged;D009497:Neurotic Disorders;D011569:Psychiatric Status Rating Scales;D012559:Schizophrenia;D019966:Substance-Related Disorders;D013997:Time Factors",1975,151
444788,A new depression scale designed to be sensitive to change.,D000293:Adolescent;D000328:Adult;D000368:Aged;D000639:Amitriptyline;D002997:Clomipramine;D003863:Depression;D004739:England;D005260:Female;D006801:Humans;D008297:Male;D008376:Maprotiline;D008803:Mianserin;D008875:Middle Aged;D011569:Psychiatric Status Rating Scales;D011594:Psychometrics;D013548:Sweden,1979,152
28592453,Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.,D015415:Biomarkers;D006801:Humans;D020961:Lewy Body Disease;D017410:Practice Guidelines as Topic,2017,53
27147117,Interference and conflict monitoring in individuals with amnestic mild cognitive impairment: A structural study of the anterior cingulate cortex.,VBM;amnestic mild cognitive impairment;anterior cingulate cortex;attentional control;conflict monitoring,2016,153
26705763,Neural correlates of attention-executive dysfunction in lewy body dementia and Alzheimer's disease.,D000368:Aged;D000544:Alzheimer Disease;D001288:Attention;D001921:Brain;D002800:Cholinesterase Inhibitors;D003463:Cues;D056344:Executive Function;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008279:Magnetic Resonance Imaging;D008297:Male;D009483:Neuropsychological Tests;D018697:Nootropic Agents;D010775:Photic Stimulation;D011930:Reaction Time;D014796:Visual Perception,2016,137
26270627,Resting state in Parkinson's disease dementia and dementia with Lewy bodies: commonalities and differences.,"D000368:Aged;D000369:Aged, 80 and over;D000704:Analysis of Variance;D001284:Atrophy;D016022:Case-Control Studies;D015331:Cohort Studies;D005260:Female;D066128:Gray Matter;D006801:Humans;D020961:Lewy Body Disease;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease",2016,154
26260856,Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease.,"D017668:Age of Onset;D000368:Aged;D000544:Alzheimer Disease;D000818:Animals;D018888:Aphasia, Primary Progressive;D001284:Atrophy;D002540:Cerebral Cortex;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009415:Nerve Net;D010641:Phenotype;D013577:Syndrome",2016,137
25059393,Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia.,"D000368:Aged;D000369:Aged, 80 and over;D000544:Alzheimer Disease;D000704:Analysis of Variance;D001284:Atrophy;D018678:Cholinergic Agents;D005260:Female;D006624:Hippocampus;D006801:Humans;D007091:Image Processing, Computer-Assisted;D020961:Lewy Body Disease;D008279:Magnetic Resonance Imaging;D008297:Male;D008609:Mental Status Schedule;D009483:Neuropsychological Tests;D016548:Prosencephalon",2015,77
23681401,"Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management.",D000818:Animals;D002540:Cerebral Cortex;D003704:Dementia;D006801:Humans;D020961:Lewy Body Disease;D009474:Neurons;D018697:Nootropic Agents;D010300:Parkinson Disease;D009435:Synaptic Transmission,2013,155
23038420,Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis.,"D000978:Antiparkinson Agents;D001923:Brain Chemistry;D003072:Cognition Disorders;D007174:Disruptive, Impulse Control, and Conduct Disorders;D056344:Executive Function;D006801:Humans;D010300:Parkinson Disease",2013,156
22500014,Visual cortex in dementia with Lewy bodies: magnetic resonance imaging study.,"D000368:Aged;D000369:Aged, 80 and over;D001931:Brain Mapping;D016022:Case-Control Studies;D002560:Cerebrovascular Circulation;D005260:Female;D006801:Humans;D016631:Lewy Bodies;D020961:Lewy Body Disease;D008279:Magnetic Resonance Imaging;D008297:Male;D009039:Motion Perception;D010775:Photic Stimulation;D014792:Visual Acuity;D014793:Visual Cortex",2012,152
21572439,Control of visual cortical signals by prefrontal dopamine.,"D000818:Animals;D001552:Benzazepines;D004298:Dopamine;D058785:GABA-A Receptor Agonists;D008253:Macaca mulatta;D009118:Muscimol;D009474:Neurons;D017397:Prefrontal Cortex;D017447:Receptors, Dopamine D1;D012438:Saccades;D014793:Visual Cortex;D014796:Visual Perception",2011,13
21514250,The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.,"D000544:Alzheimer Disease;D015415:Biomarkers;D003937:Diagnosis, Differential;D003952:Diagnostic Imaging;D018450:Disease Progression;D006801:Humans;D054561:National Institute on Aging (U.S.);D017410:Practice Guidelines as Topic;D012955:Societies, Medical;D014481:United States",2012,157
20525771,Associations between regional cortical thickness and attentional networks as measured by the attention network test.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D001288:Attention;D001931:Brain Mapping;D002540:Cerebral Cortex;D003463:Cues;D056344:Executive Function;D005260:Female;D006801:Humans;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D009415:Nerve Net;D009483:Neuropsychological Tests;D009949:Orientation;D011930:Reaction Time;D012737:Sex Factors;D013223:Statistics as Topic",2011,158
20145400,Attention network functioning in patients with dementia with Lewy bodies and Alzheimer's disease.,D000161:Acoustic Stimulation;D000368:Aged;D000544:Alzheimer Disease;D001288:Attention;D003463:Cues;D004493:Education;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008297:Male;D009415:Nerve Net;D009483:Neuropsychological Tests;D011597:Psychomotor Performance;D011930:Reaction Time;D012959:Socioeconomic Factors,2010,159
19173762,Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity.,"D000109:Acetylcholine;D000368:Aged;D000544:Alzheimer Disease;D053327:Apolipoprotein E4;D001921:Brain;D003704:Dementia;D003937:Diagnosis, Differential;D004298:Dopamine;D006801:Humans;D020961:Lewy Body Disease;D010300:Parkinson Disease;D010641:Phenotype;D051844:alpha-Synuclein",2009,160
18848632,Issues with threshold masking in voxel-based morphometry of atrophied brains.,"D000368:Aged;D000375:Aging;D000544:Alzheimer Disease;D001284:Atrophy;D001921:Brain;D001931:Brain Mapping;D003704:Dementia;D005260:Female;D006801:Humans;D007090:Image Interpretation, Computer-Assisted;D008279:Magnetic Resonance Imaging;D008297:Male;D011877:Radionuclide Imaging",2009,140
18024777,Dementia with Lewy bodies and Parkinson's disease with dementia: where two worlds collide.,"D000375:Aging;D000544:Alzheimer Disease;D001921:Brain;D003704:Dementia;D003937:Diagnosis, Differential;D018450:Disease Progression;D006801:Humans;D020961:Lewy Body Disease;D009474:Neurons;D010300:Parkinson Disease",2008,161
17972045,Cholinergic balance in dementia with Lewy bodies: reversible worsening of Parkinsonism at rivastigmine dosage modulation.,D000109:Acetylcholine;D000368:Aged;D002800:Cholinesterase Inhibitors;D018450:Disease Progression;D006801:Humans;D020961:Lewy Body Disease;D008297:Male;D020734:Parkinsonian Disorders;D048448:Phenylcarbamates;D000068836:Rivastigmine;D013997:Time Factors,2008,141
17761438,A fast diffeomorphic image registration algorithm.,"D000465:Algorithms;D001185:Artificial Intelligence;D001921:Brain;D006801:Humans;D007089:Image Enhancement;D007090:Image Interpretation, Computer-Assisted;D021621:Imaging, Three-Dimensional;D008279:Magnetic Resonance Imaging;D010363:Pattern Recognition, Automated;D015203:Reproducibility of Results;D012680:Sensitivity and Specificity;D013382:Subtraction Technique",2007,140
17542011,Clinical diagnostic criteria for dementia associated with Parkinson's disease.,"D003704:Dementia;D003937:Diagnosis, Differential;D006801:Humans;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D012720:Severity of Illness Index;D013647:Task Performance and Analysis",2008,28
17287240,Visual recognition memory differentiates dementia with Lewy bodies and Parkinson's disease dementia.,"D000368:Aged;D000369:Aged, 80 and over;D003072:Cognition Disorders;D003704:Dementia;D003937:Diagnosis, Differential;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008297:Male;D008569:Memory Disorders;D010300:Parkinson Disease;D021641:Recognition (Psychology);D014796:Visual Perception",2007,16
16772356,"Higher cortical deficits influence attentional processing in dementia with Lewy bodies, relative to patients with dementia of the Alzheimer's type and controls.","D000368:Aged;D000369:Aged, 80 and over;D000544:Alzheimer Disease;D001288:Attention;D002540:Cerebral Cortex;D003071:Cognition;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008297:Male;D008606:Mental Processes;D008609:Mental Status Schedule",2006,16
16594774,Attentional networks in normal aging and Alzheimer's disease.,"D000293:Adolescent;D000328:Adult;D000367:Age Factors;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D000544:Alzheimer Disease;D001288:Attention;D016022:Case-Control Studies;D003463:Cues;D005260:Female;D006801:Humans;D008297:Male;D009483:Neuropsychological Tests;D009949:Orientation;D010364:Pattern Recognition, Visual;D010775:Photic Stimulation;D011340:Problem Solving;D011597:Psychomotor Performance;D011930:Reaction Time",2006,162
16407544,Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies.,"D000317:Adrenergic alpha-Antagonists;D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000544:Alzheimer Disease;D003712:Dendrites;D005260:Female;D005473:Fluoxetine;D006624:Hippocampus;D006801:Humans;D019329:Idazoxan;D017403:In Situ Hybridization;D020961:Lewy Body Disease;D008125:Locus Coeruleus;D008297:Male;D008875:Middle Aged;D009419:Nerve Tissue Proteins;D009638:Norepinephrine;D050484:Norepinephrine Plasma Membrane Transport Proteins;D011224:Prazosin;D012333:RNA, Messenger;D018340:Receptors, Adrenergic, alpha-1;D018341:Receptors, Adrenergic, alpha-2;D044024:Tetralones;D014446:Tyrosine 3-Monooxygenase",2006,49
16237129,Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.,"D001921:Brain;D003342:Corpus Striatum;D003937:Diagnosis, Differential;D050483:Dopamine Plasma Membrane Transport Proteins;D004361:Drug Tolerance;D006801:Humans;D016631:Lewy Bodies;D020961:Lewy Body Disease;D020187:REM Sleep Behavior Disorder;D051844:alpha-Synuclein",2006,53
15907304,The activation of attentional networks.,D000293:Adolescent;D000328:Adult;D000465:Algorithms;D001288:Attention;D002540:Cerebral Cortex;D003463:Cues;D005260:Female;D007839:Functional Laterality;D006801:Humans;D008279:Magnetic Resonance Imaging;D008297:Male;D009415:Nerve Net;D009483:Neuropsychological Tests;D009949:Orientation;D010296:Parietal Lobe;D011597:Psychomotor Performance;D011930:Reaction Time;D013702:Temporal Lobe;D013788:Thalamus,2005,140
15558781,Anatomy of attentional networks.,"D001288:Attention;D001921:Brain;D003952:Diagnostic Imaging;D007839:Functional Laterality;D006801:Humans;D008959:Models, Neurological;D010465:Perception;D013997:Time Factors",2005,163
15324362,Mild cognitive impairment as a diagnostic entity.,D000368:Aged;D000544:Alzheimer Disease;D003072:Cognition Disorders;D006801:Humans;D009483:Neuropsychological Tests;D011569:Psychiatric Status Rating Scales;D009626:Terminology as Topic,2004,164
14966152,Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct.,"D000368:Aged;D000369:Aged, 80 and over;D000544:Alzheimer Disease;D017028:Caregivers;D003072:Cognition Disorders;D003937:Diagnosis, Differential;D018450:Disease Progression;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008297:Male;D010507:Periodicity;D012720:Severity of Illness Index",2004,16
14749292,"Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.",D000368:Aged;D000544:Alzheimer Disease;D001921:Brain;D003430:Cross-Sectional Studies;D003704:Dementia;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008279:Magnetic Resonance Imaging;D008297:Male;D010300:Parkinson Disease,2004,36
14743362,Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia.,"D000368:Aged;D000369:Aged, 80 and over;D000544:Alzheimer Disease;D003704:Dementia;D003937:Diagnosis, Differential;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008297:Male;D008875:Middle Aged;D009460:Neurologic Examination;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D011594:Psychometrics",2004,28
14568499,Regional cerebral blood flow in Parkinson's disease with and without dementia.,"D000368:Aged;D000465:Algorithms;D000544:Alzheimer Disease;D002560:Cerebrovascular Circulation;D003704:Dementia;D005260:Female;D006801:Humans;D007091:Image Processing, Computer-Assisted;D020961:Lewy Body Disease;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D015899:Tomography, Emission-Computed, Single-Photon",2003,140
12473758,Fluctuations in attention: PD dementia vs DLB with parkinsonism.,"D000368:Aged;D000369:Aged, 80 and over;D001143:Arousal;D001288:Attention;D003071:Cognition;D003704:Dementia;D004569:Electroencephalography;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008297:Male;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D011930:Reaction Time",2003,53
11970796,Testing the efficiency and independence of attentional networks.,"D000328:Adult;D000704:Analysis of Variance;D001288:Attention;D003072:Cognition Disorders;D003936:Diagnosis, Computer-Assisted;D005260:Female;D016489:Head Injuries, Closed;D006801:Humans;D008297:Male;D009483:Neuropsychological Tests;D009949:Orientation;D011597:Psychomotor Performance;D015203:Reproducibility of Results",2002,165
11405813,Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease.,"D000368:Aged;D000369:Aged, 80 and over;D000544:Alzheimer Disease;D001288:Attention;D003072:Cognition Disorders;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008297:Male;D015999:Multivariate Analysis;D009483:Neuropsychological Tests;D011446:Prospective Studies;D011930:Reaction Time",2001,125
11113036,The noradrenergic alpha2 agonist clonidine modulates behavioural and neuroanatomical correlates of human attentional orienting and alerting.,D000293:Adolescent;D000316:Adrenergic alpha-Agonists;D000328:Adult;D000704:Analysis of Variance;D001288:Attention;D003000:Clonidine;D003463:Cues;D005260:Female;D016316:Guanfacine;D006801:Humans;D008297:Male;D008875:Middle Aged;D009949:Orientation;D010296:Parietal Lobe;D011930:Reaction Time;D013702:Temporal Lobe,2001,158
10762503,"Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia.","D000368:Aged;D000369:Aged, 80 and over;D000544:Alzheimer Disease;D001288:Attention;D001931:Brain Mapping;D003072:Cognition Disorders;D015331:Cohort Studies;D015140:Dementia, Vascular;D003937:Diagnosis, Differential;D004569:Electroencephalography;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008297:Male;D009483:Neuropsychological Tests;D012372:ROC Curve;D011930:Reaction Time;D012680:Sensitivity and Specificity;D012720:Severity of Illness Index",2000,53
10720273,Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies.,"D000368:Aged;D000369:Aged, 80 and over;D001921:Brain;D003245:Consensus Development Conferences as Topic;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008297:Male;D011446:Prospective Studies;D015203:Reproducibility of Results;D012680:Sensitivity and Specificity",2000,53
9055266,Inhibition of return and visuospatial attention in healthy older adults and individuals with dementia of the Alzheimer type.,D000328:Adult;D000367:Age Factors;D000368:Aged;D000375:Aging;D000544:Alzheimer Disease;D001288:Attention;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D011930:Reaction Time;D014796:Visual Perception,1997,162
2183676,The attention system of the human brain.,"D001288:Attention;D001921:Brain;D007839:Functional Laterality;D006801:Humans;D010364:Pattern Recognition, Visual",1990,166
28164377,Disentangling the mechanisms of cognitive changes after STN-DBS: A step forward.,D003071:Cognition;D046690:Deep Brain Stimulation;D010300:Parkinson Disease;D020531:Subthalamic Nucleus,2018,28
27753157,Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease.,D000368:Aged;D060825:Cognitive Dysfunction;D046690:Deep Brain Stimulation;D003863:Depression;D005260:Female;D005500:Follow-Up Studies;D006801:Humans;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D020531:Subthalamic Nucleus;D016896:Treatment Outcome,2017,28
26011773,Brain alterations with deep brain stimulation: New insight from a neuropathological case series.,"D000368:Aged;D000369:Aged, 80 and over;D001369:Axons;D046690:Deep Brain Stimulation;D004567:Electrodes, Implanted;D020329:Essential Tremor;D005260:Female;D005549:Foreign-Body Reaction;D005911:Gliosis;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D016037:Single-Blind Method",2016,28
25842260,The medical treatment of patients with Parkinson's disease receiving subthalamic neurostimulation.,"D000368:Aged;D000928:Antidepressive Agents;D000978:Antiparkinson Agents;D046690:Deep Brain Stimulation;D018491:Dopamine Agonists;D004305:Dose-Response Relationship, Drug;D005260:Female;D005500:Follow-Up Studies;D006801:Humans;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D012189:Retrospective Studies;D020531:Subthalamic Nucleus;D016896:Treatment Outcome",2016,20
25086832,Role of fronto-striatal tract and frontal aslant tract in movement and speech: an axonal mapping study.,D000328:Adult;D001931:Brain Mapping;D001932:Brain Neoplasms;D003342:Corpus Striatum;D056324:Diffusion Tensor Imaging;D004558:Electric Stimulation;D005260:Female;D005625:Frontal Lobe;D005910:Glioma;D006801:Humans;D007802:Language;D008297:Male;D008875:Middle Aged;D009068:Movement;D017072:Neostriatum;D009434:Neural Pathways;D013060:Speech;D016896:Treatment Outcome;D014851:Wakefulness,2016,167
24050735,Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits.,D046690:Deep Brain Stimulation;D018450:Disease Progression;D006801:Humans;D010300:Parkinson Disease;D012307:Risk Factors;D020531:Subthalamic Nucleus,2013,44
23801735,Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson's disease: results from a randomized trial.,"D000368:Aged;D000978:Antiparkinson Agents;D002421:Caudate Nucleus;D003072:Cognition Disorders;D046690:Deep Brain Stimulation;D004311:Double-Blind Method;D004566:Electrodes;D005260:Female;D007839:Functional Laterality;D005917:Globus Pallidus;D006801:Humans;D007854:Lead;D007980:Levodopa;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D017063:Outcome Assessment (Health Care);D010300:Parkinson Disease;D018709:Statistics, Nonparametric;D020531:Subthalamic Nucleus",2013,36
23208668,Long-term outcomes of surgical therapies for Parkinson's disease.,D046690:Deep Brain Stimulation;D005500:Follow-Up Studies;D006801:Humans;D009043:Motor Activity;D010300:Parkinson Disease;D013997:Time Factors;D016896:Treatment Outcome,2013,28
22314706,Postmortem observation of collagenous lead tip region fibrosis as a rare complication of DBS.,D000368:Aged;D001344:Autopsy;D046690:Deep Brain Stimulation;D024022:Fibrillar Collagens;D005355:Fibrosis;D005904:Glial Fibrillary Acidic Protein;D006801:Humans;D008297:Male;D010300:Parkinson Disease,2012,28
22166423,Factors associated with neuropsychiatric side effects after STN-DBS in Parkinson's disease.,D000818:Animals;D046690:Deep Brain Stimulation;D006801:Humans;D001523:Mental Disorders;D010300:Parkinson Disease;D020531:Subthalamic Nucleus,2012,20
21894061,Abnormal T2-weighted MRI signal surrounding leads in a subset of deep brain stimulation patients.,"D000328:Adult;D000368:Aged;D046690:Deep Brain Stimulation;D004567:Electrodes, Implanted;D005260:Female;D006801:Humans;D008279:Magnetic Resonance Imaging;D008297:Male;D008839:Microelectrodes;D008875:Middle Aged;D012189:Retrospective Studies",2012,168
21692113,"Long-Term management of DBS in dystonia: response to stimulation, adverse events, battery changes, and special considerations.","D046690:Deep Brain Stimulation;D004421:Dystonia;D004567:Electrodes, Implanted;D006801:Humans;D008137:Longitudinal Studies;D011182:Postoperative Care",2011,28
21574186,Risk of surgical delivery to deep nuclei: a meta-analysis.,"D000293:Adolescent;D000328:Adult;D000368:Aged;D002543:Cerebral Hemorrhage;D002648:Child;D016208:Databases, Factual;D046690:Deep Brain Stimulation;D004567:Electrodes, Implanted;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009422:Nervous System Diseases;D012307:Risk Factors;D020521:Stroke;D055815:Young Adult",2012,28
20959310,What is the role of the uncinate fasciculus? Surgical removal and proper name retrieval.,"D000328:Adult;D000368:Aged;D001932:Brain Neoplasms;D002529:Cerebellar Nuclei;D056324:Diffusion Tensor Imaging;D005260:Female;D005625:Frontal Lobe;D005910:Glioma;D006801:Humans;D007806:Language Disorders;D008032:Limbic System;D008297:Male;D008569:Memory Disorders;D011939:Mental Recall;D008875:Middle Aged;D009413:Nerve Fibers, Myelinated;D009434:Neural Pathways;D056347:Neuroanatomical Tract-Tracing Techniques;D011183:Postoperative Complications;D013702:Temporal Lobe",2011,36
20187699,Effects of magnetic resonance imaging in patients with implanted deep brain stimulation systems.,"D046690:Deep Brain Stimulation;D004567:Electrodes, Implanted;D006801:Humans;D058542:Implantable Neurostimulators;D008279:Magnetic Resonance Imaging;D009069:Movement Disorders",2011,169
19288469,Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial.,D000328:Adult;D000368:Aged;D003072:Cognition Disorders;D046690:Deep Brain Stimulation;D004311:Double-Blind Method;D004558:Electric Stimulation;D005260:Female;D005917:Globus Pallidus;D006801:Humans;D008297:Male;D008875:Middle Aged;D019964:Mood Disorders;D009043:Motor Activity;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D011446:Prospective Studies;D011569:Psychiatric Status Rating Scales;D020531:Subthalamic Nucleus,2009,122
18538636,"Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study.",D000368:Aged;D001007:Anxiety;D001526:Behavioral Symptoms;D003071:Cognition;D046690:Deep Brain Stimulation;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D011340:Problem Solving;D011788:Quality of Life;D020531:Subthalamic Nucleus,2008,44
18073522,Magnetic resonance imaging of implanted deep brain stimulators: experience in a large series.,"D001921:Brain;D046690:Deep Brain Stimulation;D004869:Equipment Safety;D006801:Humans;D008279:Magnetic Resonance Imaging;D019047:Phantoms, Imaging;D012189:Retrospective Studies",2008,168
17443691,Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson's disease.,"D000368:Aged;D003071:Cognition;D046690:Deep Brain Stimulation;D003704:Dementia;D005260:Female;D006801:Humans;D015994:Incidence;D008137:Longitudinal Studies;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D018709:Statistics, Nonparametric;D020531:Subthalamic Nucleus;D013997:Time Factors",2007,28
17250719,Chronic subthalamic high-frequency deep brain stimulation in Parkinson's disease--a histopathological study.,D001921:Brain;D046690:Deep Brain Stimulation;D004566:Electrodes;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D020531:Subthalamic Nucleus,2007,170
16810722,Deep brain stimulation for Parkinson's disease: surgical technique and perioperative management.,"D000978:Antiparkinson Agents;D001921:Brain;D001931:Brain Mapping;D046690:Deep Brain Stimulation;D003937:Diagnosis, Differential;D004567:Electrodes, Implanted;D007839:Functional Laterality;D006801:Humans;D007980:Levodopa;D008279:Magnetic Resonance Imaging;D019635:Neurosurgical Procedures;D010300:Parkinson Disease;D018579:Patient Selection;D011182:Postoperative Care;D011300:Preoperative Care;D013238:Stereotaxic Techniques",2006,28
16810719,Deep brain stimulation: postoperative issues.,"D001424:Bacterial Infections;D001921:Brain;D003072:Cognition Disorders;D046690:Deep Brain Stimulation;D003704:Dementia;D004567:Electrodes, Implanted;D006287:Health Planning Guidelines;D006801:Humans;D008279:Magnetic Resonance Imaging;D010300:Parkinson Disease;D011182:Postoperative Care;D013064:Speech Disorders",2006,28
16781988,Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis.,D016009:Chi-Square Distribution;D003071:Cognition;D015331:Cohort Studies;D046690:Deep Brain Stimulation;D005260:Female;D006801:Humans;D016239:MEDLINE;D008297:Male;D015201:Meta-Analysis as Topic;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D012189:Retrospective Studies;D020531:Subthalamic Nucleus;D016896:Treatment Outcome,2006,44
15329356,Electron microscopy of tissue adherent to explanted electrodes in dystonia and Parkinson's disease.,"D000328:Adult;D046690:Deep Brain Stimulation;D020878:Device Removal;D004421:Dystonia;D004567:Electrodes, Implanted;D005260:Female;D015743:Giant Cells, Foreign-Body;D005917:Globus Pallidus;D015745:Granuloma, Foreign-Body;D006101:Granuloma, Giant Cell;D006801:Humans;D008297:Male;D008854:Microscopy, Electron;D008855:Microscopy, Electron, Scanning;D008875:Middle Aged;D010300:Parkinson Disease;D013499:Surface Properties;D013997:Time Factors",2005,36
15305076,Asymptomatic transient MRI signal changes after unilateral deep brain stimulation electrode implantation for movement disorder.,"D001921:Brain;D004599:Electric Stimulation Therapy;D004567:Electrodes, Implanted;D005260:Female;D006801:Humans;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D009069:Movement Disorders;D012189:Retrospective Studies",2004,168
11948773,Documentation of electrode localization.,"D000328:Adult;D000368:Aged;D004599:Electric Stimulation Therapy;D004567:Electrodes, Implanted;D005260:Female;D006801:Humans;D021621:Imaging, Three-Dimensional;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D009069:Movement Disorders;D011182:Postoperative Care;D013238:Stereotaxic Techniques",2002,28
11835450,Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease.,"D001921:Brain;D004599:Electric Stimulation Therapy;D004567:Electrodes, Implanted;D017809:Fatal Outcome;D006801:Humans;D008279:Magnetic Resonance Imaging;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D020531:Subthalamic Nucleus",2002,28
10976644,No tissue damage by chronic deep brain stimulation in Parkinson's disease.,D001921:Brain;D004599:Electric Stimulation Therapy;D006801:Humans;D010300:Parkinson Disease;D013997:Time Factors,2000,122
7936236,Long-term thalamic stimulation in Parkinson's disease: postmortem anatomoclinical study.,"D000328:Adult;D002560:Cerebrovascular Circulation;D004599:Electric Stimulation Therapy;D004567:Electrodes, Implanted;D017809:Fatal Outcome;D005911:Gliosis;D006801:Humans;D008297:Male;D009069:Movement Disorders;D010300:Parkinson Disease;D013378:Substantia Nigra;D013788:Thalamus;D014202:Tremor",1994,53
30056141,"Transcranial direct current stimulation combined with cognitive training for the treatment of Parkinson Disease: A randomized, placebo-controlled study.",Cognitive rehabilitation;Non-invasive brain stimulation;Non-pharmacological treatment;PD;tDCS,2018,171
29053684,Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability.,D000328:Adult;D005260:Female;D006801:Humans;D008297:Male;D065908:Transcranial Direct Current Stimulation;D055815:Young Adult,2018,172
28937310,"Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial.",Fatigue;multiple sclerosis;tDCS;tES;telerehabilitation;transcranial direct current stimulation,2017,173
28725706,The effect of deep brain stimulation on the non-motor symptoms of Parkinson's disease: a critical review of the current evidence.,,2017,21
28225155,Remotely Supervised Transcranial Direct Current Stimulation Increases the Benefit of At-Home Cognitive Training in Multiple Sclerosis.,"D000328:Adult;D000368:Aged;D001288:Attention;D003072:Cognition Disorders;D005260:Female;D006801:Humans;D008297:Male;D008570:Memory, Short-Term;D008875:Middle Aged;D009103:Multiple Sclerosis;D009483:Neuropsychological Tests;D012189:Retrospective Studies;D015898:Tomography Scanners, X-Ray Computed;D065908:Transcranial Direct Current Stimulation",2018,174
27866120,Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS).,D001921:Brain;D005060:Europe;D019317:Evidence-Based Medicine;D006801:Humans;D009422:Nervous System Diseases;D017410:Practice Guidelines as Topic;D016032:Randomized Controlled Trials as Topic;D065908:Transcranial Direct Current Stimulation,2017,74
27608611,Dopamine-independent effects of combining transcranial direct current stimulation with cued gait training on cortical excitability and functional mobility in Parkinson's disease.,D000328:Adult;D000368:Aged;D000071080:Cortical Excitability;D004298:Dopamine;D004311:Double-Blind Method;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D010865:Pilot Projects;D065908:Transcranial Direct Current Stimulation,2016,175
27372845,Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016.,"D000818:Animals;D001921:Brain;D003198:Computer Simulation;D004827:Epilepsy;D055317:Evidence-Based Practice;D006801:Humans;D023421:Models, Animal;D020521:Stroke;D065908:Transcranial Direct Current Stimulation",2017,171
27089545,Transcranial Direct Current Stimulation Is Feasible for Remotely Supervised Home Delivery in Multiple Sclerosis.,D000328:Adult;D000368:Aged;D004185:Disability Evaluation;D005240:Feasibility Studies;D005260:Female;D005500:Follow-Up Studies;D006699:Home Care Services;D006801:Humans;D008297:Male;D008875:Middle Aged;D009103:Multiple Sclerosis;D017216:Telemedicine;D065908:Transcranial Direct Current Stimulation;D016896:Treatment Outcome,2017,174
26880536,Mild cognitive impairment in Parkinson's disease is improved by transcranial direct current stimulation combined with physical therapy.,D000368:Aged;D060825:Cognitive Dysfunction;D003131:Combined Modality Therapy;D005081:Exercise Therapy;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D017063:Outcome Assessment (Health Care);D010300:Parkinson Disease;D017397:Prefrontal Cortex;D065908:Transcranial Direct Current Stimulation,2017,28
26780383,A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS).,D002986:Clinical Trials as Topic;D005240:Feasibility Studies;D019983:Guideline Adherence;D006801:Humans;D009103:Multiple Sclerosis;D017410:Practice Guidelines as Topic;D015203:Reproducibility of Results;D017216:Telemedicine;D065908:Transcranial Direct Current Stimulation,2016,172
26652115,"A technical guide to tDCS, and related non-invasive brain stimulation tools.",D001921:Brain;D003071:Cognition;D006801:Humans;D065908:Transcranial Direct Current Stimulation,2016,74
26645499,Health-Related Quality of Life in patients with Parkinson's disease--A systematic review based on the ICF model.,D000203:Activities of Daily Living;D006801:Humans;D009043:Motor Activity;D010300:Parkinson Disease;D011788:Quality of Life;D011795:Surveys and Questionnaires;D014944:World Health Organization,2016,176
26645310,The Attention Network Test-Interaction (ANT-I): reliability and validity in healthy older adults.,"D000161:Acoustic Stimulation;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D001288:Attention;D001921:Brain;D015331:Cohort Studies;D056344:Executive Function;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009949:Orientation;D010775:Photic Stimulation;D011446:Prospective Studies;D011930:Reaction Time;D015203:Reproducibility of Results",2016,70
25983531,Regulatory Considerations for the Clinical and Research Use of Transcranial Direct Current Stimulation (tDCS): review and recommendations from an expert panel.,,2015,177
25852494,Remotely-supervised transcranial direct current stimulation (tDCS) for clinical trials: guidelines for technology and protocols.,attention deficit hyperactivity disorder;clinical trials;depression;multiple sclerosis;palliative care;tDCS,2015,178
25686212,Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis.,D001921:Brain;D002986:Clinical Trials as Topic;D006801:Humans;D009043:Motor Activity;D010300:Parkinson Disease;D050781:Transcranial Magnetic Stimulation;D016896:Treatment Outcome,2015,179
25179996,Effects of tDCS on executive function in Parkinson's disease.,D000328:Adult;D000339:Affect;D000368:Aged;D003071:Cognition;D004311:Double-Blind Method;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009048:Motor Skills;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D017397:Prefrontal Cortex;D065908:Transcranial Direct Current Stimulation,2015,14
24826498,Comparison of the WRAT4 reading subtest and the WTAR for estimating premorbid ability level.,D000293:Adolescent;D000328:Adult;D003072:Cognition Disorders;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D011237:Predictive Value of Tests;D011932:Reading;D015203:Reproducibility of Results;D011795:Surveys and Questionnaires;D014888:Wechsler Scales;D055815:Young Adult,2014,180
24789677,Transcranial direct current stimulation for treatment of freezing of gait: a cross-over study.,"D000368:Aged;D018592:Cross-Over Studies;D004311:Double-Blind Method;D005260:Female;D046352:Freezing Reaction, Cataleptic;D020233:Gait Disorders, Neurologic;D006801:Humans;D008297:Male;D009044:Motor Cortex;D010300:Parkinson Disease;D012720:Severity of Illness Index;D065908:Transcranial Direct Current Stimulation;D016896:Treatment Outcome;D016138:Walking",2015,28
24123307,Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms.,D000368:Aged;D000978:Antiparkinson Agents;D003072:Cognition Disorders;D003863:Depression;D005260:Female;D006304:Health Status;D006801:Humans;D008137:Longitudinal Studies;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011788:Quality of Life;D012189:Retrospective Studies;D012893:Sleep Wake Disorders;D013223:Statistics as Topic,2014,28
21180627,Deep brain stimulation in Parkinson's disease.,DBS;GPi;Parkinson's disease;STN;VIM;deep brain stimulation;subthalamic nucleus,2010,181
19185021,"Effects of DBS, premotor rTMS, and levodopa on motor function and silent period in advanced Parkinson's disease.","D000368:Aged;D000978:Antiparkinson Agents;D016009:Chi-Square Distribution;D046690:Deep Brain Stimulation;D004567:Electrodes, Implanted;D004576:Electromyography;D019054:Evoked Potentials, Motor;D005260:Female;D006801:Humans;D007980:Levodopa;D008137:Longitudinal Studies;D008297:Male;D008875:Middle Aged;D009043:Motor Activity;D009044:Motor Cortex;D010300:Parkinson Disease;D012720:Severity of Illness Index;D020531:Subthalamic Nucleus;D050781:Transcranial Magnetic Stimulation",2009,28
18394576,Noninvasive brain stimulation for Parkinson's disease and dystonia.,D001921:Brain;D004421:Dystonia;D004558:Electric Stimulation;D006801:Humans;D010300:Parkinson Disease;D013238:Stereotaxic Techniques;D050781:Transcranial Magnetic Stimulation,2008,182
18217883,Is quality of life in non-demented Parkinson's disease patients related to cognitive performance? A clinic-based cross-sectional study.,D000368:Aged;D003071:Cognition;D003430:Cross-Sectional Studies;D003863:Depression;D005260:Female;D006304:Health Status;D006801:Humans;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D025341:Principal Component Analysis;D011569:Psychiatric Status Rating Scales;D011788:Quality of Life;D012044:Regression Analysis;D011795:Surveys and Questionnaires,2008,170
17443116,The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years.,D003299:Cooperative Behavior;D019992:Databases as Topic;D007256:Information Systems;D009316:National Institutes of Health (U.S.);D017063:Outcome Assessment (Health Care);D011788:Quality of Life;D012650:Self Disclosure;D014481:United States,2007,183
16817194,Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease.,"D000368:Aged;D000978:Antiparkinson Agents;D001931:Brain Mapping;D046690:Deep Brain Stimulation;D004292:Dominance, Cerebral;D004311:Double-Blind Method;D004566:Electrodes;D019054:Evoked Potentials, Motor;D005260:Female;D006801:Humans;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D009043:Motor Activity;D009044:Motor Cortex;D009048:Motor Skills;D009460:Neurologic Examination;D010300:Parkinson Disease;D017397:Prefrontal Cortex;D013223:Statistics as Topic",2007,28
12777365,"Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity.","D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D002140:California;D044469:Continental Population Groups;D005006:Ethnic Groups;D005260:Female;D006801:Humans;D015994:Incidence;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease",2003,184
3397865,Development and validation of brief measures of positive and negative affect: the PANAS scales.,D001143:Arousal;D006801:Humans;D019964:Mood Disorders;D011581:Psychological Tests;D011594:Psychometrics,1988,185
30102759,Orexins increase the firing activity of nigral dopaminergic neurons and participate in motor control in rats.,electrophysiology;motor control;orexins;substantia nigra pars compacta,2018,126
29657115,Novelty-Sensitive Dopaminergic Neurons in the Human Substantia Nigra Predict Success of Declarative Memory Formation.,DBS;ECoG;Parkinson’s;basal ganglia;dopamine;human single unit;memory;spike-field coherence;substantia nigra;theta,2018,186
29325715,Orexin knockout mice exhibit impaired spatial working memory.,"D000818:Animals;D001522:Behavior, Animal;D001921:Brain;D060825:Cognitive Dysfunction;D018782:Maze Learning;D008570:Memory, Short-Term;D051379:Mice;D018345:Mice, Knockout;D009043:Motor Activity;D000068797:Orexins;D065852:Spatial Memory",2018,14
29218419,An unexpected improvement in spatial learning and memory ability in alpha-synuclein A53T transgenic mice.,Alpha-synuclein A53T mice;Non-motor symptoms;Parkinson’s disease;Spatial learning and memory,2017,123
29138106,The Subthalamic Neurons are Activated by Both Orexin-A and Orexin-B.,"D000200:Action Potentials;D000818:Animals;D001583:Benzoxazoles;D007546:Isoquinolines;D008297:Male;D009043:Motor Activity;D009474:Neurons;D018377:Neurotransmitter Agents;D064446:Orexin Receptors;D000068797:Orexins;D011725:Pyridines;D017208:Rats, Wistar;D020531:Subthalamic Nucleus;D014508:Urea",2019,106
29107703,Orexin/hypocretin treatment restores hippocampal-dependent memory in orexin-deficient mice.,"D000818:Animals;D000067699:Ataxin-3;D001362:Avoidance Learning;D001522:Behavior, Animal;D060825:Cognitive Dysfunction;D004195:Disease Models, Animal;D005260:Female;D006624:Hippocampus;D000069077:Memory Consolidation;D008569:Memory Disorders;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D064446:Orexin Receptors;D000068797:Orexins;D012333:RNA, Messenger",2018,187
28701075,The effect of orexin-A on motor and cognitive functions in a rat model of Parkinson's disease.,"D000818:Animals;D001362:Avoidance Learning;D003072:Cognition Disorders;D004195:Disease Models, Animal;D008297:Male;D008845:Microinjections;D009043:Motor Activity;D053580:Muscle Strength;D000068797:Orexins;D016627:Oxidopamine;D010300:Parkinson Disease;D051381:Rats;D017208:Rats, Wistar;D045442:Rotarod Performance Test;D018709:Statistics, Nonparametric",2018,188
28620314,Orexin System: The Key for a Healthy Life.,emotional stress;narcolepsy;obesity;orexin,2017,189
28588546,Neuroprotective Effects of Physical Activity: Evidence from Human and Animal Studies.,growth factors;hippocampus;neurogenesis;orexins;physical activity and wellbeing,2017,6
28389870,Orexin Directly Enhances the Excitability of Globus Pallidus Internus Neurons in Rat by Co-activating OX1 and OX2 Receptors.,"D000200:Action Potentials;D000818:Animals;D004305:Dose-Response Relationship, Drug;D004558:Electric Stimulation;D018691:Excitatory Amino Acid Antagonists;D005260:Female;D005917:Globus Pallidus;D066298:In Vitro Techniques;D007395:Interneurons;D007546:Isoquinolines;D008297:Male;D064446:Orexin Receptors;D000068797:Orexins;D018408:Patch-Clamp Techniques;D011724:Pyridazines;D011725:Pyridines;D011810:Quinoxalines;D051381:Rats;D017207:Rats, Sprague-Dawley;D026941:Sodium Channel Blockers;D013779:Tetrodotoxin",2018,190
28261108,Exercise Influence on Hippocampal Function: Possible Involvement of Orexin-A.,cognition;depression;exercise;hippocampus;mood;neurogenesis;orexins;plasticity,2017,189
27909990,Orexin/Hypocretin Signaling.,D000818:Animals;D006801:Humans;D064446:Orexin Receptors;D000068797:Orexins;D015398:Signal Transduction,2017,191
27814668,Orexin-A Protects Human Neuroblastoma SH-SY5Y Cells Against 6-Hydroxydopamine-Induced Neurotoxicity: Involvement of PKC and PI3K Signaling Pathways.,"D053119:Benzophenanthridines;D002118:Calcium;D002227:Carbazoles;D045744:Cell Line, Tumor;D002470:Cell Survival;D002867:Chromones;D051546:Cyclooxygenase 2;D018840:HSP70 Heat-Shock Proteins;D006801:Humans;D042541:Intracellular Space;D053078:Membrane Potential, Mitochondrial;D009025:Morpholines;D051267:NF-E2-Related Factor 2;D009447:Neuroblastoma;D018696:Neuroprotective Agents;D009498:Neurotoxins;D064446:Orexin Receptors;D000068797:Orexins;D016627:Oxidopamine;D019869:Phosphatidylinositol 3-Kinases;D011493:Protein Kinase C;D047428:Protein Kinase Inhibitors;D011758:Pyrroles;D015398:Signal Transduction",2017,192
27796054,Orexin-A increases the firing activity of hippocampal CA1 neurons through orexin-1 receptors.,"D000200:Action Potentials;D000818:Animals;D056547:CA1 Region, Hippocampal;D008297:Male;D009474:Neurons;D064446:Orexin Receptors;D000068797:Orexins;D051381:Rats;D017208:Rats, Wistar",2018,193
27665420,Exercise increases the level of plasma orexin A in humans.,D000328:Adult;D015415:Biomarkers;D001831:Body Temperature;D015444:Exercise;D005080:Exercise Test;D005334:Fever;D006339:Heart Rate;D006801:Humans;D008297:Male;D000068797:Orexins;D055815:Young Adult,2017,194
27336845,Orexin-A increases the activity of globus pallidus neurons in both normal and parkinsonian rats.,"D000200:Action Potentials;D000818:Animals;D001583:Benzoxazoles;D005917:Globus Pallidus;D006220:Haloperidol;D008297:Male;D009474:Neurons;D000068796:Orexin Receptor Antagonists;D064446:Orexin Receptors;D000068797:Orexins;D016627:Oxidopamine;D010300:Parkinson Disease;D004856:Postural Balance;D051381:Rats;D017208:Rats, Wistar;D014508:Urea",2017,146
27301294,Functional interaction between orexin-1 and CB1 receptors in the periaqueductal gray matter during antinociception induced by chemical stimulation of the lateral hypothalamus in rats.,"D000818:Animals;D001583:Benzoxazoles;D002217:Carbachol;D004195:Disease Models, Animal;D007026:Hypothalamic Area, Lateral;D008297:Male;D008845:Microinjections;D064446:Orexin Receptors;D000068797:Orexins;D010146:Pain;D010147:Pain Measurement;D010487:Periaqueductal Gray;D010880:Piperidines;D011720:Pyrazoles;D051381:Rats;D017208:Rats, Wistar;D043884:Receptor, Cannabinoid, CB1;D013268:Stimulation, Chemical;D014508:Urea",2018,195
27245919,Low BDNF is associated with cognitive impairments in patients with Parkinson's disease.,D000368:Aged;D000704:Analysis of Variance;D019208:Brain-Derived Neurotrophic Factor;D060825:Cognitive Dysfunction;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D012044:Regression Analysis,2018,20
26944151,Relationship of circulatory BDNF with cognitive deficits in people with Parkinson's disease.,D000328:Adult;D000368:Aged;D019208:Brain-Derived Neurotrophic Factor;D003072:Cognition Disorders;D003430:Cross-Sectional Studies;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D012189:Retrospective Studies,2016,113
25866368,Heterodimerization of human orexin receptor 1 and kappa opioid receptor promotes protein kinase A/cAMP-response element binding protein signaling via a Gαs-mediated mechanism.,"D000818:Animals;D002118:Calcium;D000242:Cyclic AMP;D017362:Cyclic AMP Response Element-Binding Protein;D017868:Cyclic AMP-Dependent Protein Kinases;D019281:Dimerization;D031541:Fluorescence Resonance Energy Transfer;D043802:GTP-Binding Protein alpha Subunits, Gq-G11;D057809:HEK293 Cells;D006624:Hippocampus;D006801:Humans;D008297:Male;D064446:Orexin Receptors;D000068797:Orexins;D010766:Phosphorylation;D051381:Rats;D017207:Rats, Sprague-Dawley;D017473:Receptors, Opioid, kappa;D020218:Response Elements;D015398:Signal Transduction",2016,196
25852518,A pilot study on the effect of cognitive training on BDNF serum levels in individuals with Parkinson's disease.,BDNF;Parkinson’s disease;cognitive deficits;cognitive rehabilitation;serum levels,2015,4
25511388,Roles of the orexin system in central motor control.,D000818:Animals;D001921:Brain;D004525:Efferent Pathways;D006801:Humans;D047908:Intracellular Signaling Peptides and Proteins;D009043:Motor Activity;D009479:Neuropeptides;D000068797:Orexins;D013116:Spinal Cord,2015,176
25328140,"Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques.",D000818:Animals;D002452:Cell Count;D016923:Cell Death;D007031:Hypothalamus;D007150:Immunohistochemistry;D047908:Intracellular Signaling Peptides and Proteins;D020267:MPTP Poisoning;D008252:Macaca fascicularis;D009434:Neural Pathways;D009474:Neurons;D009479:Neuropeptides;D000068797:Orexins;D065842:Pars Compacta;D010784:Photomicrography;D013378:Substantia Nigra;D017557:Ventral Tegmental Area,2015,146
25038418,Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson's disease.,"D002460:Cell Line;D006801:Humans;D051795:Hypoxia-Inducible Factor 1, alpha Subunit;D047908:Intracellular Signaling Peptides and Proteins;D020267:MPTP Poisoning;D009479:Neuropeptides;D018696:Neuroprotective Agents;D000068797:Orexins;D013489:Suppression, Genetic;D042461:Vascular Endothelial Growth Factor A",2015,14
24389262,Parkinson's disease: a review.,D000367:Age Factors;D006801:Humans;D010300:Parkinson Disease,2014,197
24321199,Orexin-A-induced ERK1/2 activation reverses impaired spatial learning and memory in pentylenetetrazol-kindled rats via OX1R-mediated hippocampal neurogenesis.,"D000818:Animals;D001583:Benzoxazoles;D004789:Enzyme Activation;D006624:Hippocampus;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D018782:Maze Learning;D008568:Memory;D019950:Mitogen-Activated Protein Kinase 1;D048052:Mitogen-Activated Protein Kinase 3;D055495:Neurogenesis;D009479:Neuropeptides;D000068796:Orexin Receptor Antagonists;D064446:Orexin Receptors;D000068797:Orexins;D010433:Pentylenetetrazole;D017208:Rats, Wistar;D065853:Spatial Learning;D014508:Urea",2015,198
24135219,Protective effect of orexin-A on 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells.,"D045744:Cell Line, Tumor;D004298:Dopamine;D006801:Humans;D047908:Intracellular Signaling Peptides and Proteins;D009447:Neuroblastoma;D009479:Neuropeptides;D000068797:Orexins;D016627:Oxidopamine;D017382:Reactive Oxygen Species;D013050:Spectrometry, Fluorescence",2014,199
24102345,The hypocretins/orexins: integrators of multiple physiological functions.,"D000818:Animals;D001143:Arousal;D003071:Cognition;D004734:Energy Metabolism;D006801:Humans;D047908:Intracellular Signaling Peptides and Proteins;D008124:Locomotion;D009479:Neuropeptides;D064446:Orexin Receptors;D000068797:Orexins;D012201:Reward;D012677:Sensation;D012890:Sleep;D013315:Stress, Psychological",2014,200
24089383,Role of the locus coeruleus in enhanced orexin A-induced spontaneous physical activity in obesity-resistant rats.,"D050154:Adiposity;D000818:Animals;D001823:Body Composition;D004734:Energy Metabolism;D047908:Intracellular Signaling Peptides and Proteins;D008125:Locus Coeruleus;D008297:Male;D009043:Motor Activity;D009479:Neuropeptides;D009765:Obesity;D000068797:Orexins;D010641:Phenotype;D051381:Rats;D017207:Rats, Sprague-Dawley",2014,201
24068427,Orexin-A activates hypothalamic AMP-activated protein kinase signaling through a Ca²⁺-dependent mechanism involving voltage-gated L-type calcium channel.,"D055372:AMP-Activated Protein Kinases;D000818:Animals;D001111:Arcuate Nucleus of Hypothalamus;D002118:Calcium;D020746:Calcium Channels, L-Type;D054737:Calcium-Calmodulin-Dependent Protein Kinase Kinase;D002478:Cells, Cultured;D005247:Feeding Behavior;D047908:Intracellular Signaling Peptides and Proteins;D015640:Ion Channel Gating;D008297:Male;D009474:Neurons;D009478:Neuropeptide Y;D009479:Neuropeptides;D064446:Orexin Receptors;D000068797:Orexins;D011493:Protein Kinase C;D051381:Rats;D017207:Rats, Sprague-Dawley;D015398:Signal Transduction;D010738:Type C Phospholipases",2014,202
24041616,Cellular location and major terminal networks of the orexinergic system in the brain of two megachiropterans.,D000818:Animals;D001921:Brain;D002685:Chiroptera;D007150:Immunohistochemistry;D047908:Intracellular Signaling Peptides and Proteins;D009474:Neurons;D009479:Neuropeptides;D000068797:Orexins,2014,203
23516292,Hypocretin/orexin neurons contribute to hippocampus-dependent social memory and synaptic plasticity in mice.,"D000818:Animals;D000067699:Ataxin-3;D056547:CA1 Region, Hippocampal;D017362:Cyclic AMP Response Element-Binding Protein;D005260:Female;D006185:Habituation, Psychophysiologic;D007026:Hypothalamic Area, Lateral;D047908:Intracellular Signaling Peptides and Proteins;D017774:Long-Term Potentiation;D008297:Male;D008569:Memory Disorders;D057567:Memory, Long-Term;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D009434:Neural Pathways;D009473:Neuronal Plasticity;D009474:Neurons;D009479:Neuropeptides;D009687:Nuclear Proteins;D000068797:Orexins;D009924:Organ Culture Techniques;D055139:Sensory Gating;D012903:Smell;D012919:Social Behavior;D014157:Transcription Factors",2013,49
23396085,BDNF receptor blockade hinders the beneficial effects of exercise in a rat model of Parkinson's disease.,"D000704:Analysis of Variance;D000818:Animals;D001058:Apomorphine;D002227:Carbazoles;D003342:Corpus Striatum;D004195:Disease Models, Animal;D004791:Enzyme Inhibitors;D005080:Exercise Test;D005081:Exercise Therapy;D005786:Gene Expression Regulation;D026121:Indole Alkaloids;D008297:Male;D016627:Oxidopamine;D010300:Parkinson Disease;D011699:Putamen;D051381:Rats;D017208:Rats, Wistar;D020813:Receptor, trkB;D013239:Stereotyped Behavior;D013997:Time Factors;D014446:Tyrosine 3-Monooxygenase",2013,106
23299718,Central functions of the orexinergic system.,D000818:Animals;D001921:Brain;D006801:Humans;D047908:Intracellular Signaling Peptides and Proteins;D009474:Neurons;D009479:Neuropeptides;D000068797:Orexins;D012890:Sleep;D014851:Wakefulness,2013,190
23117790,Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor.,"D000818:Animals;D001362:Avoidance Learning;D001786:Blood Glucose;D015153:Blotting, Western;D002545:Brain Ischemia;D019208:Brain-Derived Neurotrophic Factor;D002544:Cerebral Infarction;D018149:Glucose Intolerance;D005954:Glucosephosphate Dehydrogenase;D007031:Hypothalamus;D007150:Immunohistochemistry;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D008568:Memory;D051379:Mice;D008845:Microinjections;D009460:Neurologic Examination;D009474:Neurons;D009479:Neuropeptides;D000068797:Orexins;D019764:Phosphoenolpyruvate Carboxykinase (ATP);D016760:Proto-Oncogene Proteins c-fos;D034741:RNA, Small Interfering;D011972:Receptor, Insulin",2013,204
22203796,"Enhanced training protects memory against amnesia produced by concurrent inactivation of amygdala and striatum, amygdala and substantia nigra, or striatum and substantia nigra.",TTX;amnesia;amygdala;inhibitory avoidance;memory consolidation;striatum;substantia nigra,2011,205
21935673,Orexinergic innervation of the extended amygdala and basal ganglia in the rat.,"D000679:Amygdala;D000818:Animals;D001369:Axons;D001479:Basal Ganglia;D022081:Cell Surface Extensions;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D009434:Neural Pathways;D009474:Neurons;D009479:Neuropeptides;D000068797:Orexins;D051381:Rats;D017208:Rats, Wistar",2012,167
21739363,Orexin a in cortical cultures: expression and effect on synaptogenesis during development.,"D000818:Animals;D000831:Animals, Newborn;D002478:Cells, Cultured;D002540:Cerebral Cortex;D018507:Gene Expression Regulation, Developmental;D007150:Immunohistochemistry;D047908:Intracellular Signaling Peptides and Proteins;D009415:Nerve Net;D055495:Neurogenesis;D009457:Neuroglia;D009474:Neurons;D009479:Neuropeptides;D064446:Orexin Receptors;D000068797:Orexins;D009924:Organ Culture Techniques;D051381:Rats;D017208:Rats, Wistar;D043562:Receptors, G-Protein-Coupled;D018013:Receptors, Neuropeptide;D013569:Synapses;D016708:Synaptophysin;D033921:Vesicular Transport Proteins",2012,206
21338887,A role for orexin in central vestibular motor control.,"D000704:Analysis of Variance;D000818:Animals;D000831:Animals, Newborn;D001522:Behavior, Animal;D001583:Benzoxazoles;D004347:Drug Interactions;D004558:Electric Stimulation;D005106:Exploratory Behavior;D019417:Hindlimb Suspension;D066298:In Vitro Techniques;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D008564:Membrane Potentials;D008845:Microinjections;D009043:Motor Activity;D009474:Neurons;D009479:Neuropeptides;D000068797:Orexins;D018408:Patch-Clamp Techniques;D011597:Psychomotor Performance;D051381:Rats;D018013:Receptors, Neuropeptide;D019831:Sodium-Calcium Exchanger;D013890:Thiourea;D014508:Urea;D003689:Vestibular Nucleus, Lateral",2011,42
21236244,Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease.,"D018663:Adrenergic Agents;D000818:Animals;D019208:Brain-Derived Neurotrophic Factor;D004298:Dopamine;D005260:Female;D005455:Fluorescent Antibody Technique;D051100:Glial Cell Line-Derived Neurotrophic Factor;D007150:Immunohistochemistry;D008297:Male;D008636:Mesencephalon;D018613:Microscopy, Confocal;D009474:Neurons;D018696:Neuroprotective Agents;D009924:Organ Culture Techniques;D016627:Oxidopamine;D010300:Parkinson Disease;D051381:Rats;D017208:Rats, Wistar;D020133:Reverse Transcriptase Polymerase Chain Reaction",2011,207
21205893,TrkB receptor controls striatal formation by regulating the number of newborn striatal neurons.,"D000818:Animals;D000831:Animals, Newborn;D017209:Apoptosis;D019208:Brain-Derived Neurotrophic Factor;D002452:Cell Count;D003342:Corpus Striatum;D015536:Down-Regulation;D004745:Enkephalins;D005260:Female;D018398:Homeodomain Proteins;D015151:Immunoblotting;D007150:Immunohistochemistry;D017403:In Situ Hybridization;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D018345:Mice, Knockout;D008822:Mice, Transgenic;D009474:Neurons;D020813:Receptor, trkB;D017448:Receptors, Dopamine D2;D013997:Time Factors",2011,12
21192928,Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration.,"D000818:Animals;D003342:Corpus Striatum;D004298:Dopamine;D051379:Mice;D057507:Mice, 129 Strain;D008810:Mice, Inbred C57BL;D008818:Mice, Neurologic Mutants;D009410:Nerve Degeneration;D010300:Parkinson Disease;D011897:Random Allocation;D020813:Receptor, trkB;D015398:Signal Transduction;D013378:Substantia Nigra;D013997:Time Factors",2011,81
20882064,Progressive changes of orexin system in a rat model of 6-hydroxydopamine-induced Parkinson's disease.,"D000818:Animals;D004195:Disease Models, Animal;D018450:Disease Progression;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D008474:Medial Forebrain Bundle;D009479:Neuropeptides;D000068797:Orexins;D016627:Oxidopamine;D020734:Parkinsonian Disorders;D011897:Random Allocation;D051381:Rats;D017207:Rats, Sprague-Dawley",2011,190
20728473,Orexin-1 receptor mediates long-term potentiation in the dentate gyrus area of freely moving rats.,"D000704:Analysis of Variance;D000818:Animals;D001583:Benzoxazoles;D018891:Dentate Gyrus;D004558:Electric Stimulation;D004594:Electrophysiology;D017774:Long-Term Potentiation;D008297:Male;D009474:Neurons;D064446:Orexin Receptors;D051381:Rats;D017208:Rats, Wistar;D043562:Receptors, G-Protein-Coupled;D018013:Receptors, Neuropeptide;D013569:Synapses;D014508:Urea",2011,208
19921532,Orexins excite neurons of the rat cerebellar nucleus interpositus via orexin 2 receptors in vitro.,"D000200:Action Potentials;D000818:Animals;D001583:Benzoxazoles;D002529:Cerebellar Nuclei;D047908:Intracellular Signaling Peptides and Proteins;D009474:Neurons;D009479:Neuropeptides;D064446:Orexin Receptors;D000068797:Orexins;D009924:Organ Culture Techniques;D018408:Patch-Clamp Techniques;D010455:Peptides;D051381:Rats;D017207:Rats, Sprague-Dawley;D043562:Receptors, G-Protein-Coupled;D018013:Receptors, Neuropeptide;D014508:Urea",2010,209
19847468,Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease.,"D000368:Aged;D000369:Aged, 80 and over;D019208:Brain-Derived Neurotrophic Factor;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011569:Psychiatric Status Rating Scales;D012044:Regression Analysis;D013223:Statistics as Topic;D018709:Statistics, Nonparametric",2010,77
19654017,Cross-talk between orexins (hypocretins) and the neuroendocrine axes (hypothalamic-pituitary axes).,D000818:Animals;D005260:Female;D006066:Gonads;D013007:Growth Hormone-Releasing Hormone;D006801:Humans;D007030:Hypothalamo-Hypophyseal System;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D009479:Neuropeptides;D009490:Neurosecretory Systems;D000068797:Orexins;D010913:Pituitary-Adrenal System;D011388:Prolactin;D015398:Signal Transduction;D012890:Sleep;D013961:Thyroid Gland;D013963:Thyroid Hormones,2010,210
19633949,Orexin-A and orexin-B during the postnatal development of the rat brain.,"D000818:Animals;D000831:Animals, Newborn;D000918:Antibody Specificity;D001921:Brain;D007031:Hypothalamus;D007150:Immunohistochemistry;D047908:Intracellular Signaling Peptides and Proteins;D009412:Nerve Fibers;D009479:Neuropeptides;D000068797:Orexins;D051381:Rats;D017208:Rats, Wistar",2010,206
19026718,Orexins increase mRNA expressions of neurotrophin-3 in rat primary cortical neuron cultures.,"D000818:Animals;D002478:Cells, Cultured;D002540:Cerebral Cortex;D004305:Dose-Response Relationship, Drug;D004622:Embryo, Mammalian;D005260:Female;D047908:Intracellular Signaling Peptides and Proteins;D009474:Neurons;D009479:Neuropeptides;D018377:Neurotransmitter Agents;D020933:Neurotrophin 3;D064446:Orexin Receptors;D000068797:Orexins;D011247:Pregnancy;D012333:RNA, Messenger;D051381:Rats;D043562:Receptors, G-Protein-Coupled;D018013:Receptors, Neuropeptide;D017481:Receptors, Somatostatin",2009,14
18160631,Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates.,"D000281:Administration, Intranasal;D000704:Analysis of Variance;D000818:Animals;D001522:Behavior, Animal;D001931:Brain Mapping;D002540:Cerebral Cortex;D003072:Cognition Disorders;D004305:Dose-Response Relationship, Drug;D019788:Fluorodeoxyglucose F18;D005947:Glucose;D007275:Injections, Intravenous;D047908:Intracellular Signaling Peptides and Proteins;D008253:Macaca mulatta;D008297:Male;D009479:Neuropeptides;D000068797:Orexins;D049268:Positron-Emission Tomography;D011597:Psychomotor Performance;D012892:Sleep Deprivation;D013566:Sympathomimetics;D013647:Task Performance and Analysis",2008,49
18077696,Interactions between the NR2B receptor and CaMKII modulate synaptic plasticity and spatial learning.,"D000818:Animals;D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2;D008024:Ligands;D017774:Long-Term Potentiation;D036881:Long-Term Synaptic Depression;D018782:Maze Learning;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D009473:Neuronal Plasticity;D009474:Neurons;D009924:Organ Culture Techniques;D010766:Phosphorylation;D011960:Receptors, Estrogen;D016194:Receptors, N-Methyl-D-Aspartate;D011993:Recombinant Fusion Proteins;D013569:Synapses;D013629:Tamoxifen",2008,49
17996959,Developmental vitamin D deficiency alters adult behaviour in 129/SvJ and C57BL/6J mice.,"D000704:Analysis of Variance;D000818:Animals;D004195:Disease Models, Animal;D005106:Exploratory Behavior;D005260:Female;D006948:Hyperkinesis;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D009043:Motor Activity;D011247:Pregnancy;D011297:Prenatal Exposure Delayed Effects;D012919:Social Behavior;D013045:Species Specificity;D014808:Vitamin D Deficiency",2008,208
17977608,The effect of antagonization of orexin 1 receptors in CA1 and dentate gyrus regions on memory processing in passive avoidance task.,"D000818:Animals;D001362:Avoidance Learning;D001583:Benzoxazoles;D003627:Data Interpretation, Statistical;D018891:Dentate Gyrus;D004121:Dimethyl Sulfoxide;D006624:Hippocampus;D008297:Male;D008568:Memory;D008845:Microinjections;D064446:Orexin Receptors;D011597:Psychomotor Performance;D051381:Rats;D017208:Rats, Wistar;D043562:Receptors, G-Protein-Coupled;D018013:Receptors, Neuropeptide;D014508:Urea",2008,208
17898005,"Parkinson's disease, sleepiness and hypocretin/orexin.",D006970:Disorders of Excessive Somnolence;D006801:Humans;D047908:Intracellular Signaling Peptides and Proteins;D009479:Neuropeptides;D000068797:Orexins;D010300:Parkinson Disease,2008,36
17619858,Spatial deficits in a mouse model of Parkinson disease.,"D000704:Analysis of Variance;D000818:Animals;D021461:Animals, Outbred Strains;D001362:Avoidance Learning;D001522:Behavior, Animal;D003072:Cognition Disorders;D003627:Data Interpretation, Statistical;D004195:Disease Models, Animal;D004298:Dopamine;D005106:Exploratory Behavior;D006185:Habituation, Psychophysiologic;D007150:Immunohistochemistry;D051379:Mice;D009043:Motor Activity;D009638:Norepinephrine;D009714:Nucleus Accumbens;D016627:Oxidopamine;D010302:Parkinson Disease, Secondary;D015203:Reproducibility of Results;D013028:Space Perception;D013037:Spatial Behavior;D013565:Sympatholytics;D013997:Time Factors",2008,142
17491094,Hypocretin (orexin) cell loss in Parkinson's disease.,"D000368:Aged;D000369:Aged, 80 and over;D002452:Cell Count;D018450:Disease Progression;D005260:Female;D005904:Glial Fibrillary Acidic Protein;D006801:Humans;D007028:Hypothalamic Hormones;D007031:Hypothalamus;D007124:Immunoenzyme Techniques;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D008543:Melanins;D008875:Middle Aged;D009474:Neurons;D009479:Neuropeptides;D000068797:Orexins;D010300:Parkinson Disease;D010907:Pituitary Hormones;D012720:Severity of Illness Index;D013378:Substantia Nigra;D051844:alpha-Synuclein",2007,36
17470494,Hypocretin (orexin) loss in Parkinson's disease.,"D000368:Aged;D000369:Aged, 80 and over;D002452:Cell Count;D005260:Female;D006801:Humans;D007031:Hypothalamus;D007124:Immunoenzyme Techniques;D047908:Intracellular Signaling Peptides and Proteins;D016631:Lewy Bodies;D008297:Male;D008875:Middle Aged;D009474:Neurons;D009479:Neuropeptides;D000068797:Orexins;D010300:Parkinson Disease;D017397:Prefrontal Cortex",2007,36
17115071,Regulation of OX1 orexin/hypocretin receptor-coupling to phospholipase C by Ca2+ influx.,"D000818:Animals;D016466:CHO Cells;D002118:Calcium;D006224:Cricetinae;D003412:Cricetulus;D006801:Humans;D017136:Ion Transport;D064446:Orexin Receptors;D011485:Protein Binding;D043562:Receptors, G-Protein-Coupled;D018013:Receptors, Neuropeptide;D010738:Type C Phospholipases",2007,200
17005202,"CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration.","D000368:Aged;D000369:Aged, 80 and over;D015415:Biomarkers;D002556:Cerebrospinal Fluid Proteins;D018450:Disease Progression;D015536:Down-Regulation;D005260:Female;D006801:Humans;D007031:Hypothalamus;D047908:Intracellular Signaling Peptides and Proteins;D020961:Lewy Body Disease;D008297:Male;D008875:Middle Aged;D009479:Neuropeptides;D000068797:Orexins;D010300:Parkinson Disease;D011237:Predictive Value of Tests;D045743:Scleroderma, Diffuse;D012893:Sleep Wake Disorders;D013129:Spinal Puncture",2007,113
16870307,Orexin neuronal changes in the locus coeruleus of the aging rhesus macaque.,"D000367:Age Factors;D000375:Aging;D000704:Analysis of Variance;D000818:Animals;D007026:Hypothalamic Area, Lateral;D017403:In Situ Hybridization;D047908:Intracellular Signaling Peptides and Proteins;D008125:Locus Coeruleus;D008253:Macaca mulatta;D008297:Male;D009474:Neurons;D009479:Neuropeptides;D000068797:Orexins;D014446:Tyrosine 3-Monooxygenase",2007,87
16809007,Orexin A mediation of time spent moving in rats: neural mechanisms.,"D000704:Analysis of Variance;D000818:Animals;D001522:Behavior, Animal;D001552:Benzazepines;D018492:Dopamine Antagonists;D004305:Dose-Response Relationship, Drug;D004347:Drug Interactions;D018755:GABA Agonists;D007026:Hypothalamic Area, Lateral;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D009068:Movement;D009118:Muscimol;D009479:Neuropeptides;D000068797:Orexins;D010286:Paraventricular Hypothalamic Nucleus;D051381:Rats;D017207:Rats, Sprague-Dawley;D013378:Substantia Nigra;D013997:Time Factors",2006,106
16402079,Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.,D000978:Antiparkinson Agents;D019208:Brain-Derived Neurotrophic Factor;D006801:Humans;D010300:Parkinson Disease,2006,211
15979595,Orexin A in the nucleus accumbens stimulates feeding and locomotor activity.,"D000818:Animals;D001583:Benzoxazoles;D005247:Feeding Behavior;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D008845:Microinjections;D009043:Motor Activity;D009479:Neuropeptides;D009714:Nucleus Accumbens;D000068797:Orexins;D051381:Rats;D017207:Rats, Sprague-Dawley;D014508:Urea",2005,207
15698637,Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.,"D000818:Animals;D001667:Binding, Competitive;D019208:Brain-Derived Neurotrophic Factor;D016923:Cell Death;D002470:Cell Survival;D004195:Disease Models, Animal;D004298:Dopamine;D018765:Dopamine Uptake Inhibitors;D015536:Down-Regulation;D008297:Male;D008454:Mazindol;D009410:Nerve Degeneration;D009474:Neurons;D018696:Neuroprotective Agents;D016376:Oligonucleotides, Antisense;D020734:Parkinsonian Disorders;D012333:RNA, Messenger;D011869:Radioligand Assay;D051381:Rats;D017207:Rats, Sprague-Dawley;D011954:Receptors, Dopamine;D013378:Substantia Nigra;D014446:Tyrosine 3-Monooxygenase",2005,81
15203246,Orexin-A (Hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats in vivo.,"D000818:Animals;D001583:Benzoxazoles;D018891:Dentate Gyrus;D004305:Dose-Response Relationship, Drug;D047908:Intracellular Signaling Peptides and Proteins;D020738:Leptin;D017774:Long-Term Potentiation;D009479:Neuropeptides;D000068797:Orexins;D051381:Rats;D017207:Rats, Sprague-Dawley;D014508:Urea",2005,198
15132732,Orexin A suppresses in vivo GH secretion.,"D000204:Activity Cycles;D000818:Animals;D019540:Area Under Curve;D002352:Carrier Proteins;D054439:Ghrelin;D013006:Growth Hormone;D013007:Growth Hormone-Releasing Hormone;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D009479:Neuropeptides;D000068797:Orexins;D036361:Peptide Hormones;D051381:Rats;D017207:Rats, Sprague-Dawley",2004,212
15090035,Orexin-A regulates growth hormone-releasing hormone mRNA content in a nucleus-specific manner and somatostatin mRNA content in a growth hormone-dependent fashion in the rat hypothalamus.,"D000818:Animals;D001111:Arcuate Nucleus of Hypothalamus;D002352:Carrier Proteins;D013007:Growth Hormone-Releasing Hormone;D007031:Hypothalamus;D007276:Injections, Intraventricular;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D009479:Neuropeptides;D000068797:Orexins;D010286:Paraventricular Hypothalamic Nucleus;D012333:RNA, Messenger;D051381:Rats;D011917:Rats, Inbred Lew;D017207:Rats, Sprague-Dawley;D013004:Somatostatin",2004,146
14656716,Orexin A (hypocretin 1) injected into hypothalamic paraventricular nucleus and spontaneous physical activity in rats.,"D000818:Animals;D001583:Benzoxazoles;D002153:Calorimetry, Indirect;D002245:Carbon Dioxide;D002352:Carrier Proteins;D004305:Dose-Response Relationship, Drug;D005247:Feeding Behavior;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D008845:Microinjections;D009043:Motor Activity;D009479:Neuropeptides;D000068797:Orexins;D010101:Oxygen Consumption;D010286:Paraventricular Hypothalamic Nucleus;D051381:Rats;D017207:Rats, Sprague-Dawley;D022722:Thermogenesis;D014508:Urea",2004,213
12939433,Low levels of ventricular CSF orexin/hypocretin in advanced PD.,D000978:Antiparkinson Agents;D001143:Arousal;D002352:Carrier Proteins;D002552:Cerebral Ventricles;D003131:Combined Modality Therapy;D006970:Disorders of Excessive Somnolence;D004599:Electric Stimulation Therapy;D005260:Female;D006801:Humans;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D009479:Neuropeptides;D000068797:Orexins;D010300:Parkinson Disease,2004,53
12796537,Alteration of the striatal dopaminergic system in human narcolepsy.,"D000368:Aged;D001549:Benzamides;D003342:Corpus Striatum;D050483:Dopamine Plasma Membrane Transport Proteins;D005260:Female;D006801:Humans;D007457:Iodine Radioisotopes;D008279:Magnetic Resonance Imaging;D008297:Male;D008562:Membrane Glycoproteins;D026901:Membrane Transport Proteins;D008875:Middle Aged;D009290:Narcolepsy;D009419:Nerve Tissue Proteins;D011759:Pyrrolidines;D017448:Receptors, Dopamine D2;D015899:Tomography, Emission-Computed, Single-Photon;D014326:Tropanes",2004,53
12469866,The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.,"D000818:Animals;D002110:Caffeine;D004195:Disease Models, Animal;D006801:Humans;D007980:Levodopa;D008569:Memory Disorders;D009474:Neurons;D020734:Parkinsonian Disorders;D051381:Rats;D011954:Receptors, Dopamine;D018047:Receptors, Purinergic P1;D013378:Substantia Nigra",2003,206
12217429,Effects of orexin-A on memory processing.,"D016229:Amyloid beta-Peptides;D000818:Animals;D001362:Avoidance Learning;D001921:Brain;D002352:Carrier Proteins;D004305:Dose-Response Relationship, Drug;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D018782:Maze Learning;D008568:Memory;D051379:Mice;D009479:Neuropeptides;D000068797:Orexins;D013997:Time Factors",2003,198
11830288,Protein distribution of the orexin-2 receptor in the rat central nervous system.,"D000818:Animals;D015153:Blotting, Western;D001933:Brain Stem;D016466:CHO Cells;D002490:Central Nervous System;D002531:Cerebellum;D006224:Cricetinae;D007150:Immunohistochemistry;D008297:Male;D008636:Mesencephalon;D064446:Orexin Receptors;D051381:Rats;D017208:Rats, Wistar;D043562:Receptors, G-Protein-Coupled;D018013:Receptors, Neuropeptide;D020133:Reverse Transcriptase Polymerase Chain Reaction;D012249:Rhombencephalon;D013116:Spinal Cord;D013687:Telencephalon;D014018:Tissue Distribution;D014162:Transfection",2002,214
11830281,Selective excitation of GABAergic neurons in the substantia nigra of the rat by orexin/hypocretin in vitro.,"D000818:Animals;D002227:Carbazoles;D002352:Carrier Proteins;D004298:Dopamine;D004594:Electrophysiology;D007211:Indoles;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D009474:Neurons;D009479:Neuropeptides;D000068797:Orexins;D011758:Pyrroles;D051381:Rats;D017208:Rats, Wistar;D015398:Signal Transduction;D013378:Substantia Nigra;D019284:Thapsigargin;D005680:gamma-Aminobutyric Acid",2002,214
11830273,Feeding and activity induced by orexin A in the lateral hypothalamus in rats.,"D000818:Animals;D002352:Carrier Proteins;D002940:Circadian Rhythm;D004435:Eating;D007026:Hypothalamic Area, Lateral;D007276:Injections, Intraventricular;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D009043:Motor Activity;D009479:Neuropeptides;D000068797:Orexins;D051381:Rats;D017207:Rats, Sprague-Dawley",2002,214
11810033,"Neuropeptide Y, but not agouti-related peptide or melanin-concentrating hormone, is a target peptide for orexin-A feeding actions in the rat hypothalamus.","D054369:Agouti-Related Protein;D000818:Animals;D001111:Arcuate Nucleus of Hypothalamus;D002352:Carrier Proteins;D005247:Feeding Behavior;D015870:Gene Expression;D007026:Hypothalamic Area, Lateral;D007028:Hypothalamic Hormones;D036341:Intercellular Signaling Peptides and Proteins;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D008543:Melanins;D009478:Neuropeptide Y;D009479:Neuropeptides;D064446:Orexin Receptors;D000068797:Orexins;D010907:Pituitary Hormones;D011498:Protein Precursors;D011506:Proteins;D012333:RNA, Messenger;D051381:Rats;D017207:Rats, Sprague-Dawley;D043562:Receptors, G-Protein-Coupled;D018013:Receptors, Neuropeptide",2002,215
11370008,Differential expression of orexin receptors 1 and 2 in the rat brain.,"D000818:Animals;D001341:Autonomic Nervous System;D002540:Cerebral Cortex;D005247:Feeding Behavior;D015870:Gene Expression;D006624:Hippocampus;D007026:Hypothalamic Area, Lateral;D017403:In Situ Hybridization;D008125:Locus Coeruleus;D008297:Male;D020644:Midline Thalamic Nuclei;D009290:Narcolepsy;D064446:Orexin Receptors;D012333:RNA, Messenger;D011903:Raphe Nuclei;D051381:Rats;D017207:Rats, Sprague-Dawley;D043562:Receptors, G-Protein-Coupled;D018013:Receptors, Neuropeptide;D012890:Sleep;D013047:Specific Pathogen-Free Organisms;D014697:Ventromedial Hypothalamic Nucleus",2001,216
11328454,The role of neuropeptide Y in orexin-induced hypothalamic-pituitary-adrenal activation.,"D000818:Animals;D000906:Antibodies;D002352:Carrier Proteins;D007030:Hypothalamo-Hypophyseal System;D007276:Injections, Intraventricular;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D009478:Neuropeptide Y;D009479:Neuropeptides;D000068797:Orexins;D010913:Pituitary-Adrenal System;D051381:Rats;D017208:Rats, Wistar",2001,217
11274794,Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord.,"D000818:Animals;D001921:Brain;D002460:Cell Line;D005727:Ganglia, Spinal;D015870:Gene Expression;D006801:Humans;D007150:Immunohistochemistry;D017403:In Situ Hybridization;D008297:Male;D064446:Orexin Receptors;D012333:RNA, Messenger;D051381:Rats;D017207:Rats, Sprague-Dawley;D043562:Receptors, G-Protein-Coupled;D018013:Receptors, Neuropeptide;D020133:Reverse Transcriptase Polymerase Chain Reaction;D013116:Spinal Cord;D014018:Tissue Distribution;D014162:Transfection",2001,106
11250867,SB-334867-A: the first selective orexin-1 receptor antagonist.,"D000818:Animals;D001583:Benzoxazoles;D016466:CHO Cells;D006224:Cricetinae;D004305:Dose-Response Relationship, Drug;D005470:Fluorometry;D006801:Humans;D064446:Orexin Receptors;D043562:Receptors, G-Protein-Coupled;D018013:Receptors, Neuropeptide;D014162:Transfection;D014508:Urea",2001,200
11031089,Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.,"D000368:Aged;D000369:Aged, 80 and over;D019208:Brain-Derived Neurotrophic Factor;D004298:Dopamine;D006801:Humans;D017403:In Situ Hybridization;D008875:Middle Aged;D009410:Nerve Degeneration;D009474:Neurons;D010300:Parkinson Disease;D012333:RNA, Messenger;D013378:Substantia Nigra",2001,81
10915829,Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system.,"D000818:Animals;D001369:Axons;D001522:Behavior, Animal;D001552:Benzazepines;D002352:Carrier Proteins;D004298:Dopamine;D018492:Dopamine Antagonists;D006220:Haloperidol;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D009043:Motor Activity;D009411:Nerve Endings;D009474:Neurons;D009479:Neuropeptides;D000068797:Orexins;D051381:Rats;D017208:Rats, Wistar;D013239:Stereotyped Behavior;D013469:Sulpiride;D013681:Tegmentum Mesencephali;D014446:Tyrosine 3-Monooxygenase",2000,207
10718305,Identification of potential compounds promoting BDNF production in nigral dopaminergic neurons: clinical implication in Parkinson's disease.,"D019208:Brain-Derived Neurotrophic Factor;D002460:Cell Line;D004298:Dopamine;D006801:Humans;D009474:Neurons;D009479:Neuropeptides;D018377:Neurotransmitter Agents;D010300:Parkinson Disease;D015398:Signal Transduction;D013268:Stimulation, Chemical;D013378:Substantia Nigra",2000,218
10698122,Differential distribution of orexin-A and orexin-B immunoreactivity in the rat brain and spinal cord.,"D000595:Amino Acid Sequence;D000818:Animals;D000918:Antibody Specificity;D001921:Brain;D002352:Carrier Proteins;D004435:Eating;D007031:Hypothalamus;D007150:Immunohistochemistry;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D008969:Molecular Sequence Data;D009479:Neuropeptides;D000068797:Orexins;D051381:Rats;D017208:Rats, Wistar;D013116:Spinal Cord;D014018:Tissue Distribution",2000,198
9822755,Neurons containing hypocretin (orexin) project to multiple neuronal systems.,"D000818:Animals;D000918:Antibody Specificity;D001794:Blood Pressure;D001923:Brain Chemistry;D002352:Carrier Proteins;D003712:Dendrites;D004435:Eating;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D008854:Microscopy, Electron;D009412:Nerve Fibers;D009475:Neurons, Afferent;D009476:Neurons, Efferent;D009479:Neuropeptides;D018377:Neurotransmitter Agents;D000068797:Orexins;D051381:Rats;D017208:Rats, Wistar",1998,49
9491897,Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.,"D000818:Animals;D016466:CHO Cells;D002352:Carrier Proteins;D002851:Chromatography, High Pressure Liquid;D006224:Cricetinae;D005215:Fasting;D005247:Feeding Behavior;D019204:GTP-Binding Proteins;D006801:Humans;D007031:Hypothalamus;D047908:Intracellular Signaling Peptides and Proteins;D007668:Kidney;D008297:Male;D008969:Molecular Sequence Data;D009474:Neurons;D009479:Neuropeptides;D064446:Orexin Receptors;D000068797:Orexins;D011498:Protein Precursors;D012333:RNA, Messenger;D011817:Rabbits;D051381:Rats;D017208:Rats, Wistar;D043562:Receptors, G-Protein-Coupled;D018013:Receptors, Neuropeptide;D017386:Sequence Homology, Amino Acid",1998,41
9130677,Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion.,"D000818:Animals;D004195:Disease Models, Animal;D004298:Dopamine;D008297:Male;D051379:Mice;D008813:Mice, Inbred ICR;D009069:Movement Disorders;D016627:Oxidopamine;D014793:Visual Cortex",1997,219
8559303,"Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.","D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine;D000818:Animals;D001921:Brain;D019208:Brain-Derived Neurotrophic Factor;D008251:Macaca;D009410:Nerve Degeneration;D009414:Nerve Growth Factors;D009419:Nerve Tissue Proteins;D009460:Neurologic Examination;D010302:Parkinson Disease, Secondary;D013378:Substantia Nigra;D014446:Tyrosine 3-Monooxygenase",1995,220
6471907,Developments of a water-maze procedure for studying spatial learning in the rat.,D000818:Animals;D003463:Cues;D004193:Discrimination Learning;D004924:Escape Reaction;D005260:Female;D008297:Male;D011939:Mental Recall;D009482:Neurophysiology;D009949:Orientation;D051381:Rats;D012153:Retention (Psychology);D013550:Swimming;D014163:Transfer (Psychology),1984,219
4714294,"Memory disruption by electrical stimulation of substantia nigra, pars compacta.","D000818:Animals;D001362:Avoidance Learning;D001933:Brain Stem;D004558:Electric Stimulation;D004567:Electrodes, Implanted;D008297:Male;D008526:Medulla Oblongata;D008568:Memory;D008636:Mesencephalon;D051381:Rats;D012012:Red Nucleus;D012154:Reticular Formation;D013378:Substantia Nigra;D013997:Time Factors",1973,18
3185926,Cognition in parkinsonism.,D003071:Cognition;D006801:Humans;D010300:Parkinson Disease;D011597:Psychomotor Performance,1988,53
2881444,Biochemical pathophysiology of Parkinson's disease.,"D001921:Brain;D002374:Catalase;D003342:Corpus Striatum;D004298:Dopamine;D005978:Glutathione;D006801:Humans;D008032:Limbic System;D008636:Mesencephalon;D009434:Neural Pathways;D009473:Neuronal Plasticity;D018377:Neurotransmitter Agents;D010084:Oxidation-Reduction;D010300:Parkinson Disease;D010544:Peroxidases;D017981:Receptors, Neurotransmitter;D013378:Substantia Nigra",1987,221
239718,Parkinson's disease and its chemotherapy.,D000978:Antiparkinson Agents;D001479:Basal Ganglia;D003342:Corpus Striatum;D004298:Dopamine;D006801:Humans;D007980:Levodopa;D018377:Neurotransmitter Agents;D010300:Parkinson Disease,1975,222
30190461,Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel.,D000818:Animals;D015374:Biosensing Techniques;D020285:Cryoelectron Microscopy;D031541:Fluorescence Resonance Energy Transfer;D057809:HEK293 Cells;D006801:Humans;D016716:PC12 Cells;D011487:Protein Conformation;D051381:Rats;D011994:Recombinant Proteins;D014961:X-Ray Diffraction;D051844:alpha-Synuclein,2018,30
30093536,14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.,14-3-3 proteins;Parkinson's disease;aggregation;dementia with Lewy bodies;exosome;α-synuclein,2018,49
30065316,Amyloid fibril structure of α-synuclein determined by cryo-electron microscopy.,,2018,223
29969391,Cryo-EM structure of alpha-synuclein fibrils.,E. coli;Parkinson's disease;alpha-synuclein;cryo-electron microscopy;fibril;human;molecular biophysics;neurodegeneration;neuroscience;structural biology,2018,224
29913007,Common Threads in Pediatric Inflammatory Diseases: Insight Into Personalized Medicine.,,2018,225
29783988,Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease.,"D019264:Adoptive Transfer;D000818:Animals;D001854:Bone Marrow Cells;D002454:Cell Differentiation;D003713:Dendritic Cells;D016178:Granulocyte-Macrophage Colony-Stimulating Factor;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D020734:Parkinsonian Disorders;D050378:T-Lymphocytes, Regulatory",2018,33
29497361,Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity.,alpha-synuclein;knockdown;major histocompatibility complex class 1 (MHC-1);microglia;neuroinflammation,2018,226
29492779,Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease.,,2018,227
29242346,Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers.,"D045744:Cell Line, Tumor;D002462:Cell Membrane;D002540:Cerebral Cortex;D006801:Humans;D008051:Lipid Bilayers;D009154:Mutation;D009474:Neurons;D019906:Nuclear Magnetic Resonance, Biomolecular;D010300:Parkinson Disease;D066263:Protein Aggregation, Pathological;D051844:alpha-Synuclein",2018,18
28923922,"TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson's disease.","D000818:Animals;D019208:Brain-Derived Neurotrophic Factor;D016923:Cell Death;D002478:Cells, Cultured;D004298:Dopamine;D059290:Dopaminergic Neurons;D006801:Humans;D008562:Membrane Glycoproteins;D051379:Mice;D008810:Mice, Inbred C57BL;D010300:Parkinson Disease;D020813:Receptor, trkB;D015398:Signal Transduction;D051844:alpha-Synuclein",2018,12
28877262,The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome.,D000544:Alzheimer Disease;D016564:Amyloid beta-Protein Precursor;D001927:Brain Diseases;D002460:Cell Line;D004721:Endoplasmic Reticulum;D056827:Endosomal Sorting Complexes Required for Transport;D057809:HEK293 Cells;D006801:Humans;D016631:Lewy Bodies;D008562:Membrane Glycoproteins;D009154:Mutation;D000075702:Nedd4 Ubiquitin Protein Ligases;D010300:Parkinson Disease;D046988:Proteasome Endopeptidase Complex;D000072417:Protein Domains;D021381:Protein Transport;D025801:Ubiquitin;D044767:Ubiquitin-Protein Ligases;D051844:alpha-Synuclein,2017,68
28860381,β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.,"D000107:Acetylation;D058665:Adrenergic beta-1 Receptor Agonists;D000319:Adrenergic beta-Antagonists;D000420:Albuterol;D000818:Animals;D045744:Cell Line, Tumor;D004742:Enhancer Elements, Genetic;D005786:Gene Expression Regulation;D006657:Histones;D006801:Humans;D008024:Ligands;D051379:Mice;D018696:Neuroprotective Agents;D009664:Norway;D010300:Parkinson Disease;D011401:Promoter Regions, Genetic;D011433:Propranolol;D018343:Receptors, Adrenergic, beta-2;D012306:Risk;D013378:Substantia Nigra;D014158:Transcription, Genetic;D051844:alpha-Synuclein",2018,18
28751258,Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.,"D000818:Animals;D006801:Humans;D019636:Neurodegenerative Diseases;D066263:Protein Aggregation, Pathological;D011487:Protein Conformation;D051844:alpha-Synuclein",2018,89
28725967,α-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading.,"D000818:Animals;D001253:Astrocytes;D002478:Cells, Cultured;D018920:Coculture Techniques;D018450:Disease Progression;D006624:Hippocampus;D051379:Mice;D009474:Neurons;D010300:Parkinson Disease;D051844:alpha-Synuclein",2018,15
28649610,"Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial.",,2017,21
28576704,α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration.,"D000110:Acetylcholinesterase;D000818:Animals;D003342:Corpus Striatum;D004195:Disease Models, Animal;D004298:Dopamine;D004305:Dose-Response Relationship, Drug;D006801:Humans;D002479:Inclusion Bodies;D051379:Mice;D008809:Mice, Inbred C3H;D008810:Mice, Inbred C57BL;D046529:Microscopy, Electron, Transmission;D019636:Neurodegenerative Diseases;D009474:Neurons;D010751:Phosphopyruvate Hydratase;D051381:Rats;D017207:Rats, Sprague-Dawley;D013378:Substantia Nigra;D014446:Tyrosine 3-Monooxygenase;D051844:alpha-Synuclein;D016875:tau Proteins",2018,89
28552073,Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity.,"D000818:Animals;D001921:Brain;D006801:Humans;D051379:Mice;D008822:Mice, Transgenic;D019636:Neurodegenerative Diseases;D051844:alpha-Synuclein",2018,33
28450268,Extensive uptake of α-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage.,"D000818:Animals;D001253:Astrocytes;D018920:Coculture Techniques;D003593:Cytoplasm;D042541:Intracellular Space;D016631:Lewy Bodies;D008810:Mice, Inbred C57BL;D008928:Mitochondria;D009474:Neurons;D009836:Oligodendroglia;D010300:Parkinson Disease;D051844:alpha-Synuclein",2018,228
28439627,"Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.","D000111:Acetylcysteine;D000367:Age Factors;D000818:Animals;D002135:Calcium-Binding Proteins;D015853:Cysteine Proteinase Inhibitors;D004195:Disease Models, Animal;D005552:Forelimb;D005904:Glial Fibrillary Acidic Protein;D005968:Glutamate Decarboxylase;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D008840:Microfilament Proteins;D008845:Microinjections;D009457:Neuroglia;D018377:Neurotransmitter Agents;D010300:Parkinson Disease;D011597:Psychomotor Performance;D013378:Substantia Nigra;D051843:Synucleins;D014446:Tyrosine 3-Monooxygenase",2018,70
28295625,Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.,"D000284:Administration, Oral;D000551:Ambroxol;D000818:Animals;D001921:Brain;D002491:Central Nervous System Agents;D005962:Glucosylceramidase;D008252:Macaca fascicularis;D008297:Male;D000074286:Preliminary Data;D054821:beta-Hexosaminidase beta Chain",2018,229
28170377,α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies.,"D000544:Alzheimer Disease;D016229:Amyloid beta-Peptides;D001343:Autophagy;D001370:Axonal Transport;D004721:Endoplasmic Reticulum;D006056:Golgi Apparatus;D006801:Humans;D020961:Lewy Body Disease;D008247:Lysosomes;D008928:Mitochondria;D058990:Molecular Targeted Therapy;D019578:Multiple System Atrophy;D009474:Neurons;D010300:Parkinson Disease;D066329:Protein Aggregates;D066263:Protein Aggregation, Pathological;D013569:Synapses;D051844:alpha-Synuclein;D016875:tau Proteins",2017,32
28122627,Therapeutic potential of autophagy-enhancing agents in Parkinson's disease.,D000818:Animals;D001343:Autophagy;D006801:Humans;D018696:Neuroprotective Agents;D010300:Parkinson Disease,2017,33
28086931,The release and trans-synaptic transmission of Tau via exosomes.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000544:Alzheimer Disease;D000818:Animals;D020285:Cryoelectron Microscopy;D018450:Disease Progression;D004797:Enzyme-Linked Immunosorbent Assay;D055354:Exosomes;D005260:Female;D005434:Flow Cytometry;D005455:Fluorescent Antibody Technique;D006801:Humans;D008297:Male;D051379:Mice;D046210:Microfluidic Analytical Techniques;D018625:Microscopy, Atomic Force;D008875:Middle Aged;D009474:Neurons;D021381:Protein Transport;D051381:Rats;D024801:Tauopathies;D016875:tau Proteins",2017,33
28049533,Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice.,"D000818:Animals;D004195:Disease Models, Animal;D004797:Enzyme-Linked Immunosorbent Assay;D005911:Gliosis;D006624:Hippocampus;D007150:Immunohistochemistry;D007249:Inflammation;D015850:Interleukin-6;D051379:Mice;D008822:Mice, Transgenic;D019636:Neurodegenerative Diseases;D051844:alpha-Synuclein",2017,33
28012041,Brain-to-stomach transfer of α-synuclein via vagal preganglionic projections.,"D000818:Animals;D001339:Autonomic Fibers, Preganglionic;D001921:Brain;D002795:Choline O-Acetyltransferase;D005260:Female;D005753:Gastric Mucosa;D049452:Green Fluorescent Proteins;D006801:Humans;D009474:Neurons;D009620:Nodose Ganglion;D012333:RNA, Messenger;D051381:Rats;D017207:Rats, Sprague-Dawley;D013997:Time Factors;D014161:Transduction, Genetic;D014630:Vagus Nerve;D051844:alpha-Synuclein",2017,15
27928028,"Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease.","D015655:1-Methyl-4-phenylpyridinium;D000818:Animals;D001343:Autophagy;D001522:Behavior, Animal;D001921:Brain;D017173:Caenorhabditis elegans;D004195:Disease Models, Animal;D004298:Dopamine;D059290:Dopaminergic Neurons;D006579:Heterozygote;D006801:Humans;D007249:Inflammation;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D008928:Mitochondria;D019636:Neurodegenerative Diseases;D009474:Neurons;D010101:Oxygen Consumption;D010300:Parkinson Disease;D011725:Pyridines;D019289:Pyruvic Acid;D015398:Signal Transduction;D013378:Substantia Nigra;D045162:Thiazolidinediones;D051844:alpha-Synuclein",2017,46
27918765,Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid.,"D016229:Amyloid beta-Peptides;D001669:Biochemical Phenomena;D003955:Diagnostic Tests, Routine;D005260:Female;D006801:Humans;D066298:In Vitro Techniques;D020961:Lewy Body Disease;D008297:Male;D019578:Multiple System Atrophy;D017063:Outcome Assessment (Health Care);D010300:Parkinson Disease;D010446:Peptide Fragments;D011237:Predictive Value of Tests;D066263:Protein Aggregation, Pathological;D057165:Proteostasis Deficiencies;D012189:Retrospective Studies;D012680:Sensitivity and Specificity;D012720:Severity of Illness Index;D051844:alpha-Synuclein;D016875:tau Proteins",2017,179
27886407,"First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.","D000328:Adult;D061067:Antibodies, Monoclonal, Humanized;D004311:Double-Blind Method;D005260:Female;D064368:Healthy Volunteers;D006801:Humans;D007074:Immunoglobulin G;D007262:Infusions, Intravenous;D008297:Male;D008875:Middle Aged;D055815:Young Adult;D051844:alpha-Synuclein",2017,28
27865851,Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.,D018450:Disease Progression;D059290:Dopaminergic Neurons;D006801:Humans;D017628:Microglia;D015213:Neuroimmunomodulation;D018384:Oxidative Stress;D010300:Parkinson Disease;D010587:Phagocytosis;D015398:Signal Transduction;D051844:alpha-Synuclein,2017,230
27733604,Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain ATP Synthase.,"D000255:Adenosine Triphosphate;D000818:Animals;D001253:Astrocytes;D001921:Brain;D002478:Cells, Cultured;D004734:Energy Metabolism;D053078:Membrane Potential, Mitochondrial;D051379:Mice;D008810:Mice, Inbred C57BL;D018345:Mice, Knockout;D008928:Mitochondria;D025261:Mitochondrial Proton-Translocating ATPases;D009243:NAD;D010101:Oxygen Consumption;D056811:Unfolded Protein Response;D051844:alpha-Synuclein",2017,49
27708076,Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.,"D000818:Animals;D015703:Antigens, CD;D059290:Dopaminergic Neurons;D004705:Endocytosis;D006801:Humans;D051379:Mice;D008822:Mice, Transgenic;D010300:Parkinson Disease;D011485:Protein Binding;D021381:Protein Transport;D051844:alpha-Synuclein",2017,18
27628239,α-Synuclein is a Novel Microtubule Dynamase.,"D006801:Humans;D008870:Microtubules;D010300:Parkinson Disease;D066263:Protein Aggregation, Pathological;D011485:Protein Binding;D017510:Protein Folding;D055503:Protein Multimerization;D014404:Tubulin;D051844:alpha-Synuclein",2018,24
27622765,Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant.,"D019943:Amino Acid Substitution;D000818:Animals;D002478:Cells, Cultured;D015870:Gene Expression;D006801:Humans;D007249:Inflammation;D018836:Inflammation Mediators;D051379:Mice;D017628:Microglia;D050505:Mutant Proteins;D010300:Parkinson Disease;D017354:Point Mutation;D017382:Reactive Oxygen Species;D015398:Signal Transduction;D051844:alpha-Synuclein",2017,68
27541985,Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats.,"D000818:Animals;D001343:Autophagy;D001522:Behavior, Animal;D000229:Dependovirus;D059290:Dopaminergic Neurons;D015536:Down-Regulation;D005260:Female;D020868:Gene Silencing;D005822:Genetic Vectors;D052119:Lysosomal-Associated Membrane Protein 2;D018832:Molecular Chaperones;D017072:Neostriatum;D009410:Nerve Degeneration;D010641:Phenotype;D034741:RNA, Small Interfering;D017208:Rats, Wistar;D000071456:Sequestosome-1 Protein;D013378:Substantia Nigra;D014161:Transduction, Genetic;D025801:Ubiquitin;D014617:Vacuoles;D051844:alpha-Synuclein",2017,231
27503075,Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease.,"D000818:Animals;D004195:Disease Models, Animal;D018450:Disease Progression;D005260:Female;D016631:Lewy Bodies;D051379:Mice;D008810:Mice, Inbred C57BL;D009434:Neural Pathways;D009830:Olfactory Bulb;D066208:Olfactory Tubercle;D010300:Parkinson Disease;D066263:Protein Aggregation, Pathological;D051844:alpha-Synuclein",2017,232
27192565,"Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.","D000818:Animals;D015703:Antigens, CD;D060908:CTLA-4 Antigen;D000072597:Hepatitis A Virus Cellular Receptor 2;D006801:Humans;D007108:Immune Tolerance;D008213:Lymphocyte Activation;D061026:Programmed Cell Death 1 Receptor;D020239:Receptor Cross-Talk;D011971:Receptors, Immunologic;D015398:Signal Transduction;D013601:T-Lymphocytes",2017,91
27107797,Microglial phenotypes in Parkinson's disease and animal models of the disease.,"D000818:Animals;D004195:Disease Models, Animal;D006801:Humans;D017628:Microglia;D010300:Parkinson Disease;D010641:Phenotype",2018,84
27075649,Structural and functional properties of prefibrillar α-synuclein oligomers.,"D045744:Cell Line, Tumor;D002470:Cell Survival;D006801:Humans;D046911:Macromolecular Substances;D008853:Microscopy;D009474:Neurons;D011487:Protein Conformation;D055503:Protein Multimerization;D051844:alpha-Synuclein",2017,24
27030592,Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases.,D000544:Alzheimer Disease;D016229:Amyloid beta-Peptides;D000818:Animals;D006801:Humans;D010300:Parkinson Disease;D057165:Proteostasis Deficiencies;D051844:alpha-Synuclein,2017,28
27018801,Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein.,"D000595:Amino Acid Sequence;D000682:Amyloid;D000818:Animals;D002478:Cells, Cultured;D006801:Humans;D006860:Hydrogen Bonding;D016631:Lewy Bodies;D051379:Mice;D009474:Neurons;D019906:Nuclear Magnetic Resonance, Biomolecular;D010300:Parkinson Disease;D000072417:Protein Domains;D017510:Protein Folding;D020836:Protein Structure, Quaternary;D017433:Protein Structure, Secondary;D051844:alpha-Synuclein",2017,233
26989132,Ca2+ is a key factor in α-synuclein-induced neurotoxicity.,"D019943:Amino Acid Substitution;D000818:Animals;D001253:Astrocytes;D002118:Calcium;D020013:Calcium Signaling;D016923:Cell Death;D002478:Cells, Cultured;D020125:Mutation, Missense;D009474:Neurons;D010300:Parkinson Disease;D017510:Protein Folding;D055503:Protein Multimerization;D051381:Rats;D017207:Rats, Sprague-Dawley;D051844:alpha-Synuclein",2017,234
26915902,Intracellular soluble α-synuclein oligomers reduce pyramidal cell excitability.,"D000200:Action Potentials;D000818:Animals;D006801:Humans;D007424:Intracellular Fluid;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D009924:Organ Culture Techniques;D017966:Pyramidal Cells;D051844:alpha-Synuclein",2017,235
26858591,Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates.,Parkinson's disease;alpha-synuclein;dopamine;non-human primates;substantia nigra,2016,8
26808901,Parkinson's disease: Disorder in the court.,D006801:Humans;D042541:Intracellular Space;D051844:alpha-Synuclein,2016,13
26808899,Structural disorder of monomeric α-synuclein persists in mammalian cells.,"D000107:Acetylation;D002460:Cell Line;D003593:Cytoplasm;D004578:Electron Spin Resonance Spectroscopy;D006367:HeLa Cells;D006801:Humans;D042541:Intracellular Space;D009474:Neurons;D019906:Nuclear Magnetic Resonance, Biomolecular;D011487:Protein Conformation;D051844:alpha-Synuclein",2016,13
26799377,Stabilization of α-Synuclein Fibril Clusters Prevents Fragmentation and Reduces Seeding Activity and Toxicity.,"D000544:Alzheimer Disease;D000682:Amyloid;D006801:Humans;D010300:Parkinson Disease;D066263:Protein Aggregation, Pathological;D017510:Protein Folding;D055550:Protein Stability;D051844:alpha-Synuclein",2016,236
26782965,Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.,D000368:Aged;D000544:Alzheimer Disease;D016229:Amyloid beta-Peptides;D000818:Animals;D015415:Biomarkers;D001921:Brain;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D010766:Phosphorylation;D055503:Protein Multimerization;D051844:alpha-Synuclein;D016875:tau Proteins,2016,33
26769968,Stimulating the Release of Exosomes Increases the Intercellular Transfer of Prions.,D000814:Aniline Compounds;D000818:Animals;D001597:Benzylidene Compounds;D002460:Cell Line;D002462:Cell Membrane;D055354:Exosomes;D051379:Mice;D008985:Monensin;D011328:Prions;D055550:Protein Stability;D021381:Protein Transport;D011817:Rabbits,2016,100
26761717,Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases.,"D015655:1-Methyl-4-phenylpyridinium;D000143:Acids;D000468:Alkalies;D000818:Animals;D016923:Cell Death;D059290:Dopaminergic Neurons;D006801:Humans;D006863:Hydrogen-Ion Concentration;D007276:Injections, Intraventricular;D019344:Lactic Acid;D016464:Lysosomal Storage Diseases;D008247:Lysosomes;D051379:Mice;D008954:Models, Biological;D008957:Models, Genetic;D053758:Nanoparticles;D017072:Neostriatum;D009410:Nerve Degeneration;D010300:Parkinson Disease;D011100:Polyglycolic Acid;D000077182:Polylactic Acid-Polyglycolic Acid Copolymer",2016,231
26704735,Development of Passive Immunotherapies for Synucleinopathies.,"D000818:Animals;D004195:Disease Models, Animal;D007116:Immunization, Passive;D020961:Lewy Body Disease;D019578:Multiple System Atrophy;D010300:Parkinson Disease;D051844:alpha-Synuclein",2016,28
26647156,Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.,D002555:Cerebrospinal Fluid;D015331:Cohort Studies;D003430:Cross-Sectional Studies;D055354:Exosomes;D005260:Female;D005500:Follow-Up Studies;D006801:Humans;D020961:Lewy Body Disease;D008137:Longitudinal Studies;D008297:Male;D010300:Parkinson Disease;D066329:Protein Aggregates;D051844:alpha-Synuclein,2016,36
26576561,Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes.,"D000375:Aging;D000818:Animals;D002478:Cells, Cultured;D002850:Chromatography, Gel;D004797:Enzyme-Linked Immunosorbent Assay;D055354:Exosomes;D005260:Female;D005434:Flow Cytometry;D006801:Humans;D015151:Immunoblotting;D051379:Mice;D017628:Microglia;D009000:Monocytes;D010300:Parkinson Disease;D010587:Phagocytosis;D051844:alpha-Synuclein",2016,15
26436904,Depletion of microglia and inhibition of exosome synthesis halt tau propagation.,"D000544:Alzheimer Disease;D000818:Animals;D004195:Disease Models, Animal;D018728:Entorhinal Cortex;D055354:Exosomes;D006624:Hippocampus;D008297:Male;D008822:Mice, Transgenic;D017628:Microglia;D009474:Neurons;D016875:tau Proteins",2016,51
26352473,Structure of the toxic core of α-synuclein from invisible crystals.,"D000682:Amyloid;D020285:Cryoelectron Microscopy;D004583:Electrons;D006801:Humans;D016631:Lewy Bodies;D008958:Models, Molecular;D053758:Nanoparticles;D010300:Parkinson Disease;D017434:Protein Structure, Tertiary;D012542:Scattering, Radiation;D051844:alpha-Synuclein",2015,13
26347034,Alpha-synuclein propagation: New insights from animal models.,"D000818:Animals;D004195:Disease Models, Animal;D019636:Neurodegenerative Diseases;D051844:alpha-Synuclein",2016,28
26324905,Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism.,"D000368:Aged;D000818:Animals;D001921:Brain;D005091:Exons;D005260:Female;D057809:HEK293 Cells;D006801:Humans;D007150:Immunohistochemistry;D008297:Male;D051379:Mice;D008822:Mice, Transgenic;D008856:Microscopy, Fluorescence;D008875:Middle Aged;D019578:Multiple System Atrophy;D019636:Neurodegenerative Diseases;D020734:Parkinsonian Disorders;D010766:Phosphorylation;D020641:Polymorphism, Single Nucleotide;D011328:Prions;D014451:Ubiquinone;D051844:alpha-Synuclein",2016,12
26323479,α-synuclein assemblies sequester neuronal α3-Na+/K+-ATPase and impair Na+ gradient.,D006429:Hemiplegia;D006801:Humans;D046912:Multiprotein Complexes;D009154:Mutation;D009474:Neurons;D020734:Parkinsonian Disorders;D000254:Sodium-Potassium-Exchanging ATPase;D051844:alpha-Synuclein,2016,237
26286986,Propagation of prions causing synucleinopathies in cultured cells.,D000818:Animals;D057809:HEK293 Cells;D006801:Humans;D051379:Mice;D019636:Neurodegenerative Diseases;D011328:Prions;D051844:alpha-Synuclein,2016,12
26260853,Active immunization therapies for Parkinson's disease and multiple system atrophy.,D000818:Animals;D006801:Humans;D019578:Multiple System Atrophy;D010300:Parkinson Disease;D014611:Vaccination;D051844:alpha-Synuclein,2016,28
26221742,The ubiquitin proteasome system as a potential therapeutic target for treatment of neurodegenerative diseases.,"D000818:Animals;D001921:Brain;D006801:Humans;D008959:Models, Neurological;D058990:Molecular Targeted Therapy;D009419:Nerve Tissue Proteins;D019636:Neurodegenerative Diseases;D018696:Neuroprotective Agents;D046988:Proteasome Endopeptidase Complex;D043743:Ubiquitin-Protein Ligase Complexes;D014452:Ubiquitins",2016,238
26181201,Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons.,"D000818:Animals;D042967:Electron Transport Complex I;D006801:Humans;D053078:Membrane Potential, Mitochondrial;D051379:Mice;D008928:Mitochondria;D028361:Mitochondrial Diseases;D009154:Mutation;D009474:Neurons;D018384:Oxidative Stress;D010300:Parkinson Disease;D066263:Protein Aggregation, Pathological;D017382:Reactive Oxygen Species;D051844:alpha-Synuclein",2016,239
26093169,Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.,"D000818:Animals;D003342:Corpus Striatum;D004195:Disease Models, Animal;D059290:Dopaminergic Neurons;D008297:Male;D051379:Mice;D009043:Motor Activity;D009410:Nerve Degeneration;D051381:Rats;D017207:Rats, Sprague-Dawley;D013378:Substantia Nigra;D014828:Vocalization, Animal;D051844:alpha-Synuclein",2016,89
26076669,Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation.,"D000818:Animals;D001921:Brain;D004797:Enzyme-Linked Immunosorbent Assay;D006801:Humans;D015151:Immunoblotting;D007150:Immunohistochemistry;D057026:Induced Pluripotent Stem Cells;D051379:Mice;D020125:Mutation, Missense;D009474:Neurons;D010300:Parkinson Disease;D020836:Protein Structure, Quaternary;D051381:Rats;D017207:Rats, Sprague-Dawley;D051844:alpha-Synuclein",2016,30
26075822,shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.,"D000818:Animals;D004195:Disease Models, Animal;D059290:Dopaminergic Neurons;D055785:Gene Knockdown Techniques;D008297:Male;D009410:Nerve Degeneration;D020734:Parkinsonian Disorders;D012333:RNA, Messenger;D034741:RNA, Small Interfering;D051381:Rats;D011917:Rats, Inbred Lew;D055647:Rats, Transgenic;D012402:Rotenone;D013378:Substantia Nigra;D051844:alpha-Synuclein",2015,240
26061766,α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.,"D000818:Animals;D001812:Blood-Brain Barrier;D001921:Brain;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D019578:Multiple System Atrophy;D010300:Parkinson Disease;D010641:Phenotype;D051381:Rats;D017208:Rats, Wistar;D013378:Substantia Nigra;D013569:Synapses;D051844:alpha-Synuclein",2015,13
26050140,Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.,D000818:Animals;D055808:Drug Discovery;D006801:Humans;D010300:Parkinson Disease;D051844:alpha-Synuclein,2015,44
25983062,P2X7 receptor is critical in α-synuclein--mediated microglial NADPH oxidase activation.,"D000818:Animals;D016923:Cell Death;D002478:Cells, Cultured;D059290:Dopaminergic Neurons;D004789:Enzyme Activation;D008297:Male;D008562:Membrane Glycoproteins;D008810:Mice, Inbred C57BL;D017628:Microglia;D058990:Molecular Targeted Therapy;D009154:Mutation;D000074662:NADPH Oxidase 2;D019255:NADPH Oxidases;D018384:Oxidative Stress;D010300:Parkinson Disease;D019869:Phosphatidylinositol 3-Kinases;D051057:Proto-Oncogene Proteins c-akt;D058486:Receptors, Purinergic P2X7;D015398:Signal Transduction;D051844:alpha-Synuclein",2016,87
25855634,Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation.,"D000682:Amyloid;D020285:Cryoelectron Microscopy;D057927:Hydrophobic and Hydrophilic Interactions;D021621:Imaging, Three-Dimensional;D008958:Models, Molecular;D008970:Molecular Weight;D055503:Protein Multimerization;D017433:Protein Structure, Secondary;D051844:alpha-Synuclein",2015,12
25853980,Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury.,"D000818:Animals;D001921:Brain;D004195:Disease Models, Animal;D005260:Female;D018014:Gene Transfer Techniques;D006801:Humans;D008526:Medulla Oblongata;D009410:Nerve Degeneration;D009434:Neural Pathways;D009474:Neurons;D010300:Parkinson Disease;D051381:Rats;D017207:Rats, Sprague-Dawley;D051844:alpha-Synuclein",2016,241
25825709,"α-Synuclein, a chemoattractant, directs microglial migration via H2O2-dependent Lyn phosphorylation.","D000818:Animals;D000831:Animals, Newborn;D039481:CD11b Antigen;D002465:Cell Movement;D002478:Cells, Cultured;D002630:Chemotactic Factors;D051356:Cortactin;D006861:Hydrogen Peroxide;D015151:Immunoblotting;D008562:Membrane Glycoproteins;D008810:Mice, Inbred C57BL;D018345:Mice, Knockout;D017628:Microglia;D018613:Microscopy, Confocal;D000074662:NADPH Oxidase 2;D019255:NADPH Oxidases;D009474:Neurons;D016877:Oxidants;D010766:Phosphorylation;D034622:RNA Interference;D051381:Rats;D015398:Signal Transduction;D051844:alpha-Synuclein;D019061:src-Family Kinases",2015,12
25816357,Seeking a mechanism for the toxicity of oligomeric α-synuclein.,"D000682:Amyloid;D000818:Animals;D006801:Humans;D009154:Mutation;D019636:Neurodegenerative Diseases;D066263:Protein Aggregation, Pathological;D055503:Protein Multimerization;D051844:alpha-Synuclein",2016,242
25659148,Identification of synaptosomal proteins binding to monomeric and oligomeric α-synuclein.,D000818:Animals;D001921:Brain;D006801:Humans;D009419:Nerve Tissue Proteins;D011485:Protein Binding;D055503:Protein Multimerization;D040901:Proteomics;D013552:Swine;D013574:Synaptosomes;D051844:alpha-Synuclein,2016,68
25658425,Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.,"D000704:Analysis of Variance;D000818:Animals;D000906:Antibodies;D001522:Behavior, Animal;D016923:Cell Death;D000229:Dependovirus;D059290:Dopaminergic Neurons;D005822:Genetic Vectors;D049452:Green Fluorescent Proteins;D006801:Humans;D007150:Immunohistochemistry;D007167:Immunotherapy;D007274:Injections, Intraperitoneal;D010300:Parkinson Disease;D051381:Rats;D013378:Substantia Nigra;D051844:alpha-Synuclein",2016,68
25451814,Serotonin stimulates secretion of exosomes from microglia cells.,"D000818:Animals;D002460:Cell Line;D018920:Coculture Techniques;D055354:Exosomes;D051379:Mice;D017628:Microglia;D009474:Neurons;D044402:Receptor, Serotonin, 5-HT2A;D044403:Receptor, Serotonin, 5-HT2B;D044422:Receptors, Serotonin, 5-HT4;D012701:Serotonin;D015398:Signal Transduction;D013234:Stem Cells",2015,243
25425650,Acceleration of α-synuclein aggregation by exosomes.,D055354:Exosomes;D005677:G(M1) Ganglioside;D005678:G(M2) Ganglioside;D005679:G(M3) Ganglioside;D006801:Humans;D010300:Parkinson Disease;D010743:Phospholipids;D053835:Unilamellar Liposomes;D051844:alpha-Synuclein,2015,100
25392495,ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein.,D000818:Animals;D002460:Cell Line;D002540:Cerebral Cortex;D056827:Endosomal Sorting Complexes Required for Transport;D055354:Exosomes;D006801:Humans;D008297:Male;D051379:Mice;D009154:Mutation;D009474:Neurons;D020734:Parkinsonian Disorders;D061251:Primary Cell Culture;D006180:Proton-Translocating ATPases;D051844:alpha-Synuclein,2015,49
25363075,Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.,"D000368:Aged;D000369:Aged, 80 and over;D000818:Animals;D002478:Cells, Cultured;D002540:Cerebral Cortex;D004195:Disease Models, Animal;D004622:Embryo, Mammalian;D004791:Enzyme Inhibitors;D005260:Female;D005786:Gene Expression Regulation;D005910:Glioma;D006801:Humans;D018942:Macrolides;D008297:Male;D051379:Mice;D008822:Mice, Transgenic;D008875:Middle Aged;D009474:Neurons;D047495:PPAR gamma;D010300:Parkinson Disease;D000071248:Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha;D012319:RNA Polymerase II;D000077185:Resveratrol;D013267:Stilbenes;D013378:Substantia Nigra;D035181:TATA-Box Binding Protein;D014157:Transcription Factors;D051844:alpha-Synuclein",2015,122
25296989,Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats.,"D000818:Animals;D001370:Axonal Transport;D001921:Brain;D045744:Cell Line, Tumor;D004195:Disease Models, Animal;D018450:Disease Progression;D041981:Gastrointestinal Tract;D006801:Humans;D010300:Parkinson Disease;D017207:Rats, Sprague-Dawley;D011994:Recombinant Proteins;D014630:Vagus Nerve;D051844:alpha-Synuclein",2015,15
25112864,Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice.,"D000818:Animals;D001921:Brain;D045744:Cell Line, Tumor;D003713:Dendritic Cells;D055354:Exosomes;D005786:Gene Expression Regulation;D005822:Genetic Vectors;D006023:Glycoproteins;D006801:Humans;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D009154:Mutation;D009447:Neuroblastoma;D010446:Peptide Fragments;D012333:RNA, Messenger;D034741:RNA, Small Interfering;D013997:Time Factors;D014162:Transfection;D014764:Viral Proteins;D051844:alpha-Synuclein",2015,28
25095794,Pathological alpha-synuclein propagates through neural networks.,"D000818:Animals;D001921:Brain;D004268:DNA-Binding Proteins;D051379:Mice;D008810:Mice, Inbred C57BL;D018345:Mice, Knockout;D009415:Nerve Net;D010766:Phosphorylation;D011328:Prions;D011994:Recombinant Proteins;D051844:alpha-Synuclein;D016875:tau Proteins",2015,241
25051958,A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons.,"D000818:Animals;D017209:Apoptosis;D019703:Calcineurin;D065095:Calcineurin Inhibitors;D016572:Cyclosporine;D059290:Dopaminergic Neurons;D005786:Gene Expression Regulation;D057809:HEK293 Cells;D006801:Humans;D008636:Mesencephalon;D051379:Mice;D008822:Mice, Transgenic;D009154:Mutation;D050778:NFATC Transcription Factors;D010300:Parkinson Disease;D061251:Primary Cell Culture;D015398:Signal Transduction;D051844:alpha-Synuclein",2015,37
25009275,Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.,"D000818:Animals;D000911:Antibodies, Monoclonal;D001921:Brain;D004195:Disease Models, Animal;D006801:Humans;D007167:Immunotherapy;D051379:Mice;D008822:Mice, Transgenic;D009069:Movement Disorders;D020734:Parkinsonian Disorders;D014018:Tissue Distribution;D016896:Treatment Outcome;D051844:alpha-Synuclein",2014,49
25008355,ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.,"D020816:Amino Acid Motifs;D000818:Animals;D001055:Apolipoproteins B;D001343:Autophagy;D001522:Behavior, Animal;D001921:Brain;D002460:Cell Line;D056827:Endosomal Sorting Complexes Required for Transport;D023061:Gene Order;D005822:Genetic Vectors;D016086:Lentivirus;D051379:Mice;D008822:Mice, Transgenic;D009410:Nerve Degeneration;D009419:Nerve Tissue Proteins;D009457:Neuroglia;D009474:Neurons;D011485:Protein Binding;D021381:Protein Transport;D059748:Proteolysis;D051381:Rats;D057127:Single-Chain Antibodies;D014161:Transduction, Genetic;D051844:alpha-Synuclein",2015,244
24997849,Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000818:Animals;D001921:Brain;D016022:Case-Control Studies;D015331:Cohort Studies;D055354:Exosomes;D005260:Female;D006801:Humans;D008297:Male;D013058:Mass Spectrometry;D051379:Mice;D008854:Microscopy, Electron;D008875:Middle Aged;D039842:Neural Cell Adhesion Molecule L1;D010300:Parkinson Disease;D012372:ROC Curve;D051844:alpha-Synuclein",2015,15
24942732,"Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction.","D000818:Animals;D001704:Biopolymers;D002118:Calcium;D042967:Electron Transport Complex I;D006801:Humans;D053078:Membrane Potential, Mitochondrial;D051379:Mice;D008928:Mitochondria;D013844:Thiazoles;D051844:alpha-Synuclein",2014,100
24931606,Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.,"D000818:Animals;D000911:Antibodies, Monoclonal;D005260:Female;D007167:Immunotherapy;D020961:Lewy Body Disease;D008297:Male;D051379:Mice;D009474:Neurons;D010300:Parkinson Disease;D051844:alpha-Synuclein",2015,43
24878508,Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread.,"D000368:Aged;D000369:Aged, 80 and over;D000906:Antibodies;D001253:Astrocytes;D001921:Brain;D005110:Extracellular Space;D005260:Female;D005911:Gliosis;D006801:Humans;D042541:Intracellular Space;D016631:Lewy Bodies;D020961:Lewy Body Disease;D008297:Male;D017628:Microglia;D008875:Middle Aged;D009474:Neurons;D010300:Parkinson Disease;D017433:Protein Structure, Secondary;D051844:alpha-Synuclein",2015,89
24851801,Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice.,"D000818:Animals;D000911:Antibodies, Monoclonal;D001921:Brain;D004797:Enzyme-Linked Immunosorbent Assay;D005260:Female;D006801:Humans;D007116:Immunization, Passive;D007274:Injections, Intraperitoneal;D008297:Male;D008822:Mice, Transgenic;D009043:Motor Activity;D009154:Mutation;D020734:Parkinsonian Disorders;D012720:Severity of Illness Index;D013116:Spinal Cord;D051844:alpha-Synuclein",2015,89
24768993,A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies.,"D016229:Amyloid beta-Peptides;D001425:Bacterial Outer Membrane Proteins;D017104:Bacteriophage M13;D036022:Capsid Proteins;D029968:Escherichia coli Proteins;D006801:Humans;D007700:Kinetics;D026901:Membrane Transport Proteins;D008958:Models, Molecular;D019636:Neurodegenerative Diseases;D011485:Protein Binding;D011487:Protein Conformation;D017510:Protein Folding;D054730:Protein Interaction Domains and Motifs;D055503:Protein Multimerization;D011993:Recombinant Fusion Proteins;D051844:alpha-Synuclein;D016875:tau Proteins",2014,245
24746855,"The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.","D000409:Alanine;D000818:Animals;D001343:Autophagy;D001921:Brain;D001927:Brain Diseases;D002461:Cell Line, Transformed;D004195:Disease Models, Animal;D006801:Humans;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D009043:Motor Activity;D009154:Mutation;D011392:Proline;D012697:Serine Endopeptidases;D015842:Serine Proteinase Inhibitors;D013997:Time Factors;D051844:alpha-Synuclein",2015,89
24736453,MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration.,"D059331:Adrenergic Neurons;D000368:Aged;D000369:Aged, 80 and over;D000818:Animals;D002470:Cell Survival;D004298:Dopamine;D059290:Dopaminergic Neurons;D005260:Female;D020869:Gene Expression Profiling;D005805:Genes, MHC Class I;D015395:Histocompatibility Antigens Class I;D006801:Humans;D007371:Interferon-gamma;D008125:Locus Coeruleus;D008297:Male;D008543:Melanins;D051379:Mice;D017628:Microglia;D008875:Middle Aged;D018384:Oxidative Stress;D010300:Parkinson Disease;D012333:RNA, Messenger;D013378:Substantia Nigra;D013602:T-Lymphocytes, Cytotoxic;D051844:alpha-Synuclein",2015,30
24728187,"The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.","D001921:Brain;D002021:Buffers;D002454:Cell Differentiation;D002460:Cell Line;D002462:Cell Membrane;D002467:Cell Nucleus;D002478:Cells, Cultured;D006801:Humans;D002479:Inclusion Bodies;D008928:Mitochondria;D009154:Mutation;D009447:Neuroblastoma;D009474:Neurons;D009685:Nuclear Envelope;D010300:Parkinson Disease;D010766:Phosphorylation;D066329:Protein Aggregates;D066263:Protein Aggregation, Pathological;D011485:Protein Binding;D017433:Protein Structure, Secondary;D021381:Protein Transport;D012441:Saccharomyces cerevisiae;D012967:Sodium Dodecyl Sulfate;D013347:Subcellular Fractions;D053835:Unilamellar Liposomes;D051844:alpha-Synuclein",2015,37
24662516,Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo.,"D000544:Alzheimer Disease;D000818:Animals;D001921:Brain;D004195:Disease Models, Animal;D005786:Gene Expression Regulation;D018698:Glutamic Acid;D006801:Humans;D020961:Lewy Body Disease;D008239:Lysine;D008569:Memory Disorders;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D009154:Mutation;D009410:Nerve Degeneration;D009419:Nerve Tissue Proteins;D009474:Neurons;D013569:Synapses;D018800:Thy-1 Antigens;D051844:alpha-Synuclein",2014,36
24659240,"Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice.","D000686:Amyloidosis;D000818:Animals;D001921:Brain;D002478:Cells, Cultured;D004926:Escherichia coli;D018014:Gene Transfer Techniques;D006801:Humans;D008809:Mice, Inbred C3H;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D009413:Nerve Fibers, Myelinated;D009434:Neural Pathways;D016900:Neurofilament Proteins;D009457:Neuroglia;D009474:Neurons;D011994:Recombinant Proteins;D013045:Species Specificity;D051844:alpha-Synuclein",2014,15
24603074,Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes.,D001343:Autophagy;D055354:Exosomes;D006706:Homeostasis;D006801:Humans;D009474:Neurons;D010300:Parkinson Disease;D006180:Proton-Translocating ATPases;D015032:Zinc;D051844:alpha-Synuclein,2015,37
24574503,Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000551:Ambroxol;D002478:Cells, Cultured;D005260:Female;D005347:Fibroblasts;D005776:Gaucher Disease;D020869:Gene Expression Profiling;D005786:Gene Expression Regulation;D005962:Glucosylceramidase;D006026:Glycoside Hydrolases;D006801:Humans;D008297:Male;D008875:Middle Aged;D009154:Mutation;D009447:Neuroblastoma;D018384:Oxidative Stress;D010300:Parkinson Disease",2014,36
24525765,Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.,"D000818:Animals;D000906:Antibodies;D001369:Axons;D002421:Caudate Nucleus;D002986:Clinical Trials as Topic;D004195:Disease Models, Animal;D006801:Humans;D020961:Lewy Body Disease;D008569:Memory Disorders;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D017628:Microglia;D009043:Motor Activity;D009410:Nerve Degeneration;D010300:Parkinson Disease;D011699:Putamen;D013569:Synapses;D013601:T-Lymphocytes;D014611:Vaccination;D051844:alpha-Synuclein",2015,15
24468877,Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases.,"D000818:Animals;D045604:Extracellular Fluid;D006801:Humans;D020961:Lewy Body Disease;D008958:Models, Molecular;D009474:Neurons;D051844:alpha-Synuclein",2014,34
24399444,Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction.,D001343:Autophagy;D001692:Biological Transport;D006706:Homeostasis;D006801:Humans;D008928:Mitochondria;D009154:Mutation;D020734:Parkinsonian Disorders;D006180:Proton-Translocating ATPases;D017382:Reactive Oxygen Species;D015032:Zinc,2015,37
24337465,"Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance.","D000544:Alzheimer Disease;D000682:Amyloid;D000818:Animals;D001343:Autophagy;D045744:Cell Line, Tumor;D004795:Enzyme Stability;D006624:Hippocampus;D006801:Humans;D008297:Male;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D047428:Protein Kinase Inhibitors;D011743:Pyrimidines;D051381:Rats;D044767:Ubiquitin-Protein Ligases;D054875:Ubiquitination",2014,246
24334770,Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation.,D006706:Homeostasis;D006801:Humans;D008247:Lysosomes;D020734:Parkinsonian Disorders;D006180:Proton-Translocating ATPases;D015032:Zinc;D051844:alpha-Synuclein,2015,37
24243558,Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.,"D000818:Animals;D003342:Corpus Striatum;D059290:Dopaminergic Neurons;D005260:Female;D006801:Humans;D016631:Lewy Bodies;D008253:Macaca mulatta;D051379:Mice;D018345:Mice, Knockout;D008845:Microinjections;D009410:Nerve Degeneration;D010300:Parkinson Disease;D013378:Substantia Nigra;D014020:Tissue Extracts;D051844:alpha-Synuclein",2014,122
24236103,Preconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation.,"D000634:Aminoquinolines;D000818:Animals;D001119:Arginase;D001412:Bacillus subtilis;D053148:Caspase 3;D016764:Cell Polarity;D002478:Cells, Cultured;D016207:Cytokines;D015870:Gene Expression;D000077271:Imiquimod;D007113:Immunity, Innate;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D017628:Microglia;D052247:Nitric Oxide Synthase Type II;D010457:Peptidoglycan;D011070:Poly I-C;D051193:Toll-Like Receptors;D051844:alpha-Synuclein",2014,68
24108358,Structural and functional characterization of two alpha-synuclein strains.,"D045744:Cell Line, Tumor;D002470:Cell Survival;D004926:Escherichia coli;D006801:Humans;D009474:Neurons;D017510:Protein Folding;D020033:Protein Isoforms;D055503:Protein Multimerization;D017433:Protein Structure, Secondary;D011994:Recombinant Proteins;D053838:Scattering, Small Angle;D017550:Spectroscopy, Fourier Transform Infrared;D014961:X-Ray Diffraction;D051844:alpha-Synuclein",2014,30
23983262,Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo.,"D000704:Analysis of Variance;D000818:Animals;D017931:DNA Primers;D004591:Electrophoresis, Polyacrylamide Gel;D005786:Gene Expression Regulation;D057809:HEK293 Cells;D006801:Humans;D007150:Immunohistochemistry;D047468:Immunoprecipitation;D010300:Parkinson Disease;D010766:Phosphorylation;D017346:Protein-Serine-Threonine Kinases;D059748:Proteolysis;D051381:Rats;D051844:alpha-Synuclein",2013,12
23925565,Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice.,"D000818:Animals;D001370:Axonal Transport;D001921:Brain;D002452:Cell Count;D004396:Coloring Agents;D005260:Female;D005455:Fluorescent Antibody Technique;D005456:Fluorescent Dyes;D006801:Humans;D007150:Immunohistochemistry;D016631:Lewy Bodies;D051379:Mice;D008810:Mice, Inbred C57BL;D017628:Microglia;D009434:Neural Pathways;D009830:Olfactory Bulb;D010300:Parkinson Disease;D011994:Recombinant Proteins;D013238:Stereotaxic Techniques;D051844:alpha-Synuclein",2014,15
23916651,Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000595:Amino Acid Sequence;D019943:Amino Acid Substitution;D005260:Female;D056726:Genetic Association Studies;D006801:Humans;D008297:Male;D008875:Middle Aged;D008969:Molecular Sequence Data;D020125:Mutation, Missense;D010300:Parkinson Disease;D010375:Pedigree;D051844:alpha-Synuclein",2014,20
23874151,Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication.,"D000818:Animals;D002450:Cell Communication;D002470:Cell Survival;D055354:Exosomes;D005260:Female;D018698:Glutamic Acid;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D009474:Neurons;D018377:Neurotransmitter Agents;D009836:Oligodendroglia;D015398:Signal Transduction",2014,247
23859557,"Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by ""molecular tweezers"" - from the test tube to animal models.","D000595:Amino Acid Sequence;D058227:Amyloidogenic Proteins;D000818:Animals;D001952:Bridged-Ring Compounds;D002986:Clinical Trials as Topic;D006801:Humans;D057927:Hydrophobic and Hydrophilic Interactions;D023421:Models, Animal;D008969:Molecular Sequence Data;D010755:Organophosphates;D066263:Protein Aggregation, Pathological;D055503:Protein Multimerization;D055672:Static Electricity;D013569:Synapses;D051844:alpha-Synuclein",2015,90
23792198,Exosomes of BV-2 cells induced by alpha-synuclein: important mediator of neurodegeneration in PD.,D000818:Animals;D017209:Apoptosis;D002460:Cell Line;D055354:Exosomes;D051379:Mice;D017628:Microglia;D009410:Nerve Degeneration;D010300:Parkinson Disease;D051844:alpha-Synuclein,2014,14
23790379,In vitro study of α-synuclein protofibrils by cryo-EM suggests a Cu(2+)-dependent aggregation pathway.,D000682:Amyloid;D000818:Animals;D003300:Copper;D020285:Cryoelectron Microscopy;D006801:Humans;D055503:Protein Multimerization;D051844:alpha-Synuclein,2014,248
23765500,Properties of native brain α-synuclein.,D000818:Animals;D006801:Humans;D051844:alpha-Synuclein,2013,13
23757764,Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration.,"D000661:Amphetamine;D000704:Analysis of Variance;D000818:Animals;D001058:Apomorphine;D001343:Autophagy;D002478:Cells, Cultured;D002540:Cerebral Cortex;D003342:Corpus Striatum;D000229:Dependovirus;D004298:Dopamine;D004622:Embryo, Mammalian;D004791:Enzyme Inhibitors;D005260:Female;D005786:Gene Expression Regulation;D005822:Genetic Vectors;D049452:Green Fluorescent Proteins;D006388:Hemagglutinins;D006801:Humans;D052119:Lysosomal-Associated Membrane Protein 2;D051907:Lysosome-Associated Membrane Glycoproteins;D018942:Macrolides;D051379:Mice;D018832:Molecular Chaperones;D009043:Motor Activity;D009410:Nerve Degeneration;D009447:Neuroblastoma;D009474:Neurons;D051381:Rats;D014162:Transfection;D014446:Tyrosine 3-Monooxygenase;D051844:alpha-Synuclein",2013,36
23744071,α-Synuclein oligomers impair neuronal microtubule-kinesin interplay.,"D002460:Cell Line;D002470:Cell Survival;D003598:Cytoskeletal Proteins;D059290:Dopaminergic Neurons;D004591:Electrophoresis, Polyacrylamide Gel;D006801:Humans;D016547:Kinesin;D008856:Microscopy, Fluorescence;D008869:Microtubule-Associated Proteins;D008870:Microtubules;D009154:Mutation;D016501:Neurites;D011485:Protein Binding;D055503:Protein Multimerization;D014404:Tubulin;D051844:alpha-Synuclein;D016875:tau Proteins",2013,100
23739956,"MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration.","D000818:Animals;D000831:Animals, Newborn;D015496:CD4-Positive T-Lymphocytes;D049109:Cell Proliferation;D002478:Cells, Cultured;D059290:Dopaminergic Neurons;D005802:Genes, MHC Class II;D006801:Humans;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D018345:Mice, Knockout;D017628:Microglia;D009410:Nerve Degeneration;D010300:Parkinson Disease;D051844:alpha-Synuclein",2013,49
23703938,Caudo-rostral brain spreading of α-synuclein through vagal connections.,"D000256:Adenoviridae;D000818:Animals;D001921:Brain;D001933:Brain Stem;D004195:Disease Models, Animal;D005260:Female;D015870:Gene Expression;D005822:Genetic Vectors;D006801:Humans;D010300:Parkinson Disease;D021381:Protein Transport;D051381:Rats;D017207:Rats, Sprague-Dawley;D015854:Up-Regulation;D014630:Vagus Nerve;D051844:alpha-Synuclein",2013,47
23666528,Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.,"D000328:Adult;D000818:Animals;D001343:Autophagy;D001921:Brain;D004195:Disease Models, Animal;D004298:Dopamine;D059290:Dopaminergic Neurons;D016313:Genes, abl;D006801:Humans;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D020734:Parkinsonian Disorders;D017354:Point Mutation;D016315:Proto-Oncogene Proteins c-abl;D011743:Pyrimidines;D013378:Substantia Nigra;D051844:alpha-Synuclein",2014,37
23637226,A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD).,"D000682:Amyloid;D000818:Animals;D000978:Antiparkinson Agents;D001812:Blood-Brain Barrier;D004330:Drosophila;D005260:Female;D005456:Fluorescent Dyes;D018840:HSP70 Heat-Shock Proteins;D006624:Hippocampus;D006801:Humans;D008124:Locomotion;D008297:Male;D008353:Mannitol;D051379:Mice;D008810:Mice, Inbred C57BL;D008811:Mice, Inbred DBA;D008822:Mice, Transgenic;D046529:Microscopy, Electron, Transmission;D019579:Neocortex;D010300:Parkinson Disease;D055503:Protein Multimerization;D017433:Protein Structure, Secondary;D013844:Thiazoles;D051844:alpha-Synuclein",2013,100
23610405,TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity.,"D000818:Animals;D051017:Apoptosis Regulatory Proteins;D001343:Autophagy;D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors;D000071186:Beclin-1;D001921:Brain;D001931:Brain Mapping;D000229:Dependovirus;D004298:Dopamine;D005260:Female;D057809:HEK293 Cells;D006801:Humans;D007150:Immunohistochemistry;D008247:Lysosomes;D008636:Mesencephalon;D009474:Neurons;D018696:Neuroprotective Agents;D010300:Parkinson Disease;D011485:Protein Binding;D051381:Rats;D017207:Rats, Sprague-Dawley;D051844:alpha-Synuclein",2013,12
23604588,Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease.,"D000818:Animals;D001921:Brain;D018929:Cell Culture Techniques;D004195:Disease Models, Animal;D005260:Female;D006801:Humans;D051379:Mice;D008810:Mice, Inbred C57BL;D010300:Parkinson Disease;D017096:Prion Diseases;D011328:Prions;D011720:Pyrazoles;D011743:Pyrimidines;D012402:Rotenone;D051844:alpha-Synuclein",2013,15
23512373,α-Synuclein and mitochondria: partners in crime?,D000818:Animals;D042967:Electron Transport Complex I;D006801:Humans;D008928:Mitochondria;D010300:Parkinson Disease;D051844:alpha-Synuclein,2014,182
23506036,Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity.,"D000818:Animals;D001921:Brain;D004195:Disease Models, Animal;D006801:Humans;D008214:Lymphocytes;D017628:Microglia;D009474:Neurons;D010300:Parkinson Disease;D051844:alpha-Synuclein",2013,249
23466394,Prion-like spreading of pathological α-synuclein in brain.,"D000281:Administration, Intranasal;D000818:Animals;D001522:Behavior, Animal;D001921:Brain;D004195:Disease Models, Animal;D005260:Female;D006801:Humans;D007276:Injections, Intraventricular;D020961:Lewy Body Disease;D051379:Mice;D008810:Mice, Inbred C57BL;D011328:Prions;D011994:Recombinant Proteins;D013997:Time Factors;D051844:alpha-Synuclein",2013,36
23463005,Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia.,"D000818:Animals;D002478:Cells, Cultured;D018925:Chemokines;D002850:Chromatography, Gel;D059290:Dopaminergic Neurons;D006801:Humans;D007150:Immunohistochemistry;D020961:Lewy Body Disease;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D017628:Microglia;D009474:Neurons;D019899:Paracrine Communication;D011487:Protein Conformation;D020836:Protein Structure, Quaternary;D051381:Rats;D017207:Rats, Sprague-Dawley;D015398:Signal Transduction;D051195:Toll-Like Receptor 2;D015854:Up-Regulation;D051844:alpha-Synuclein",2013,30
23431141,Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking.,"D000818:Animals;D005089:Exocytosis;D050356:Lipid Metabolism;D008959:Models, Neurological;D009474:Neurons;D009498:Neurotoxins;D016716:PC12 Cells;D011485:Protein Binding;D020836:Protein Structure, Quaternary;D011510:Proteolipids;D051381:Rats;D011993:Recombinant Fusion Proteins;D050600:SNARE Proteins;D022142:Secretory Vesicles;D014161:Transduction, Genetic;D050988:Vesicle-Associated Membrane Protein 2;D051844:alpha-Synuclein",2013,12
23384597,Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.,D000818:Animals;D006801:Humans;D007167:Immunotherapy;D019636:Neurodegenerative Diseases;D051844:alpha-Synuclein,2013,250
23363402,Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.,"D000818:Animals;D000911:Antibodies, Monoclonal;D015153:Blotting, Western;D001921:Brain;D018076:DNA, Complementary;D004797:Enzyme-Linked Immunosorbent Assay;D000939:Epitopes;D005561:Formates;D006801:Humans;D007150:Immunohistochemistry;D020961:Lewy Body Disease;D051379:Mice;D008822:Mice, Transgenic;D009154:Mutation;D013347:Subcellular Fractions;D051844:alpha-Synuclein",2013,126
23205266,Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice.,"D000818:Animals;D001370:Axonal Transport;D001921:Brain;D017615:Enteric Nervous System;D006801:Humans;D007306:Insecticides;D051379:Mice;D009474:Neurons;D010302:Parkinson Disease, Secondary;D061251:Primary Cell Culture;D012402:Rotenone;D013562:Sympathectomy;D014628:Vagotomy;D051844:alpha-Synuclein",2013,24
23199590,"A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.",D000704:Analysis of Variance;D000978:Antiparkinson Agents;D018450:Disease Progression;D018491:Dopamine Agonists;D004311:Double-Blind Method;D005260:Female;D005500:Follow-Up Studies;D005677:G(M1) Ganglioside;D006801:Humans;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D016896:Treatment Outcome,2013,113
23186369,The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia.,"D000704:Analysis of Variance;D000818:Animals;D000831:Animals, Newborn;D001921:Brain;D002478:Cells, Cultured;D016207:Cytokines;D004797:Enzyme-Linked Immunosorbent Assay;D005786:Gene Expression Regulation;D006801:Humans;D017493:Leukocyte Common Antigens;D051379:Mice;D008810:Mice, Inbred C57BL;D018345:Mice, Knockout;D017628:Microglia;D029543:Nucleocytoplasmic Transport Proteins;D014176:Protein Biosynthesis;D017452:Receptors, IgG;D015398:Signal Transduction;D013997:Time Factors;D051844:alpha-Synuclein",2013,104
23173708,Wnt3a induces exosome secretion from primary cultured rat microglia.,"D000818:Animals;D002540:Cerebral Cortex;D055354:Exosomes;D018836:Inflammation Mediators;D008297:Male;D017628:Microglia;D009419:Nerve Tissue Proteins;D009474:Neurons;D061251:Primary Cell Culture;D020543:Proteome;D051381:Rats;D017207:Rats, Sprague-Dawley;D060509:Wnt3A Protein",2013,117
23161999,Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.,"D000818:Animals;D002478:Cells, Cultured;D003342:Corpus Striatum;D004298:Dopamine;D059290:Dopaminergic Neurons;D007267:Injections;D016631:Lewy Bodies;D051379:Mice;D020734:Parkinsonian Disorders;D017510:Protein Folding;D021381:Protein Transport;D011994:Recombinant Proteins;D013378:Substantia Nigra;D051844:alpha-Synuclein",2012,18
23154633,Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease.,D000818:Animals;D016503:Drug Delivery Systems;D005110:Extracellular Space;D006801:Humans;D010300:Parkinson Disease;D011328:Prions;D059748:Proteolysis;D051844:alpha-Synuclein,2014,251
23109146,Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport.,"D016229:Amyloid beta-Peptides;D000818:Animals;D001370:Axonal Transport;D005456:Fluorescent Dyes;D007150:Immunohistochemistry;D008301:Maleimides;D051379:Mice;D046210:Microfluidic Analytical Techniques;D018613:Microscopy, Confocal;D008856:Microscopy, Fluorescence;D009454:Neurofibrils;D009457:Neuroglia;D009474:Neurons;D010446:Peptide Fragments;D009435:Synaptic Transmission;D051844:alpha-Synuclein",2013,122
23108585,Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia.,"D000818:Animals;D001253:Astrocytes;D002478:Cells, Cultured;D054360:Chemokine CXCL1;D005911:Gliosis;D007249:Inflammation;D015850:Interleukin-6;D051379:Mice;D018345:Mice, Knockout;D017628:Microglia;D016328:NF-kappa B;D010587:Phagocytosis;D021381:Protein Transport;D017382:Reactive Oxygen Species;D051197:Toll-Like Receptor 4;D014409:Tumor Necrosis Factor-alpha;D051844:alpha-Synuclein",2013,243
23070648,The ends and means of artificially induced targeted protein degradation.,"D005827:Genetics, Microbial;D008967:Molecular Biology;D010447:Peptide Hydrolases;D010455:Peptides;D046988:Proteasome Endopeptidase Complex;D011506:Proteins;D059748:Proteolysis;D025801:Ubiquitin",2013,252
23015436,Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission.,"D000682:Amyloid;D000704:Analysis of Variance;D000818:Animals;D000906:Antibodies;D015703:Antigens, CD;D001253:Astrocytes;D001921:Brain;D002135:Calcium-Binding Proteins;D002402:Cathepsin D;D051242:Caveolin 1;D002450:Cell Communication;D002460:Cell Line;D002850:Chromatography, Gel;D017077:Culture Media, Conditioned;D016207:Cytokines;D004195:Disease Models, Animal;D005110:Extracellular Space;D006801:Humans;D007116:Immunization, Passive;D020961:Lewy Body Disease;D051379:Mice;D008822:Mice, Transgenic;D008840:Microfilament Proteins;D046529:Microscopy, Electron, Transmission;D009410:Nerve Degeneration;D009457:Neuroglia;D010751:Phosphopyruvate Hydratase;D010982:Platelet-Derived Growth Factor;D009435:Synaptic Transmission;D051844:alpha-Synuclein",2012,49
22941029,α-Synuclein and protein degradation systems: a reciprocal relationship.,D000818:Animals;D001343:Autophagy;D006801:Humans;D010300:Parkinson Disease;D059748:Proteolysis;D015398:Signal Transduction;D051844:alpha-Synuclein,2014,105
22920859,Exosomal cell-to-cell transmission of alpha synuclein oligomers.,D002450:Cell Communication;D004797:Enzyme-Linked Immunosorbent Assay;D055354:Exosomes;D006801:Humans;D015151:Immunoblotting;D009474:Neurons;D009842:Oligopeptides;D014162:Transfection;D051844:alpha-Synuclein,2013,33
22915117,Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation.,"D018750:6-Cyano-7-nitroquinoxaline-2,3-dione;D000818:Animals;D001703:Biophysics;D019921:Biotinylation;D045744:Cell Line, Tumor;D018691:Excitatory Amino Acid Antagonists;D019706:Excitatory Postsynaptic Potentials;D045604:Extracellular Fluid;D006624:Hippocampus;D006801:Humans;D007328:Insulin;D007770:L-Lactate Dehydrogenase;D017774:Long-Term Potentiation;D008297:Male;D009447:Neuroblastoma;D009924:Organ Culture Techniques;D018408:Patch-Clamp Techniques;D051381:Rats;D017208:Rats, Wistar;D016194:Receptors, N-Methyl-D-Aspartate;D013569:Synapses;D009435:Synaptic Transmission;D014633:Valine;D051844:alpha-Synuclein",2012,49
22914327,"IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease.",,2012,239
22880029,Single-channel electrophysiology reveals a distinct and uniform pore complex formed by α-synuclein oligomers in lipid membranes.,"D002412:Cations;D004553:Electric Conductivity;D055724:Electrophysiological Phenomena;D006801:Humans;D008051:Lipid Bilayers;D008954:Models, Biological;D016062:Porosity;D020836:Protein Structure, Quaternary;D013997:Time Factors;D051844:alpha-Synuclein",2013,68
22632969,Direct observation of the interconversion of normal and toxic forms of α-synuclein.,"D000818:Animals;D002478:Cells, Cultured;D019286:Endopeptidase K;D031541:Fluorescence Resonance Energy Transfer;D006801:Humans;D007700:Kinetics;D008958:Models, Molecular;D009474:Neurons;D018384:Oxidative Stress;D051381:Rats;D051844:alpha-Synuclein",2012,41
22373667,"A novel ""molecular tweezer"" inhibitor of α-synuclein neurotoxicity in vitro and in vivo.","D000818:Animals;D002478:Cells, Cultured;D015316:Genetic Therapy;D057809:HEK293 Cells;D006801:Humans;D009154:Mutation;D020258:Neurotoxicity Syndromes;D046988:Proteasome Endopeptidase Complex;D011487:Protein Conformation;D015027:Zebrafish;D051844:alpha-Synuclein",2013,182
22301995,Alpha-synuclein's degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease.,"D000818:Animals;D001343:Autophagy;D001921:Brain;D006801:Humans;D008247:Lysosomes;D051379:Mice;D008954:Models, Biological;D010300:Parkinson Disease;D010588:Phagosomes;D046988:Proteasome Endopeptidase Complex;D059748:Proteolysis;D015398:Signal Transduction;D025801:Ubiquitin;D051844:alpha-Synuclein",2012,231
22251432,Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation.,"D000818:Animals;D002462:Cell Membrane;D020961:Lewy Body Disease;D008051:Lipid Bilayers;D009474:Neurons;D010300:Parkinson Disease;D017433:Protein Structure, Secondary;D051381:Rats;D014407:Tumor Cells, Cultured;D051844:alpha-Synuclein",2013,253
22233220,"A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.","D000818:Animals;D015153:Blotting, Western;D001921:Brain;D018929:Cell Culture Techniques;D045744:Cell Line, Tumor;D002470:Cell Survival;D006801:Humans;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D008856:Microscopy, Fluorescence;D009043:Motor Activity;D018384:Oxidative Stress;D020734:Parkinsonian Disorders;D011392:Proline;D020133:Reverse Transcriptase Polymerase Chain Reaction;D012697:Serine Endopeptidases;D015842:Serine Proteinase Inhibitors;D014162:Transfection;D051844:alpha-Synuclein",2012,200
22186024,PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity.,"D000251:Adenosine Triphosphatases;D000818:Animals;D001343:Autophagy;D001921:Brain;D002118:Calcium;D002478:Cells, Cultured;D022162:Cytoplasmic Vesicles;D059290:Dopaminergic Neurons;D006801:Humans;D006863:Hydrogen-Ion Concentration;D016631:Lewy Bodies;D008565:Membrane Proteins;D051379:Mice;D008928:Mitochondria;D016501:Neurites;D009474:Neurons;D010300:Parkinson Disease;D006180:Proton-Translocating ATPases;D017966:Pyramidal Cells;D034622:RNA Interference;D051381:Rats;D013378:Substantia Nigra",2012,37
22098189,NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease.,"D000818:Animals;D016923:Cell Death;D002460:Cell Line;D002467:Cell Nucleus;D003342:Corpus Striatum;D004249:DNA Damage;D059290:Dopaminergic Neurons;D015870:Gene Expression;D020868:Gene Silencing;D006801:Humans;D009247:NADH, NADPH Oxidoreductases;D000074624:NADPH Oxidase 1;D018384:Oxidative Stress;D016627:Oxidopamine;D010300:Parkinson Disease;D021381:Protein Transport;D051381:Rats;D017382:Reactive Oxygen Species;D020830:rac1 GTP-Binding Protein",2012,101
22009045,Kinetic measurements give new insights into lipid membrane permeabilization by α-synuclein oligomers.,"D009327:4-Chloro-7-nitrobenzofurazan;D004227:Dithionite;D006801:Humans;D007700:Kinetics;D008563:Membrane Lipids;D010539:Permeability;D010713:Phosphatidylcholines;D020836:Protein Structure, Quaternary;D053835:Unilamellar Liposomes;D051844:alpha-Synuclein",2012,254
21982369,Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death.,"D000818:Animals;D001370:Axonal Transport;D016923:Cell Death;D004705:Endocytosis;D006624:Hippocampus;D006801:Humans;D016631:Lewy Bodies;D051379:Mice;D008810:Mice, Inbred C57BL;D009410:Nerve Degeneration;D009419:Nerve Tissue Proteins;D016501:Neurites;D009474:Neurons;D061251:Primary Cell Culture;D013569:Synapses;D056969:Voltage-Sensitive Dye Imaging;D051844:alpha-Synuclein",2011,42
21915101,Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain.,"D000281:Administration, Intranasal;D000818:Animals;D000893:Anti-Inflammatory Agents;D001932:Brain Neoplasms;D004337:Drug Carriers;D004681:Encephalomyelitis, Autoimmune, Experimental;D055354:Exosomes;D006801:Humans;D051379:Mice;D017628:Microglia",2012,244
21841800,α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation.,"D000818:Animals;D015153:Blotting, Western;D019556:COS Cells;D045744:Cell Line, Tumor;D002522:Cercopithecus aethiops;D004912:Erythrocytes;D004926:Escherichia coli;D057809:HEK293 Cells;D006367:HeLa Cells;D006801:Humans;D050356:Lipid Metabolism;D051379:Mice;D017510:Protein Folding;D011994:Recombinant Proteins;D013997:Time Factors;D051844:alpha-Synuclein",2011,13
21813214,Prion-like acceleration of a synucleinopathy in a transgenic mouse model.,"D000367:Age Factors;D000818:Animals;D004195:Disease Models, Animal;D006801:Humans;D007381:Intermediate Filament Proteins;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D009069:Movement Disorders;D009154:Mutation;D010766:Phosphorylation;D017096:Prion Diseases;D012694:Serine;D016019:Survival Analysis",2012,87
21772323,Fighting neurodegeneration with rapamycin: mechanistic insights.,D006801:Humans;D009410:Nerve Degeneration;D019636:Neurodegenerative Diseases;D015398:Signal Transduction;D020123:Sirolimus;D058570:TOR Serine-Threonine Kinases,2011,85
21747756,α-Synuclein Alters Toll-Like Receptor Expression.,DAMP;Parkinson's disease;inflammation;microglial activation;pattern recognition receptors,2011,8
21562258,Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model.,"D000818:Animals;D001253:Astrocytes;D015153:Blotting, Western;D001921:Brain;D002460:Cell Line;D002478:Cells, Cultured;D003712:Dendrites;D004195:Disease Models, Animal;D007150:Immunohistochemistry;D008745:Methylation;D051379:Mice;D008822:Mice, Transgenic;D017628:Microglia;D019636:Neurodegenerative Diseases;D009474:Neurons;D010749:Phosphoprotein Phosphatases;D010766:Phosphorylation;D012701:Serotonin;D051844:alpha-Synuclein",2011,49
21559417,Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.,"D000818:Animals;D000911:Antibodies, Monoclonal;D001522:Behavior, Animal;D045744:Cell Line, Tumor;D004195:Disease Models, Animal;D007116:Immunization, Passive;D007150:Immunohistochemistry;D020961:Lewy Body Disease;D008247:Lysosomes;D018782:Maze Learning;D051379:Mice;D008822:Mice, Transgenic;D009410:Nerve Degeneration;D051381:Rats;D051844:alpha-Synuclein",2011,68
21554732,Expression of mutant alpha-synuclein modulates microglial phenotype in vitro.,"D000818:Animals;D002460:Cell Line;D051545:Cyclooxygenase 1;D051546:Cyclooxygenase 2;D006801:Humans;D015850:Interleukin-6;D052118:Lysosomal-Associated Membrane Protein 1;D008247:Lysosomes;D051379:Mice;D008810:Mice, Inbred C57BL;D017628:Microglia;D009154:Mutation;D009573:Nitrites;D010300:Parkinson Disease;D010587:Phagocytosis;D010641:Phenotype;D010739:Phospholipase D;D026361:Reactive Nitrogen Species;D014409:Tumor Necrosis Factor-alpha;D051844:alpha-Synuclein",2011,104
21399908,Mice lacking major brain gangliosides develop parkinsonism.,"D000368:Aged;D000818:Animals;D001921:Brain;D001923:Brain Chemistry;D005260:Female;D005732:Gangliosides;D006801:Humans;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D018345:Mice, Knockout;D009474:Neurons;D009483:Neuropsychological Tests;D020734:Parkinsonian Disorders;D011597:Psychomotor Performance;D051844:alpha-Synuclein",2012,255
21375481,Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.,"D000544:Alzheimer Disease;D023582:Alzheimer Vaccines;D016229:Amyloid beta-Peptides;D000818:Animals;D002986:Clinical Trials as Topic;D004195:Disease Models, Animal;D006801:Humans;D007116:Immunization, Passive;D016233:Immunotherapy, Active;D018448:Models, Immunological",2011,90
21343881,Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease.,"D000368:Aged;D001344:Autopsy;D015922:Complement C1q;D004076:Digoxigenin;D005110:Extracellular Space;D005260:Female;D005455:Fluorescent Antibody Technique;D006801:Humans;D007091:Image Processing, Computer-Assisted;D007113:Immunity, Innate;D007150:Immunohistochemistry;D017403:In Situ Hybridization;D008297:Male;D008543:Melanins;D010300:Parkinson Disease;D010587:Phagocytosis;D013378:Substantia Nigra;D016707:Tissue Fixation;D015854:Up-Regulation;D014544:Uridine Triphosphate",2011,19
21325059,In vivo demonstration that alpha-synuclein oligomers are toxic.,D000818:Animals;D001704:Biopolymers;D001921:Brain;D016086:Lentivirus;D051381:Rats;D051844:alpha-Synuclein,2011,12
21303699,Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission.,"D015153:Blotting, Western;D002460:Cell Line;D049109:Cell Proliferation;D002478:Cells, Cultured;D004797:Enzyme-Linked Immunosorbent Assay;D055354:Exosomes;D006801:Humans;D007150:Immunohistochemistry;D008247:Lysosomes;D009474:Neurons;D010300:Parkinson Disease;D018709:Statistics, Nonparametric;D051844:alpha-Synuclein",2011,89
21252228,Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy.,"D019943:Amino Acid Substitution;D000818:Animals;D001343:Autophagy;D004195:Disease Models, Animal;D020868:Gene Silencing;D008565:Membrane Proteins;D008928:Mitochondria;D024101:Mitochondrial Proteins;D020125:Mutation, Missense;D009474:Neurons;D016716:PC12 Cells;D010300:Parkinson Disease;D051381:Rats;D017208:Rats, Wistar;D044767:Ubiquitin-Protein Ligases;D051844:alpha-Synuclein",2011,100
21245577,α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.,"D000818:Animals;D001921:Brain;D017690:Cell Transplantation;D002478:Cells, Cultured;D018920:Coculture Techniques;D017077:Culture Media, Conditioned;D004298:Dopamine;D057809:HEK293 Cells;D006801:Humans;D016631:Lewy Bodies;D051379:Mice;D009474:Neurons;D010300:Parkinson Disease;D051381:Rats;D011993:Recombinant Fusion Proteins;D051844:alpha-Synuclein",2011,240
21245015,"Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.","D000578:Amidines;D000818:Animals;D030801:Animals, Genetically Modified;D001596:Benzylamines;D004195:Disease Models, Animal;D007274:Injections, Intraperitoneal;D016631:Lewy Bodies;D008070:Lipopolysaccharides;D051379:Mice;D019255:NADPH Oxidases;D009410:Nerve Degeneration;D019636:Neurodegenerative Diseases;D052247:Nitric Oxide Synthase Type II;D009861:Onium Compounds;D018384:Oxidative Stress;D010300:Parkinson Disease;D013378:Substantia Nigra;D051844:alpha-Synuclein",2011,256
21242314,Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis.,"D000818:Animals;D001692:Biological Transport;D055354:Exosomes;D005802:Genes, MHC Class II;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D017628:Microglia;D009836:Oligodendroglia;D010873:Pinocytosis;D013601:T-Lymphocytes",2011,234
21068151,Integration of clearance mechanisms: the proteasome and autophagy.,"D001343:Autophagy;D008247:Lysosomes;D008954:Models, Biological;D018832:Molecular Chaperones;D046988:Proteasome Endopeptidase Complex;D011487:Protein Conformation;D011506:Proteins;D054875:Ubiquitination",2011,257
20977765,"Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease.",,2010,33
20711464,Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra.,"D000818:Animals;D001483:Base Sequence;D004298:Dopamine;D005260:Female;D005786:Gene Expression Regulation;D055785:Gene Knockdown Techniques;D008297:Male;D034741:RNA, Small Interfering;D012453:Saimiri;D013378:Substantia Nigra;D051844:alpha-Synuclein",2010,68
20711177,Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease.,"D000328:Adult;D017668:Age of Onset;D000368:Aged;D000369:Aged, 80 and over;D016022:Case-Control Studies;D005260:Female;D008040:Genetic Linkage;D020022:Genetic Predisposition to Disease;D014644:Genetic Variation;D055106:Genome-Wide Association Study;D006680:HLA Antigens;D006801:Humans;D008297:Male;D015201:Meta-Analysis as Topic;D008875:Middle Aged;D016017:Odds Ratio;D010300:Parkinson Disease;D055815:Young Adult",2010,17
20701279,Redox reactions of the α-synuclein-Cu(2+) complex and their effects on neuronal cell viability.,D001205:Ascorbic Acid;D002470:Cell Survival;D003300:Copper;D004298:Dopamine;D006801:Humans;D006861:Hydrogen Peroxide;D009474:Neurons;D010084:Oxidation-Reduction;D018384:Oxidative Stress;D010300:Parkinson Disease;D010455:Peptides;D051844:alpha-Synuclein,2010,236
20551914,In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration.,"D000818:Animals;D001921:Brain;D020868:Gene Silencing;D006801:Humans;D015151:Immunoblotting;D007150:Immunohistochemistry;D018613:Microscopy, Confocal;D034622:RNA Interference;D051381:Rats;D013378:Substantia Nigra;D051844:alpha-Synuclein",2010,244
20511551,Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1.,"D000595:Amino Acid Sequence;D000818:Animals;D019898:Autocrine Communication;D045744:Cell Line, Tumor;D002478:Cells, Cultured;D005786:Gene Expression Regulation;D006801:Humans;D018836:Inflammation Mediators;D008070:Lipopolysaccharides;D061965:Matrix Metalloproteinase Inhibitors;D020782:Matrix Metalloproteinases;D017628:Microglia;D008969:Molecular Sequence Data;D019899:Paracrine Communication;D011499:Protein Processing, Post-Translational;D051381:Rats;D017207:Rats, Sprague-Dawley;D044463:Receptor, PAR-1;D051844:alpha-Synuclein",2010,119
20445061,Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains.,"D000368:Aged;D002540:Cerebral Cortex;D019175:DNA Methylation;D044127:Epigenesis, Genetic;D005260:Female;D020022:Genetic Predisposition to Disease;D006801:Humans;D007438:Introns;D008297:Male;D010300:Parkinson Disease;D011699:Putamen;D013378:Substantia Nigra;D051844:alpha-Synuclein",2010,49
20433710,Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model.,"D017209:Apoptosis;D045744:Cell Line, Tumor;D003474:Curcumin;D006801:Humans;D008954:Models, Biological;D009474:Neurons;D018696:Neuroprotective Agents;D009498:Neurotoxins;D018384:Oxidative Stress;D010300:Parkinson Disease;D017382:Reactive Oxygen Species;D013378:Substantia Nigra;D051844:alpha-Synuclein",2010,117
20385841,EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity.,"D000682:Amyloid;D017772:Amyloid Neuropathies;D016229:Amyloid beta-Peptides;D000818:Animals;D015153:Blotting, Western;D016466:CHO Cells;D002392:Catechin;D002846:Chromatography, Affinity;D002942:Circular Dichroism;D006224:Cricetinae;D003412:Cricetulus;D004926:Escherichia coli;D006801:Humans;D018625:Microscopy, Atomic Force;D046529:Microscopy, Electron, Transmission;D008856:Microscopy, Fluorescence;D018696:Neuroprotective Agents;D016716:PC12 Cells;D051381:Rats;D051844:alpha-Synuclein",2010,12
20200163,Lysosomal degradation of alpha-synuclein in vivo.,"D000818:Animals;D001343:Autophagy;D004195:Disease Models, Animal;D050883:HSC70 Heat-Shock Proteins;D006540:Herbicides;D006801:Humans;D052119:Lysosomal-Associated Membrane Protein 2;D008247:Lysosomes;D008297:Male;D008636:Mesencephalon;D051379:Mice;D008822:Mice, Transgenic;D009474:Neurons;D010269:Paraquat;D010300:Parkinson Disease;D051844:alpha-Synuclein",2010,100
20118279,Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease.,"D019264:Adoptive Transfer;D000818:Animals;D015496:CD4-Positive T-Lymphocytes;D003342:Corpus Striatum;D004298:Dopamine;D005434:Flow Cytometry;D006801:Humans;D007150:Immunohistochemistry;D007371:Interferon-gamma;D020381:Interleukin-17;D053645:Interleukin-2 Receptor alpha Subunit;D020267:MPTP Poisoning;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D009474:Neurons;D013378:Substantia Nigra;D006377:T-Lymphocytes, Helper-Inducer;D050378:T-Lymphocytes, Regulatory;D014409:Tumor Necrosis Factor-alpha;D051844:alpha-Synuclein",2010,119
20089925,Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.,"D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine;D000704:Analysis of Variance;D000818:Animals;D016923:Cell Death;D003513:Cycloheximide;D004195:Disease Models, Animal;D004305:Dose-Response Relationship, Drug;D004334:Drug Administration Schedule;D004791:Enzyme Inhibitors;D005786:Gene Expression Regulation;D049452:Green Fluorescent Proteins;D006801:Humans;D047908:Intracellular Signaling Peptides and Proteins;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D020932:Nerve Growth Factor;D009474:Neurons;D018696:Neuroprotective Agents;D016627:Oxidopamine;D016716:PC12 Cells;D010300:Parkinson Disease;D020734:Parkinsonian Disorders;D017346:Protein-Serine-Threonine Kinases;D051381:Rats;D012694:Serine;D020123:Sirolimus;D058570:TOR Serine-Threonine Kinases;D013997:Time Factors;D014157:Transcription Factors;D014162:Transfection;D014446:Tyrosine 3-Monooxygenase",2010,49
20071342,Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies.,"D000818:Animals;D001253:Astrocytes;D002454:Cell Differentiation;D045744:Cell Line, Tumor;D017077:Culture Media, Conditioned;D006801:Humans;D007249:Inflammation;D008297:Male;D051379:Mice;D008822:Mice, Transgenic;D008954:Models, Biological;D019636:Neurodegenerative Diseases;D009474:Neurons;D051381:Rats;D017207:Rats, Sprague-Dawley;D051844:alpha-Synuclein",2010,100
19864570,Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases.,"D000818:Animals;D051017:Apoptosis Regulatory Proteins;D001343:Autophagy;D000071186:Beclin-1;D001921:Brain;D045744:Cell Line, Tumor;D004195:Disease Models, Animal;D018014:Gene Transfer Techniques;D006801:Humans;D020961:Lewy Body Disease;D051379:Mice;D008822:Mice, Transgenic;D009410:Nerve Degeneration;D009474:Neurons;D010300:Parkinson Disease;D051381:Rats;D015398:Signal Transduction;D051844:alpha-Synuclein",2009,49
19858467,Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset.,D017668:Age of Onset;D000483:Alleles;D004252:DNA Mutational Analysis;D005190:Family;D005787:Gene Frequency;D006580:Genetic Carrier Screening;D020022:Genetic Predisposition to Disease;D014644:Genetic Variation;D005838:Genotype;D005962:Glucosylceramidase;D006579:Heterozygote;D006801:Humans;D009154:Mutation;D010300:Parkinson Disease,2009,53
19640926,LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model.,"D048868:Adaptor Proteins, Signal Transducing;D001343:Autophagy;D001921:Brain;D021941:Caveolae;D002460:Cell Line;D011992:Endosomes;D049452:Green Fluorescent Proteins;D006801:Humans;D015151:Immunoblotting;D047468:Immunoprecipitation;D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2;D021962:Membrane Microdomains;D016253:Microscopy, Immunoelectron;D008869:Microtubule-Associated Proteins;D008871:Microvilli;D009154:Mutation;D010300:Parkinson Disease;D011485:Protein Binding;D017346:Protein-Serine-Threonine Kinases;D034741:RNA, Small Interfering;D011993:Recombinant Fusion Proteins;D000071456:Sequestosome-1 Protein;D014162:Transfection",2010,37
19526281,Mutant alpha-synuclein overexpression mediates early proinflammatory activity.,"D000367:Age Factors;D000818:Animals;D000831:Animals, Newborn;D018955:CD36 Antigens;D002135:Calcium-Binding Proteins;D002478:Cells, Cultured;D002540:Cerebral Cortex;D016207:Cytokines;D004195:Disease Models, Animal;D005786:Gene Expression Regulation;D006801:Humans;D007381:Intermediate Filament Proteins;D020267:MPTP Poisoning;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D008840:Microfilament Proteins;D017628:Microglia;D009154:Mutation;D052247:Nitric Oxide Synthase Type II;D012333:RNA, Messenger;D017382:Reactive Oxygen Species;D013997:Time Factors;D014446:Tyrosine 3-Monooxygenase",2010,258
19457162,Alpha-synuclein induces migration of BV-2 microglial cells by up-regulation of CD44 and MT1-MMP.,"D000818:Animals;D001921:Brain;D002465:Cell Movement;D017690:Cell Transplantation;D002478:Cells, Cultured;D017077:Culture Media, Conditioned;D004195:Disease Models, Animal;D018960:Hyaluronan Receptors;D053511:Matrix Metalloproteinase 14;D051379:Mice;D008810:Mice, Inbred C57BL;D017628:Microglia;D048052:Mitogen-Activated Protein Kinase 3;D020929:Mitogen-Activated Protein Kinase Kinases;D016627:Oxidopamine;D010300:Parkinson Disease;D012333:RNA, Messenger;D034741:RNA, Small Interfering;D015398:Signal Transduction;D013378:Substantia Nigra;D014162:Transfection;D015854:Up-Regulation;D051844:alpha-Synuclein",2009,126
19182805,Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity.,"D000818:Animals;D017173:Caenorhabditis elegans;D002478:Cells, Cultured;D017124:Conserved Sequence;D004351:Drug Resistance;D004843:Epistasis, Genetic;D053263:Gene Regulatory Networks;D008345:Manganese;D009154:Mutation;D009474:Neurons;D010300:Parkinson Disease;D006180:Proton-Translocating ATPases;D012441:Saccharomyces cerevisiae;D029701:Saccharomyces cerevisiae Proteins;D014018:Tissue Distribution;D051844:alpha-Synuclein",2009,17
19104149,Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease.,"D000368:Aged;D000369:Aged, 80 and over;D000818:Animals;D001921:Brain;D015496:CD4-Positive T-Lymphocytes;D016923:Cell Death;D004195:Disease Models, Animal;D004298:Dopamine;D053222:Fas Ligand Protein;D018398:Homeodomain Proteins;D006801:Humans;D007107:Immune System;D007371:Interferon-gamma;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D018345:Mice, Knockout;D009410:Nerve Degeneration;D009474:Neurons;D010300:Parkinson Disease;D020734:Parkinsonian Disorders",2009,240
18976489,In vivo silencing of alpha-synuclein using naked siRNA.,,2008,33
18704197,Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.,"D000682:Amyloid;D000818:Animals;D001921:Brain;D004195:Disease Models, Animal;D004298:Dopamine;D050956:HSP40 Heat-Shock Proteins;D018840:HSP70 Heat-Shock Proteins;D006360:Heat-Shock Proteins;D006801:Humans;D008954:Models, Biological;D019636:Neurodegenerative Diseases;D010300:Parkinson Disease;D011485:Protein Binding;D051381:Rats;D051844:alpha-Synuclein",2008,240
18391963,Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation.,D016380:Brain Tissue Transplantation;D018450:Disease Progression;D016332:Fetal Tissue Transplantation;D006801:Humans;D007150:Immunohistochemistry;D016631:Lewy Bodies;D010300:Parkinson Disease;D016896:Treatment Outcome;D051844:alpha-Synuclein,2008,32
18391962,Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.,D016380:Brain Tissue Transplantation;D018450:Disease Progression;D005260:Female;D016332:Fetal Tissue Transplantation;D006801:Humans;D007150:Immunohistochemistry;D016631:Lewy Bodies;D008875:Middle Aged;D010300:Parkinson Disease;D013378:Substantia Nigra;D016896:Treatment Outcome;D025801:Ubiquitin;D051844:alpha-Synuclein,2008,32
18391961,Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years.,D016380:Brain Tissue Transplantation;D016332:Fetal Tissue Transplantation;D006801:Humans;D007150:Immunohistochemistry;D008297:Male;D008875:Middle Aged;D009474:Neurons;D010300:Parkinson Disease;D049268:Positron-Emission Tomography;D016896:Treatment Outcome;D014446:Tyrosine 3-Monooxygenase,2008,32
18226468,Exosomes: the Trojan horses of neurodegeneration.,"D000544:Alzheimer Disease;D002450:Cell Communication;D002451:Cell Compartmentation;D022162:Cytoplasmic Vesicles;D005089:Exocytosis;D006801:Humans;D008954:Models, Biological;D009410:Nerve Degeneration",2008,259
18189141,Curcumin inhibits aggregation of alpha-synuclein.,"D045744:Cell Line, Tumor;D003474:Curcumin;D004305:Dose-Response Relationship, Drug;D004791:Enzyme Inhibitors;D049452:Green Fluorescent Proteins;D006801:Humans;D009154:Mutation;D009447:Neuroblastoma;D021381:Protein Transport;D013997:Time Factors;D014162:Transfection;D051844:alpha-Synuclein",2008,15
18167537,Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons.,"D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine;D019264:Adoptive Transfer;D000818:Animals;D002478:Cells, Cultured;D004797:Enzyme-Linked Immunosorbent Assay;D000939:Epitopes;D005434:Flow Cytometry;D007150:Immunohistochemistry;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D009474:Neurons;D009566:Nitrates;D013378:Substantia Nigra;D051844:alpha-Synuclein",2008,68
17914185,Pore-forming proteins share structural and functional homology with amyloid oligomers.,"D000595:Amino Acid Sequence;D016229:Amyloid beta-Peptides;D000906:Antibodies;D001427:Bacterial Toxins;D003840:Deoxycholic Acid;D029968:Escherichia coli Proteins;D006460:Hemolysin Proteins;D006801:Humans;D010446:Peptide Fragments;D054353:Perforin;D017433:Protein Structure, Secondary;D013329:Structure-Activity Relationship;D013602:T-Lymphocytes, Cytotoxic",2007,260
17376993,Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons.,"D000328:Adult;D000368:Aged;D000818:Animals;D002452:Cell Count;D016923:Cell Death;D002478:Cells, Cultured;D018920:Coculture Techniques;D004298:Dopamine;D006801:Humans;D007371:Interferon-gamma;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D018345:Mice, Knockout;D017628:Microglia;D008875:Middle Aged;D009474:Neurons;D010300:Parkinson Disease",2007,49
17204153,Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein.,"D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine;D000818:Animals;D006801:Humans;D020961:Lewy Body Disease;D051379:Mice;D008807:Mice, Inbred BALB C;D018345:Mice, Knockout;D017628:Microglia;D018078:Receptors, Prostaglandin E;D058307:Receptors, Prostaglandin E, EP2 Subtype;D051844:alpha-Synuclein",2007,104
16964263,"Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase.",D000251:Adenosine Triphosphatases;D003704:Dementia;D004721:Endoplasmic Reticulum;D005260:Female;D006801:Humans;D008247:Lysosomes;D008297:Male;D008636:Mesencephalon;D009154:Mutation;D009474:Neurons;D020734:Parkinsonian Disorders;D006180:Proton-Translocating ATPases,2006,17
16959795,Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.,"D000107:Acetylation;D000818:Animals;D001921:Brain;D045744:Cell Line, Tumor;D002467:Cell Nucleus;D004330:Drosophila;D056572:Histone Deacetylase Inhibitors;D006657:Histones;D006801:Humans;D051379:Mice;D009474:Neurons;D030781:Organisms, Genetically Modified;D010300:Parkinson Disease;D051844:alpha-Synuclein",2006,37
16896109,Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.,"D000328:Adult;D017668:Age of Onset;D000368:Aged;D000369:Aged, 80 and over;D000483:Alleles;D018900:Dinucleotide Repeats;D005260:Female;D020022:Genetic Predisposition to Disease;D014644:Genetic Variation;D005838:Genotype;D006239:Haplotypes;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011401:Promoter Regions, Genetic;D051844:alpha-Synuclein",2006,261
16219675,A possible role for humoral immunity in the pathogenesis of Parkinson's disease.,"D000368:Aged;D000369:Aged, 80 and over;D018450:Disease Progression;D005260:Female;D015395:Histocompatibility Antigens Class I;D006801:Humans;D007074:Immunoglobulin G;D007075:Immunoglobulin M;D016631:Lewy Bodies;D008297:Male;D017628:Microglia;D008875:Middle Aged;D009154:Mutation;D009474:Neurons;D010300:Parkinson Disease;D017452:Receptors, IgG;D013378:Substantia Nigra;D044767:Ubiquitin-Protein Ligases;D014793:Visual Cortex;D051844:alpha-Synuclein",2005,36
16182554,In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease.,D000368:Aged;D001569:Benzodiazepines;D001921:Brain;D002250:Carbon Radioisotopes;D003952:Diagnostic Imaging;D005260:Female;D006801:Humans;D007546:Isoquinolines;D008297:Male;D017628:Microglia;D008875:Middle Aged;D010300:Parkinson Disease;D049268:Positron-Emission Tomography,2006,89
15935098,Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition.,,2005,104
15834418,Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease.,"D019943:Amino Acid Substitution;D000818:Animals;D030801:Animals, Genetically Modified;D001224:Aspartic Acid;D001921:Brain;D002490:Central Nervous System;D017868:Cyclic AMP-Dependent Protein Kinases;D004195:Disease Models, Animal;D004298:Dopamine;D004330:Drosophila;D029721:Drosophila Proteins;D054769:G-Protein-Coupled Receptor Kinase 2;D002479:Inclusion Bodies;D009410:Nerve Degeneration;D009419:Nerve Tissue Proteins;D009474:Neurons;D010300:Parkinson Disease;D010766:Phosphorylation;D017354:Point Mutation;D012160:Retina;D012694:Serine;D051843:Synucleins;D051844:alpha-Synuclein;D051552:beta-Adrenergic Receptor Kinases",2005,51
15451224,Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.,"D000328:Adult;D017668:Age of Onset;D000368:Aged;D000369:Aged, 80 and over;D005260:Female;D018628:Gene Dosage;D020440:Gene Duplication;D006801:Humans;D017404:In Situ Hybridization, Fluorescence;D020961:Lewy Body Disease;D008297:Male;D018895:Microsatellite Repeats;D008875:Middle Aged;D020125:Mutation, Missense;D009419:Nerve Tissue Proteins;D010300:Parkinson Disease;D016133:Polymerase Chain Reaction;D051843:Synucleins;D051844:alpha-Synuclein",2004,38
15333840,Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.,"D020816:Amino Acid Motifs;D000818:Animals;D015703:Antigens, CD;D001343:Autophagy;D002478:Cells, Cultured;D005987:Glyceraldehyde-3-Phosphate Dehydrogenases;D006207:Half-Life;D007425:Intracellular Membranes;D051907:Lysosome-Associated Membrane Glycoproteins;D008247:Lysosomes;D008297:Male;D051379:Mice;D018832:Molecular Chaperones;D009154:Mutation;D009419:Nerve Tissue Proteins;D009474:Neurons;D016716:PC12 Cells;D011485:Protein Binding;D021381:Protein Transport;D051381:Rats;D017208:Rats, Wistar;D051843:Synucleins;D051844:alpha-Synuclein",2004,18
12411925,Pharmacological prevention of Parkinson disease in Drosophila.,"D000818:Animals;D030801:Animals, Genetically Modified;D016227:Benzoquinones;D004195:Disease Models, Animal;D004298:Dopamine;D004331:Drosophila melanogaster;D047029:Lactams, Macrocyclic;D009419:Nerve Tissue Proteins;D009474:Neurons;D010300:Parkinson Disease;D011809:Quinones;D051843:Synucleins",2003,32
12377775,Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions.,D000368:Aged;D000595:Amino Acid Sequence;D001921:Brain;D003488:Cyanogen Bromide;D005260:Female;D006801:Humans;D008297:Male;D008969:Molecular Sequence Data;D009419:Nerve Tissue Proteins;D019636:Neurodegenerative Diseases;D010766:Phosphorylation;D051843:Synucleins;D025801:Ubiquitin;D051844:alpha-Synuclein,2003,100
11286556,Conformational properties of alpha-synuclein in its free and lipid-associated states.,"D002244:Carbon;D002942:Circular Dichroism;D006801:Humans;D050356:Lipid Metabolism;D008081:Liposomes;D009682:Magnetic Resonance Spectroscopy;D008823:Micelles;D008958:Models, Molecular;D009419:Nerve Tissue Proteins;D009584:Nitrogen;D010300:Parkinson Disease;D011485:Protein Binding;D017510:Protein Folding;D017433:Protein Structure, Secondary;D011522:Protons;D012967:Sodium Dodecyl Sulfate;D051843:Synucleins;D051844:alpha-Synuclein",2001,245
9726379,Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D002531:Cerebellum;D003704:Dementia;D005625:Frontal Lobe;D006801:Humans;D007150:Immunohistochemistry;D016631:Lewy Bodies;D008875:Middle Aged;D019578:Multiple System Atrophy;D009419:Nerve Tissue Proteins;D010300:Parkinson Disease;D011149:Pons;D051843:Synucleins;D051844:alpha-Synuclein",1998,14
9600990,alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.,D001344:Autopsy;D001921:Brain;D003704:Dementia;D006801:Humans;D007150:Immunohistochemistry;D016631:Lewy Bodies;D009419:Nerve Tissue Proteins;D010300:Parkinson Disease;D051843:Synucleins;D051844:alpha-Synuclein,1998,12
1502878,Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins.,"D000368:Aged;D000369:Aged, 80 and over;D000906:Antibodies;D001369:Axons;D003167:Complement Activation;D003165:Complement System Proteins;D003712:Dendrites;D006801:Humans;D007150:Immunohistochemistry;D007163:Immunosorbent Techniques;D016631:Lewy Bodies;D008875:Middle Aged;D009836:Oligodendroglia;D010300:Parkinson Disease",1992,15
28332488,Parkinson disease.,D000978:Antiparkinson Agents;D015415:Biomarkers;D018491:Dopamine Agonists;D015316:Genetic Therapy;D006801:Humans;D007980:Levodopa;D008928:Mitochondria;D018384:Oxidative Stress;D010300:Parkinson Disease;D011788:Quality of Life;D051844:alpha-Synuclein,2018,262
27744249,Effects of belt speed on the body's center of mass motion relative to the center of pressure during treadmill walking.,D001696:Biomechanical Phenomena;D001835:Body Weight;D005080:Exercise Test;D005684:Gait;D006801:Humans;D008297:Male;D009038:Motion;D011312:Pressure;D016138:Walking;D055815:Young Adult,2017,58
27694060,Dynamic gait stability of treadmill versus overground walking in young adults.,"D000328:Adult;D001696:Biomechanical Phenomena;D005080:Exercise Test;D005081:Exercise Therapy;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D018482:Muscle, Skeletal;D016138:Walking",2017,263
27632061,Adaptive gait responses to awareness of an impending slip during treadmill walking.,"D000058:Accidental Falls;D000222:Adaptation, Physiological;D000328:Adult;D001364:Awareness;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D064368:Healthy Volunteers;D006801:Humans;D008297:Male;D009038:Motion;D004856:Postural Balance;D016138:Walking;D055815:Young Adult",2018,58
27264400,Complexity of human gait pattern at different ages assessed using multiscale entropy: From development to decline.,"D000293:Adolescent;D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D001696:Biomechanical Phenomena;D002648:Child;D002675:Child, Preschool;D019277:Entropy;D005260:Female;D005684:Gait;D006801:Humans;D007223:Infant;D007231:Infant, Newborn;D008297:Male;D008875:Middle Aged;D015233:Models, Statistical;D000072797:Walking Speed",2018,58
26979893,Sagittal plane momentum control during walking in elderly fallers.,"D000054:Acceleration;D000058:Accidental Falls;D000368:Aged;D005260:Female;D005528:Foot;D005684:Gait;D006801:Humans;D008297:Male;D008962:Models, Theoretical;D009038:Motion;D016138:Walking",2016,58
26970886,Locomotor stability and adaptation during perturbed walking across the adult female lifespan.,"D000222:Adaptation, Physiological;D000328:Adult;D000368:Aged;D000375:Aging;D001696:Biomechanical Phenomena;D005080:Exercise Test;D005260:Female;D005528:Foot;D005684:Gait;D006801:Humans;D007866:Leg;D008875:Middle Aged;D004856:Postural Balance;D016138:Walking;D055815:Young Adult",2017,79
26929929,"The Effect of Walking Speed on Gait Variability in Healthy Young, Middle-aged and Elderly Individuals.",age;gait variability;walking speed,2015,264
26615477,Effect of active arm swing to local dynamic stability during walking.,D000328:Adult;D000843:Ankle Joint;D001132:Arm;D005080:Exercise Test;D005260:Female;D005684:Gait;D006801:Humans;D007719:Knee Joint;D008297:Male;D009043:Motor Activity;D004856:Postural Balance;D016138:Walking;D055815:Young Adult,2016,59
26233581,Gait variability in healthy old adults is more affected by a visual perturbation than by a cognitive or narrow step placement demand.,"D000368:Aged;D000704:Analysis of Variance;D003071:Cognition;D005080:Exercise Test;D056228:Feedback, Sensory;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008875:Middle Aged;D014796:Visual Perception;D016138:Walking",2016,58
25894561,Wearable sensor use for assessing standing balance and walking stability in people with Parkinson's disease: a systematic review.,D006801:Humans;D010300:Parkinson Disease;D010827:Physiology;D004856:Postural Balance;D016138:Walking,2016,68
25670653,Older adults prioritize postural stability in the anterior-posterior direction to regain balance following volitional lateral step.,"D000058:Accidental Falls;D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D004856:Postural Balance;D011312:Pressure;D014796:Visual Perception;D055815:Young Adult",2015,58
25557656,Quantifying dynamic and postural balance difficulty during gait perturbations using stabilizing/destabilizing forces.,D000328:Adult;D001696:Biomechanical Phenomena;D005080:Exercise Test;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D004856:Postural Balance;D011187:Posture;D016138:Walking;D055815:Young Adult,2015,79
25458148,Can stability really predict an impending slip-related fall among older adults?,D000058:Accidental Falls;D000368:Aged;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006801:Humans;D016015:Logistic Models;D008297:Male;D009038:Motion;D004856:Postural Balance;D012306:Risk;D018570:Risk Assessment;D016138:Walking,2015,79
25455700,Older adults who have previously fallen due to a trip walk differently than those who have fallen due to a slip.,D000058:Accidental Falls;D000368:Aged;D001696:Biomechanical Phenomena;D001837:Body Weights and Measures;D005260:Female;D005684:Gait;D006801:Humans;D007389:Internal-External Control;D008124:Locomotion;D008297:Male;D009068:Movement;D004856:Postural Balance;D020127:Recovery of Function;D012189:Retrospective Studies;D016138:Walking;D014947:Wounds and Injuries,2015,58
25455699,Effect of age on the variability and stability of gait: a cross-sectional treadmill study in healthy individuals between 20 and 69 years of age.,D000054:Acceleration;D061725:Accelerometry;D000328:Adult;D000368:Aged;D000375:Aging;D000704:Analysis of Variance;D000886:Anthropometry;D003430:Cross-Sectional Studies;D005080:Exercise Test;D005260:Female;D005684:Gait;D006801:Humans;D016014:Linear Models;D008297:Male;D008875:Middle Aged;D004856:Postural Balance;D012016:Reference Values;D060726:Torso;D016138:Walking;D055815:Young Adult,2015,58
25311450,The effect of walking speed on local dynamic stability is sensitive to calculation methods.,D000054:Acceleration;D000328:Adult;D005080:Exercise Test;D005260:Female;D006801:Humans;D008297:Male;D016138:Walking;D055815:Young Adult,2015,79
25242294,"Associations between measures of gait stability, leg strength and fear of falling.","D000058:Accidental Falls;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D001007:Anxiety;D001696:Biomechanical Phenomena;D015987:Effect Modifier, Epidemiologic;D005080:Exercise Test;D005260:Female;D005684:Gait;D006801:Humans;D007719:Knee Joint;D007866:Leg;D016014:Linear Models;D016015:Logistic Models;D008297:Male;D008875:Middle Aged;D015999:Multivariate Analysis;D053580:Muscle Strength;D004856:Postural Balance;D011788:Quality of Life;D019415:Torque;D016138:Walking",2015,58
25138223,Good lateral harmonic stability combined with adequate gait speed is required for low fall risk in older people.,"D000058:Accidental Falls;D000368:Aged;D000369:Aged, 80 and over;D001696:Biomechanical Phenomena;D005080:Exercise Test;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D004856:Postural Balance;D012306:Risk;D018570:Risk Assessment;D013997:Time Factors;D016138:Walking",2015,265
25095816,Prevention of falls in Parkinson's disease: a review of fall risk factors and the role of physical interventions.,D000058:Accidental Falls;D006801:Humans;D010300:Parkinson Disease;D011379:Prognosis;D016032:Randomized Controlled Trials as Topic;D012307:Risk Factors,2015,266
24835473,Reduced intensity in gait-slip training can still improve stability.,"D000058:Accidental Falls;D000222:Adaptation, Physiological;D000328:Adult;D001696:Biomechanical Phenomena;D001835:Body Weight;D004867:Equipment Design;D005081:Exercise Therapy;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D009068:Movement;D004856:Postural Balance;D055815:Young Adult",2014,79
24790168,A neuromechanical strategy for mediolateral foot placement in walking humans.,"D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006801:Humans;D007866:Leg;D008297:Male;D018482:Muscle, Skeletal;D016138:Walking;D055815:Young Adult",2015,65
24609821,Lower safety factor for old adults during walking at preferred velocity.,D000058:Accidental Falls;D000368:Aged;D000375:Aging;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006801:Humans;D008124:Locomotion;D008297:Male;D004856:Postural Balance;D016138:Walking,2015,267
24465708,Detrended fluctuation analysis and adaptive fractal analysis of stride time data in Parkinson's disease: stitching together short gait trials.,"D000368:Aged;D001696:Biomechanical Phenomena;D016022:Case-Control Studies;D017709:Fractals;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D016014:Linear Models;D008875:Middle Aged;D010300:Parkinson Disease;D012984:Software;D018709:Statistics, Nonparametric;D016138:Walking;D055815:Young Adult",2014,68
24305993,Gait and upper limb variability in Parkinson's disease patients with and without freezing of gait.,"D000368:Aged;D000978:Antiparkinson Agents;D003627:Data Interpretation, Statistical;D020820:Dyskinesias;D005260:Female;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D009068:Movement;D009460:Neurologic Examination;D010300:Parkinson Disease;D011795:Surveys and Questionnaires;D034941:Upper Extremity",2014,77
23978691,Alteration in community-dwelling older adults' level walking following perturbation training.,"D000058:Accidental Falls;D000222:Adaptation, Physiological;D000368:Aged;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D004856:Postural Balance;D016138:Walking",2014,79
23603517,Adaptation and generalization to opposing perturbations in walking.,"D000222:Adaptation, Physiological;D000328:Adult;D005260:Female;D005793:Generalization (Psychology);D006801:Humans;D008297:Male;D011597:Psychomotor Performance;D016138:Walking;D055815:Young Adult",2014,106
23516062,Assessing the stability of human locomotion: a review of current measures.,"D000058:Accidental Falls;D001696:Biomechanical Phenomena;D005684:Gait;D006801:Humans;D008124:Locomotion;D008954:Models, Biological;D004856:Postural Balance;D012307:Risk Factors",2013,268
23370318,Split-belt locomotion in Parkinson's disease with and without freezing of gait.,"D005080:Exercise Test;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease",2013,106
23141636,Generalization of treadmill-slip training to prevent a fall following a sudden (novel) slip in over-ground walking.,"D000058:Accidental Falls;D000222:Adaptation, Physiological;D000328:Adult;D005260:Female;D006801:Humans;D008297:Male;D016138:Walking;D055815:Young Adult",2013,79
22776685,Phase-dependent changes in local dynamic stability of human gait.,"D000328:Adult;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008954:Models, Biological;D004856:Postural Balance;D016138:Walking",2013,79
22749389,Effects of perturbation magnitude on dynamic stability when walking in destabilizing environments.,"D000328:Adult;D001696:Biomechanical Phenomena;D006801:Humans;D008297:Male;D008954:Models, Biological;D004856:Postural Balance;D014796:Visual Perception;D016138:Walking",2012,79
22748312,Local dynamic stability and variability of gait are associated with fall history in elderly subjects.,"D000054:Acceleration;D000058:Accidental Falls;D000368:Aged;D000375:Aging;D001696:Biomechanical Phenomena;D015331:Cohort Studies;D016001:Confidence Intervals;D005080:Exercise Test;D005260:Female;D005684:Gait;D015577:Geriatric Assessment;D006801:Humans;D015994:Incidence;D008297:Male;D008875:Middle Aged;D015999:Multivariate Analysis;D004856:Postural Balance;D011446:Prospective Studies;D012044:Regression Analysis;D018570:Risk Assessment;D018709:Statistics, Nonparametric;D013647:Task Performance and Analysis;D016138:Walking",2013,58
22541943,Older adults have unstable gait kinematics during weight transfer.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D001696:Biomechanical Phenomena;D001835:Body Weight;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D016138:Walking;D055815:Young Adult",2012,79
22377431,Adaptive control reduces trip-induced forward gait instability among young adults.,"D000058:Accidental Falls;D000222:Adaptation, Physiological;D000328:Adult;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008954:Models, Biological;D016138:Walking;D055815:Young Adult",2012,79
22326059,Dynamic margins of stability during human walking in destabilizing environments.,"D000328:Adult;D003198:Computer Simulation;D005260:Female;D005528:Foot;D006801:Humans;D008297:Male;D008954:Models, Biological;D016138:Walking",2012,79
22240093,Symmetry and reproducibility of the components of dynamic stability in young adults at different walking velocities on the treadmill.,D000328:Adult;D005080:Exercise Test;D005260:Female;D005684:Gait;D006801:Humans;D007596:Joints;D035002:Lower Extremity;D004856:Postural Balance;D015203:Reproducibility of Results;D016138:Walking;D055815:Young Adult,2012,263
22080998,Gait variability in Parkinson's disease: influence of walking speed and dopaminergic treatment.,D000368:Aged;D000978:Antiparkinson Agents;D005260:Female;D005684:Gait;D006801:Humans;D007980:Levodopa;D008297:Male;D010300:Parkinson Disease;D016138:Walking,2012,188
22041097,Age- and speed-related differences in harmonic ratios during walking.,"D000054:Acceleration;D000328:Adult;D000367:Age Factors;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D000704:Analysis of Variance;D015331:Cohort Studies;D004734:Energy Metabolism;D005260:Female;D005684:Gait;D006706:Homeostasis;D006801:Humans;D016014:Linear Models;D008297:Male;D008875:Middle Aged;D004856:Postural Balance;D011237:Predictive Value of Tests;D016059:Range of Motion, Articular;D012016:Reference Values;D016138:Walking;D055815:Young Adult",2012,58
21880615,Kinematic measures for assessing gait stability in elderly individuals: a systematic review.,D000058:Accidental Falls;D000203:Activities of Daily Living;D000368:Aged;D000375:Aging;D000465:Algorithms;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D004856:Postural Balance;D012306:Risk;D012307:Risk Factors;D012656:Self-Help Devices;D016138:Walking,2012,268
21715166,Repetitive stepping in place identifies and measures freezing episodes in subjects with Parkinson's disease.,"D000465:Algorithms;D000704:Analysis of Variance;D016022:Case-Control Studies;D020233:Gait Disorders, Neurologic;D006801:Humans;D009068:Movement;D010300:Parkinson Disease;D012815:Signal Processing, Computer-Assisted",2012,58
21530728,"Dynamic gait stability, clinical correlates, and prognosis of falls among community-dwelling older adults.","D000058:Accidental Falls;D000368:Aged;D000369:Aged, 80 and over;D005260:Female;D005684:Gait;D015577:Geriatric Assessment;D006801:Humans;D008297:Male;D004856:Postural Balance;D012111:Residence Characteristics",2011,269
21382449,Walking patterns in Parkinson's disease with and without freezing of gait.,"D000368:Aged;D004185:Disability Evaluation;D005080:Exercise Test;D005260:Female;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D016138:Walking",2012,106
21345241,"Kinematic variability, fractal dynamics and local dynamic stability of treadmill walking.",D000328:Adult;D001696:Biomechanical Phenomena;D005080:Exercise Test;D005684:Gait;D006801:Humans;D008297:Male;D016138:Walking,2011,7
21211977,Center of mass and base of support interaction during gait.,"D000058:Accidental Falls;D000328:Adult;D000367:Age Factors;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D000886:Anthropometry;D001696:Biomechanical Phenomena;D001823:Body Composition;D015331:Cohort Studies;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D004856:Postural Balance;D012678:Sensation Disorders;D016474:Weight-Bearing;D055815:Young Adult",2011,58
21094944,Dynamic stability of human walking in visually and mechanically destabilizing environments.,"D003198:Computer Simulation;D003463:Cues;D004777:Environment;D056228:Feedback, Sensory;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008954:Models, Biological;D011434:Proprioception;D014796:Visual Perception;D016138:Walking;D055815:Young Adult",2011,79
21075935,The effects of arm swing on human gait stability.,D000328:Adult;D001132:Arm;D001696:Biomechanical Phenomena;D005684:Gait;D006801:Humans;D008297:Male;D009068:Movement;D013997:Time Factors,2011,270
20923910,Validation of a measure of smoothness of walking.,D000328:Adult;D000367:Age Factors;D000368:Aged;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D016138:Walking,2011,271
20737542,Falls in Parkinson's disease: kinematic evidence for impaired head and trunk control.,"D000058:Accidental Falls;D000368:Aged;D001696:Biomechanical Phenomena;D005260:Female;D005500:Follow-Up Studies;D020233:Gait Disorders, Neurologic;D006257:Head;D006801:Humans;D007717:Knee;D008297:Male;D009068:Movement;D010300:Parkinson Disease;D011597:Psychomotor Performance;D012189:Retrospective Studies;D016138:Walking",2011,28
20655606,Measures of dynamic stability: Detecting differences between walking overground and on a compliant surface.,D000054:Acceleration;D000328:Adult;D004777:Environment;D005260:Female;D007839:Functional Laterality;D005684:Gait;D006365:Heel;D006801:Humans;D008297:Male;D011140:Polyurethanes;D013499:Surface Properties;D014034:Toes;D016138:Walking,2011,59
20605097,Re-interpreting detrended fluctuation analyses of stride-to-stride variability in human walking.,D000054:Acceleration;D000293:Adolescent;D000328:Adult;D000704:Analysis of Variance;D001696:Biomechanical Phenomena;D001699:Biometry;D016009:Chi-Square Distribution;D003430:Cross-Sectional Studies;D005080:Exercise Test;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D004856:Postural Balance;D012016:Reference Values;D016138:Walking;D055815:Young Adult,2011,58
20574039,Predictors of future falls in Parkinson disease.,"D000058:Accidental Falls;D000203:Activities of Daily Living;D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D005260:Female;D005684:Gait;D015577:Geriatric Assessment;D006801:Humans;D008297:Male;D008875:Middle Aged;D016017:Odds Ratio;D010300:Parkinson Disease;D004856:Postural Balance;D012372:ROC Curve;D012306:Risk;D018570:Risk Assessment;D012720:Severity of Illness Index;D011795:Surveys and Questionnaires",2010,53
20354902,Estimating dynamic gait stability using data from non-aligned inertial sensors.,"D001696:Biomechanical Phenomena;D005080:Exercise Test;D005684:Gait;D006801:Humans;D008124:Locomotion;D008297:Male;D018670:Monitoring, Ambulatory;D055096:Optical Devices;D016138:Walking",2010,272
20346453,Walking variability during continuous pseudo-random oscillations of the support surface and visual field.,"D000222:Adaptation, Physiological;D000328:Adult;D005684:Gait;D006801:Humans;D008297:Male;D009949:Orientation;D009991:Oscillometry;D014794:Visual Fields;D014796:Visual Perception;D016138:Walking",2010,79
20185314,Variation in trunk kinematics influences variation in step width during treadmill walking by older and younger adults.,D000328:Adult;D000367:Age Factors;D001696:Biomechanical Phenomena;D005080:Exercise Test;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008875:Middle Aged;D004856:Postural Balance;D012044:Regression Analysis;D013909:Thorax;D016138:Walking,2010,58
20129786,Measures of frontal plane stability during treadmill and overground walking.,"D000058:Accidental Falls;D000704:Analysis of Variance;D001696:Biomechanical Phenomena;D005080:Exercise Test;D005260:Female;D006801:Humans;D008124:Locomotion;D008297:Male;D004856:Postural Balance;D012815:Signal Processing, Computer-Assisted;D016138:Walking;D055815:Young Adult",2010,58
19713694,Gait variability among healthy adults: low and high stride-to-stride variability are both a reflection of gait stability.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D001288:Attention;D004185:Disability Evaluation;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D004856:Postural Balance;D016138:Walking;D055815:Young Adult",2010,265
19621072,Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.,D055317:Evidence-Based Practice;D006801:Humans;D015201:Meta-Analysis as Topic;D010506:Periodicals as Topic;D017594:Publication Bias;D011643:Publishing;D011786:Quality Control;D012196:Review Literature as Topic;D009626:Terminology as Topic,2009,273
19566273,"Gait dynamics in Parkinson's disease: common and distinct behavior among stride length, gait variability, and fractal-like scaling.","D000161:Acoustic Stimulation;D001696:Biomechanical Phenomena;D055592:Biophysical Phenomena;D016022:Case-Control Studies;D000697:Central Nervous System Stimulants;D017709:Fractals;D020233:Gait Disorders, Neurologic;D006801:Humans;D008774:Methylphenidate;D008954:Models, Biological;D017711:Nonlinear Dynamics;D010300:Parkinson Disease;D016138:Walking",2009,274
19502060,Dynamic stability of superior vs. inferior segments during walking in young and older adults.,D000058:Accidental Falls;D000328:Adult;D000367:Age Factors;D000368:Aged;D000375:Aging;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D004856:Postural Balance,2009,58
19446294,Is slow walking more stable?,"D000058:Accidental Falls;D000328:Adult;D000704:Analysis of Variance;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008954:Models, Biological;D017711:Nonlinear Dynamics;D004856:Postural Balance;D016138:Walking;D055815:Young Adult",2009,79
19221191,Acceleration patterns of the head and pelvis during gait in older people with Parkinson's disease: a comparison of fallers and nonfallers.,"D000054:Acceleration;D000058:Accidental Falls;D000222:Adaptation, Physiological;D000368:Aged;D000886:Anthropometry;D001696:Biomechanical Phenomena;D016022:Case-Control Studies;D005080:Exercise Test;D005260:Female;D005684:Gait;D020233:Gait Disorders, Neurologic;D015577:Geriatric Assessment;D019416:Head Movements;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D010388:Pelvis;D004856:Postural Balance;D016138:Walking",2009,271
19218229,Whole-body responses: neural control and implications for rehabilitation and fall prevention.,D000058:Accidental Falls;D000818:Animals;D005081:Exercise Therapy;D006801:Humans;D008124:Locomotion;D004856:Postural Balance;D011187:Posture;D011597:Psychomotor Performance,2009,275
19135478,Statistical precision and sensitivity of measures of dynamic gait stability.,"D000328:Adult;D001696:Biomechanical Phenomena;D005684:Gait;D006801:Humans;D008297:Male;D008954:Models, Biological;D009483:Neuropsychological Tests;D004856:Postural Balance;D016138:Walking",2009,219
19014631,Control of the upper body accelerations in young and elderly women during level walking.,D000054:Acceleration;D000328:Adult;D000368:Aged;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006257:Head;D019416:Head Movements;D006801:Humans;D004856:Postural Balance;D016138:Walking,2009,7
18973258,Walking stability using harmonic ratios in Parkinson's disease.,D000054:Acceleration;D000368:Aged;D000978:Antiparkinson Agents;D001696:Biomechanical Phenomena;D016022:Case-Control Studies;D005260:Female;D020235:Gait Apraxia;D006801:Humans;D008297:Male;D008875:Middle Aged;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D016138:Walking,2009,28
18668626,The role of gait rhythmicity and bilateral coordination of stepping in the pathophysiology of freezing of gait in Parkinson's disease.,D007839:Functional Laterality;D005684:Gait;D006801:Humans;D010300:Parkinson Disease;D010507:Periodicity;D011597:Psychomotor Performance;D016138:Walking,2008,28
18412621,Bilateral coordination of walking and freezing of gait in Parkinson's disease.,"D000978:Antiparkinson Agents;D005260:Female;D007839:Functional Laterality;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011597:Psychomotor Performance;D016138:Walking",2008,146
18163154,Fluctuation and synchronization of gait intervals and gait force profiles distinguish stages of Parkinson's disease.,,2007,276
17895436,Gait variability and the risk of incident mobility disability in community-dwelling older adults.,"D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D015331:Cohort Studies;D005260:Female;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D008297:Male;D051346:Mobility Limitation;D011446:Prospective Studies;D012307:Risk Factors;D016138:Walking",2007,271
17826461,Six weeks of intensive treadmill training improves gait and quality of life in patients with Parkinson's disease: a pilot study.,D000368:Aged;D005081:Exercise Therapy;D017079:Exercise Tolerance;D005260:Female;D005500:Follow-Up Studies;D005684:Gait;D006801:Humans;D008297:Male;D010300:Parkinson Disease;D010865:Pilot Projects;D011788:Quality of Life;D011795:Surveys and Questionnaires;D013997:Time Factors;D016896:Treatment Outcome,2007,269
17686633,Dynamic stability differences in fall-prone and healthy adults.,D000057:Accident Proneness;D000058:Accidental Falls;D000328:Adult;D000368:Aged;D001696:Biomechanical Phenomena;D006801:Humans;D004856:Postural Balance;D011187:Posture;D016138:Walking,2008,263
17655480,Differences between local and orbital dynamic stability during human walking.,"D000328:Adult;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008954:Models, Biological;D016138:Walking",2007,277
17618701,"Gait dynamics, fractals and falls: finding meaning in the stride-to-stride fluctuations of human walking.","D000054:Acceleration;D000058:Accidental Falls;D000328:Adult;D000368:Aged;D000375:Aging;D001289:Attention Deficit Disorder with Hyperactivity;D002490:Central Nervous System;D004562:Electrocardiography;D017709:Fractals;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D006816:Huntington Disease;D008875:Middle Aged;D010300:Parkinson Disease;D017933:Peripheral Nervous System;D011603:Psychophysiology;D011619:Psychotropic Drugs;D016138:Walking",2008,59
17503027,A new measure for quantifying the bilateral coordination of human gait: effects of aging and Parkinson's disease.,D000328:Adult;D000368:Aged;D000375:Aging;D000704:Analysis of Variance;D005260:Female;D007839:Functional Laterality;D005684:Gait;D006801:Humans;D008297:Male;D010300:Parkinson Disease;D011597:Psychomotor Performance,2008,70
17004944,Marked alterations in the gait timing and rhythmicity of patients with de novo Parkinson's disease.,D000368:Aged;D000704:Analysis of Variance;D005260:Female;D007839:Functional Laterality;D005684:Gait;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D010507:Periodicity;D011930:Reaction Time;D013028:Space Perception;D013996:Time and Motion Studies,2007,146
16982195,Walking speed influences on gait cycle variability.,D000328:Adult;D005260:Female;D005684:Gait;D006801:Humans;D012420:Running;D016138:Walking,2007,58
16713924,Epidemiology of Parkinson's disease.,D000367:Age Factors;D006801:Humans;D010300:Parkinson Disease;D011379:Prognosis;D012307:Risk Factors,2006,44
16621565,The influence of gait speed on local dynamic stability of walking.,"D000054:Acceleration;D000328:Adult;D000465:Algorithms;D001696:Biomechanical Phenomena;D005080:Exercise Test;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008954:Models, Biological;D012044:Regression Analysis;D016138:Walking",2007,58
16518128,Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study.,D000368:Aged;D001288:Attention;D000697:Central Nervous System Stimulants;D003071:Cognition;D004334:Drug Administration Schedule;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008774:Methylphenidate;D009043:Motor Activity;D009483:Neuropsychological Tests;D010300:Parkinson Disease;D010865:Pilot Projects;D011340:Problem Solving;D011597:Psychomotor Performance,2006,139
16491406,Adaptations of walking pattern on a compliant surface to regulate dynamic stability.,"D000222:Adaptation, Physiological;D000328:Adult;D001696:Biomechanical Phenomena;D003627:Data Interpretation, Statistical;D004576:Electromyography;D005260:Female;D005528:Foot;D006801:Humans;D007866:Leg;D008124:Locomotion;D008297:Male;D010812:Physical Stimulation;D004856:Postural Balance;D013499:Surface Properties;D013909:Thorax;D014034:Toes;D016138:Walking",2006,70
16432700,A direct comparison of local dynamic stability during unperturbed standing and walking.,D000293:Adolescent;D000328:Adult;D000367:Age Factors;D000368:Aged;D000704:Analysis of Variance;D001696:Biomechanical Phenomena;D005080:Exercise Test;D006801:Humans;D008875:Middle Aged;D017711:Nonlinear Dynamics;D004856:Postural Balance;D011187:Posture;D012399:Rotation;D016138:Walking,2006,70
16389084,Kinematic variability and local dynamic stability of upper body motions when walking at different speeds.,D000328:Adult;D000704:Analysis of Variance;D001696:Biomechanical Phenomena;D005260:Female;D006801:Humans;D008297:Male;D016138:Walking,2006,79
16125264,Age-related differences in head and trunk coordination during walking.,D000328:Adult;D000367:Age Factors;D000368:Aged;D000375:Aging;D000886:Anthropometry;D006257:Head;D006801:Humans;D008875:Middle Aged;D010388:Pelvis;D013909:Thorax;D016138:Walking,2006,59
16053531,Effect of gait speed on gait rhythmicity in Parkinson's disease: variability of stride time and swing time respond differently.,,2005,7
16042812,Too much or too little step width variability is associated with a fall history in older persons who walk at or near normal gait speed.,,2005,7
16033650,"Gait variability: methods, modeling and meaning.",,2005,7
15929090,Treadmill walking as an external pacemaker to improve gait rhythm and stability in Parkinson's disease.,D000886:Anthropometry;D003463:Cues;D003710:Demography;D005080:Exercise Test;D005260:Female;D005684:Gait;D006801:Humans;D008875:Middle Aged;D010300:Parkinson Disease;D010507:Periodicity;D026741:Physical Therapy Modalities;D016138:Walking,2005,28
15639397,"Gait instability and fractal dynamics of older adults with a ""cautious"" gait: why do certain older adults walk fearfully?","D000058:Accidental Falls;D000368:Aged;D016022:Case-Control Studies;D003863:Depression;D005116:Extrapyramidal Tracts;D005239:Fear;D005260:Female;D005625:Frontal Lobe;D005684:Gait;D006801:Humans;D008279:Magnetic Resonance Imaging;D008297:Male;D018482:Muscle, Skeletal;D011569:Psychiatric Status Rating Scales;D014057:Tomography, X-Ray Computed",2005,58
15531176,Upper body accelerations during walking in healthy young and elderly men.,D000328:Adult;D000367:Age Factors;D000368:Aged;D001696:Biomechanical Phenomena;D005684:Gait;D006801:Humans;D008297:Male;D013647:Task Performance and Analysis;D013997:Time Factors;D034941:Upper Extremity;D016138:Walking,2005,58
15519333,The condition for dynamic stability.,"D000054:Acceleration;D000328:Adult;D001696:Biomechanical Phenomena;D001827:Body Height;D005260:Female;D005528:Foot;D006112:Gravitation;D006801:Humans;D007866:Leg;D008297:Male;D008954:Models, Biological;D004856:Postural Balance;D011312:Pressure;D013997:Time Factors",2005,79
15300651,"Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena.","D000058:Accidental Falls;D004576:Electromyography;D007839:Functional Laterality;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D007103:Immobilization;D010300:Parkinson Disease;D010808:Physical Examination;D004856:Postural Balance;D016896:Treatment Outcome",2004,28
15211023,Relationship between balance and gait stability in healthy older adults.,"D000058:Accidental Falls;D000222:Adaptation, Physiological;D000328:Adult;D000367:Age Factors;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D016022:Case-Control Studies;D005260:Female;D005684:Gait;D006304:Health Status;D006801:Humans;D008297:Male;D004856:Postural Balance;D016138:Walking",2004,278
14766505,Control of gait initiation.,,1991,279
14654205,The effect of gait speed on lateral balance control during walking in healthy elderly.,D000054:Acceleration;D000368:Aged;D000375:Aging;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D004856:Postural Balance;D012044:Regression Analysis;D013909:Thorax;D016138:Walking,2004,58
12882986,Energy cost of walking and gait instability in healthy 65- and 80-yr-olds.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D001481:Basal Metabolism;D001823:Body Composition;D004734:Energy Metabolism;D005684:Gait;D006801:Humans;D007866:Leg;D008875:Middle Aged;D008954:Models, Biological;D009043:Motor Activity;D018482:Muscle, Skeletal;D010101:Oxygen Consumption;D004856:Postural Balance;D016138:Walking",2004,280
12730255,Acceleration patterns of the head and pelvis when walking are associated with risk of falling in community-dwelling older people.,"D000054:Acceleration;D000058:Accidental Falls;D000368:Aged;D000369:Aged, 80 and over;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006257:Head;D006801:Humans;D008297:Male;D010388:Pelvis;D004856:Postural Balance;D011446:Prospective Studies;D012307:Risk Factors;D016138:Walking",2003,271
12611998,Role of the unperturbed limb and arms in the reactive recovery response to an unexpected slip during locomotion.,"D000058:Accidental Falls;D000328:Adult;D001132:Arm;D001696:Biomechanical Phenomena;D005260:Female;D006801:Humans;D007700:Kinetics;D007866:Leg;D008124:Locomotion;D008297:Male;D018482:Muscle, Skeletal;D004856:Postural Balance",2003,65
12610686,Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait.,"D000368:Aged;D005260:Female;D005684:Gait;D020233:Gait Disorders, Neurologic;D006801:Humans;D018476:Hypokinesia;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D012044:Regression Analysis;D018709:Statistics, Nonparametric;D016138:Walking",2003,70
12297254,Reference data for normal subjects obtained with an accelerometric device.,"D000054:Acceleration;D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008875:Middle Aged;D012016:Reference Values;D015203:Reproducibility of Results",2003,58
12091559,Strategies for dynamic stability during locomotion on a slippery surface: effects of prior experience and knowledge.,"D000222:Adaptation, Physiological;D000328:Adult;D001132:Arm;D005260:Female;D006801:Humans;D019359:Knowledge;D007866:Leg;D008297:Male;D009068:Movement;D018482:Muscle, Skeletal;D004856:Postural Balance;D011187:Posture;D013997:Time Factors",2002,65
11748737,Abnormalities of the spatiotemporal characteristics of gait at the onset of freezing in Parkinson's disease.,D000368:Aged;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006801:Humans;D018476:Hypokinesia;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D016138:Walking,2002,28
11494184,Gait variability and fall risk in community-living older adults: a 1-year prospective study.,"D000058:Accidental Falls;D000203:Activities of Daily Living;D000368:Aged;D000369:Aged, 80 and over;D005260:Female;D005684:Gait;D005853:Geriatrics;D006304:Health Status;D006801:Humans;D008297:Male;D011237:Predictive Value of Tests;D011446:Prospective Studies;D012307:Risk Factors",2001,269
11277298,Local dynamic stability versus kinematic variability of continuous overground and treadmill walking.,"D000328:Adult;D001696:Biomechanical Phenomena;D005080:Exercise Test;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008954:Models, Biological;D012016:Reference Values;D016138:Walking",2001,277
10940402,Active control of lateral balance in human walking.,"D001696:Biomechanical Phenomena;D005246:Feedback;D005684:Gait;D006801:Humans;D008954:Models, Biological;D004856:Postural Balance;D014722:Vestibule, Labyrinth;D014785:Vision, Ocular;D016138:Walking",2001,79
10821982,Functional changes of the basal ganglia circuitry in Parkinson's disease.,D000818:Animals;D001479:Basal Ganglia;D001921:Brain;D002540:Cerebral Cortex;D006801:Humans;D009410:Nerve Degeneration;D010300:Parkinson Disease,2000,84
9613733,Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D001479:Basal Ganglia;D001480:Basal Ganglia Diseases;D003937:Diagnosis, Differential;D005260:Female;D005684:Gait;D006801:Humans;D006816:Huntington Disease;D008124:Locomotion;D008297:Male;D008875:Middle Aged;D009460:Neurologic Examination;D010300:Parkinson Disease;D011930:Reaction Time;D012016:Reference Values",1998,28
9084350,Increased gait unsteadiness in community-dwelling elderly fallers.,"D000058:Accidental Falls;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D002318:Cardiovascular Diseases;D016022:Case-Control Studies;D015897:Comorbidity;D005221:Fatigue;D005260:Female;D005684:Gait;D006801:Humans;D008124:Locomotion;D008297:Male;D015999:Multivariate Analysis;D009140:Musculoskeletal Diseases;D004856:Postural Balance;D012189:Retrospective Studies",1997,269
9075002,Center of mass velocity-position predictions for balance control.,"D000058:Accidental Falls;D005528:Foot;D006801:Humans;D008954:Models, Biological;D009068:Movement;D004856:Postural Balance;D011187:Posture",1997,79
9063277,Gait changes in older adults: predictors of falls or indicators of fear.,"D000058:Accidental Falls;D000203:Activities of Daily Living;D000368:Aged;D000369:Aged, 80 and over;D000375:Aging;D000886:Anthropometry;D005239:Fear;D005260:Female;D005684:Gait;D015577:Geriatric Assessment;D006801:Humans;D008297:Male;D016017:Odds Ratio;D011446:Prospective Studies;D012307:Risk Factors;D012680:Sensitivity and Specificity",1997,281
8727526,Fractal dynamics of human gait: stability of long-range correlations in stride interval fluctuations.,D000328:Adult;D005684:Gait;D006801:Humans;D008124:Locomotion;D008297:Male;D013223:Statistics as Topic;D013997:Time Factors;D016138:Walking,1996,280
8514809,Control of whole body balance in the frontal plane during human walking.,"D000005:Abdomen;D000054:Acceleration;D000328:Adult;D000843:Ankle Joint;D001696:Biomechanical Phenomena;D005528:Foot;D006112:Gravitation;D006257:Head;D006615:Hip;D006621:Hip Joint;D006801:Humans;D007717:Knee;D008159:Lumbar Vertebrae;D008297:Male;D008954:Models, Biological;D009132:Muscles;D010388:Pelvis;D004856:Postural Balance;D011187:Posture;D013909:Thorax;D016138:Walking",1993,79
8366265,Dynamic stability in the elderly: identifying a possible measure.,"D000054:Acceleration;D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D005684:Gait;D015577:Geriatric Assessment;D006801:Humans;D004856:Postural Balance;D016138:Walking",1993,282
8172506,Quantitative gait assessment as a predictor of prospective and retrospective falls in community-dwelling older women.,"D000058:Accidental Falls;D000368:Aged;D000369:Aged, 80 and over;D001696:Biomechanical Phenomena;D005260:Female;D005684:Gait;D006293:Health Promotion;D006801:Humans;D016015:Logistic Models;D008875:Middle Aged;D004856:Postural Balance;D011237:Predictive Value of Tests;D011446:Prospective Studies;D016059:Range of Motion, Articular;D012189:Retrospective Studies;D012307:Risk Factors;D013997:Time Factors;D014743:Videotape Recording;D016138:Walking",1994,269
7713836,Is walking a random walk? Evidence for long-range correlations in stride interval of human gait.,"D000328:Adult;D005583:Fourier Analysis;D017709:Fractals;D005684:Gait;D006801:Humans;D008297:Male;D008390:Markov Chains;D008954:Models, Biological",1995,280
2230833,Quantitative analysis of gait in Parkinson patients: increased variability of stride length.,"D000368:Aged;D000369:Aged, 80 and over;D005260:Female;D005684:Gait;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D012016:Reference Values;D012044:Regression Analysis;D013997:Time Factors;D016138:Walking",1990,113
29807534,Abnormalities of age-related T cell senescence in Parkinson's disease.,Immune markers;Immunosenescence;Parkinson’s disease;T cells,2018,104
28649603,The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis?,,2017,21
28636593,T cells from patients with Parkinson's disease recognize α-synuclein peptides.,"D000368:Aged;D000369:Aged, 80 and over;D000483:Alleles;D000595:Amino Acid Sequence;D015551:Autoimmunity;D018984:Epitopes, T-Lymphocyte;D005260:Female;D006680:HLA Antigens;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D010446:Peptide Fragments;D013601:T-Lymphocytes;D013602:T-Lymphocytes, Cytotoxic;D006377:T-Lymphocytes, Helper-Inducer;D051844:alpha-Synuclein",2017,13
27488222,Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril.,"D000682:Amyloid;D000818:Animals;D002478:Cells, Cultured;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008070:Lipopolysaccharides;D051379:Mice;D008810:Mice, Inbred C57BL;D017628:Microglia;D019578:Multiple System Atrophy;D009474:Neurons;D010300:Parkinson Disease;D066329:Protein Aggregates;D017434:Protein Structure, Tertiary;D021381:Protein Transport;D051844:alpha-Synuclein",2018,24
26999434,Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).,D000368:Aged;D015415:Biomarkers;D002097:C-Reactive Protein;D016207:Cytokines;D018450:Disease Progression;D005260:Female;D005500:Follow-Up Studies;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011379:Prognosis,2017,28
26084020,Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common Theme.,D000818:Animals;D020170:Caspase 1;D006801:Humans;D007109:Immunity;D007249:Inflammation;D007375:Interleukin-1;D008407:Mast Cells;D009504:Neutrophils;D010447:Peptide Hydrolases;D059748:Proteolysis,2015,91
25478795,Residual endotoxin contaminations in recombinant proteins are sufficient to activate human CD1c+ dendritic cells.,"D018949:Antigens, CD1;D002478:Cells, Cultured;D003713:Dendritic Cells;D004731:Endotoxins;D004926:Escherichia coli;D006023:Glycoproteins;D006801:Humans;D008070:Lipopolysaccharides;D011994:Recombinant Proteins",2015,68
24702516,Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review.,D015415:Biomarkers;D006801:Humans;D010300:Parkinson Disease;D051844:alpha-Synuclein,2015,283
23383169,"Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies.","D000704:Analysis of Variance;D015153:Blotting, Western;D002352:Carrier Proteins;D056148:Chromatography, Reverse-Phase;D017931:DNA Primers;D006801:Humans;D058847:Inflammasomes;D007249:Inflammation;D053583:Interleukin-1beta;D016631:Lewy Bodies;D018625:Microscopy, Atomic Force;D018613:Microscopy, Confocal;D046529:Microscopy, Electron, Transmission;D000071199:NLR Family, Pyrin Domain-Containing 3 Protein;D009474:Neurons;D010300:Parkinson Disease;D010587:Phagocytosis;D060888:Real-Time Polymerase Chain Reaction;D013050:Spectrometry, Fluorescence;D013056:Spectrophotometry, Ultraviolet;D013844:Thiazoles;D051195:Toll-Like Receptor 2;D051844:alpha-Synuclein",2013,68
22523201,"CNS infections, sepsis and risk of Parkinson's disease.",D000368:Aged;D016022:Case-Control Studies;D002494:Central Nervous System Infections;D004198:Disease Susceptibility;D005260:Female;D006801:Humans;D008297:Male;D010300:Parkinson Disease;D015995:Prevalence;D012042:Registries;D012307:Risk Factors;D018805:Sepsis;D013548:Sweden,2013,284
22361232,Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.,D000818:Animals;D006801:Humans;D007249:Inflammation;D018836:Inflammation Mediators;D010300:Parkinson Disease,2012,92
22315722,Inflammation and adaptive immunity in Parkinson's disease.,"D056704:Adaptive Immunity;D001253:Astrocytes;D002490:Central Nervous System;D004660:Encephalitis;D006801:Humans;D007113:Immunity, Innate;D007167:Immunotherapy;D017628:Microglia;D010300:Parkinson Disease;D017510:Protein Folding",2012,285
21317042,α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000544:Alzheimer Disease;D015415:Biomarkers;D015331:Cohort Studies;D003430:Cross-Sectional Studies;D005260:Female;D006801:Humans;D020961:Lewy Body Disease;D008297:Male;D008875:Middle Aged;D019578:Multiple System Atrophy;D010300:Parkinson Disease;D051844:alpha-Synuclein;D016875:tau Proteins",2011,44
21048992,Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.,"D000818:Animals;D001483:Base Sequence;D018925:Chemokines;D016207:Cytokines;D017931:DNA Primers;D004591:Electrophoresis, Polyacrylamide Gel;D005455:Fluorescent Antibody Technique;D007113:Immunity, Innate;D051379:Mice;D008810:Mice, Inbred C57BL;D017628:Microglia;D010300:Parkinson Disease;D010587:Phagocytosis;D020133:Reverse Transcriptase Polymerase Chain Reaction;D051844:alpha-Synuclein",2011,68
19664708,The blood-brain barrier and immune function and dysfunction.,"D000818:Animals;D001812:Blood-Brain Barrier;D016207:Cytokines;D006801:Humans;D008070:Lipopolysaccharides;D008959:Models, Neurological;D015213:Neuroimmunomodulation",2010,89
18678243,Peripheral cytokines profile in Parkinson's disease.,"D000368:Aged;D016022:Case-Control Studies;D018932:Chemokine CCL2;D054405:Chemokine CCL3;D018946:Chemokine CCL5;D016207:Cytokines;D004797:Enzyme-Linked Immunosorbent Assay;D005260:Female;D020869:Gene Expression Profiling;D006801:Humans;D007371:Interferon-gamma;D053583:Interleukin-1beta;D016209:Interleukin-8;D007963:Leukocytes, Mononuclear;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011134:Polysaccharides;D012333:RNA, Messenger;D020133:Reverse Transcriptase Polymerase Chain Reaction;D014409:Tumor Necrosis Factor-alpha",2009,286
18599350,Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression.,"D000818:Animals;D018450:Disease Progression;D006801:Humans;D007249:Inflammation;D018448:Models, Immunological;D019636:Neurodegenerative Diseases",2008,128
18157654,Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease.,D000818:Animals;D001921:Brain;D004660:Encephalitis;D005089:Exocytosis;D045604:Extracellular Fluid;D005911:Gliosis;D006801:Humans;D017628:Microglia;D009474:Neurons;D010300:Parkinson Disease;D051844:alpha-Synuclein,2008,287
18018486,The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.,D001933:Brain Stem;D002540:Cerebral Cortex;D004798:Enzymes;D006801:Humans;D016631:Lewy Bodies;D009419:Nerve Tissue Proteins;D010300:Parkinson Disease;D051844:alpha-Synuclein,2008,288
17339843,Inflammation as a causative factor in the aetiology of Parkinson's disease.,"D000818:Animals;D000893:Anti-Inflammatory Agents;D000978:Antiparkinson Agents;D001812:Blood-Brain Barrier;D003167:Complement Activation;D016207:Cytokines;D004195:Disease Models, Animal;D004298:Dopamine;D006098:Granulocytes;D006801:Humans;D008070:Lipopolysaccharides;D017628:Microglia;D009443:Neuritis;D009474:Neurons;D009569:Nitric Oxide;D010300:Parkinson Disease;D017382:Reactive Oxygen Species;D013378:Substantia Nigra",2007,200
17166628,Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia.,D002460:Cell Line;D006801:Humans;D007155:Immunologic Factors;D047908:Intracellular Signaling Peptides and Proteins;D017628:Microglia;D009000:Monocytes;D018384:Oxidative Stress;D011494:Protein Kinases;D015398:Signal Transduction;D051844:alpha-Synuclein,2008,87
16507759,Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.,"D000368:Aged;D000369:Aged, 80 and over;D015415:Biomarkers;D001704:Biopolymers;D002850:Chromatography, Gel;D004797:Enzyme-Linked Immunosorbent Assay;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D010300:Parkinson Disease;D011237:Predictive Value of Tests;D011993:Recombinant Fusion Proteins;D012680:Sensitivity and Specificity;D051844:alpha-Synuclein",2006,289
15791003,Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.,"D000818:Animals;D001253:Astrocytes;D001921:Brain;D002478:Cells, Cultured;D015232:Dinoprostone;D004298:Dopamine;D004622:Embryo, Mammalian;D004789:Enzyme Activation;D006801:Humans;D007150:Immunohistochemistry;D008636:Mesencephalon;D051379:Mice;D018345:Mice, Knockout;D017628:Microglia;D019255:NADPH Oxidases;D009410:Nerve Degeneration;D009457:Neuroglia;D009474:Neurons;D009569:Nitric Oxide;D009573:Nitrites;D018384:Oxidative Stress;D010300:Parkinson Disease;D010587:Phagocytosis;D011108:Polymers;D051381:Rats;D011916:Rats, Inbred F344;D017382:Reactive Oxygen Species;D011994:Recombinant Proteins;D013378:Substantia Nigra;D014316:Tritium;D014409:Tumor Necrosis Factor-alpha;D014446:Tyrosine 3-Monooxygenase;D051844:alpha-Synuclein;D005680:gamma-Aminobutyric Acid",2005,289
10705937,Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease.,"D000368:Aged;D016207:Cytokines;D004797:Enzyme-Linked Immunosorbent Assay;D006801:Humans;D007963:Leukocytes, Mononuclear;D008264:Macrophages;D009000:Monocytes;D010300:Parkinson Disease;D012016:Reference Values;D012720:Severity of Illness Index",2000,283
10349502,"IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease.","D002455:Cell Division;D016207:Cytokines;D005260:Female;D006801:Humans;D066298:In Vitro Techniques;D007375:Interleukin-1;D007376:Interleukin-2;D015850:Interleukin-6;D007378:Interleukins;D007963:Leukocytes, Mononuclear;D007980:Levodopa;D008297:Male;D008875:Middle Aged;D008934:Mitogens;D010300:Parkinson Disease;D014409:Tumor Necrosis Factor-alpha",1999,290
9278044,Alpha-synuclein in Lewy bodies.,D006801:Humans;D007150:Immunohistochemistry;D016631:Lewy Bodies;D009419:Nerve Tissue Proteins;D010300:Parkinson Disease;D051843:Synucleins;D051844:alpha-Synuclein,2001,13
9197268,Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.,"D017668:Age of Onset;D000595:Amino Acid Sequence;D000818:Animals;D001483:Base Sequence;D002874:Chromosome Mapping;D002894:Chromosomes, Human, Pair 4;D005260:Female;D005799:Genes, Dominant;D005819:Genetic Markers;D006115:Greece;D006801:Humans;D007558:Italy;D008297:Male;D008969:Molecular Sequence Data;D009419:Nerve Tissue Proteins;D010300:Parkinson Disease;D010375:Pedigree;D010641:Phenotype;D017354:Point Mutation;D016133:Polymerase Chain Reaction;D017433:Protein Structure, Secondary;D051843:Synucleins;D051844:alpha-Synuclein",1997,18
26336525,A young patient with atypical type-B Wolff-Parkinson-White syndrome accompanied by left ventricular dysfunction.,Ablation;Accessory pathway;Atypical delta wave;Dyssynchrony,2015,291
20552060,Dyssynchronous ventricular activation in asymptomatic wolff-Parkinson-white syndrome: a risk factor for development of dilated cardiomyopathy.,Wolf-Parkinson-White syndrome;accessory pathway;catheter ablation;dilated cardiomyopathy;dyssynchrony;speckle tracking imaging,2010,292
19879594,Dilated cardiomyopathy in children with ventricular preexcitation: the location of the accessory pathway is predictive of this association.,"D000293:Adolescent;D000328:Adult;D002311:Cardiomyopathy, Dilated;D002648:Child;D002675:Child, Preschool;D004562:Electrocardiography;D005260:Female;D006329:Heart Conduction System;D006801:Humans;D007223:Infant;D008297:Male;D015203:Reproducibility of Results;D012680:Sensitivity and Specificity;D018879:Ventricular Premature Complexes;D055815:Young Adult",2010,293
19804548,Septal dyskinesia and global left ventricular dysfunction in pediatric Wolff-Parkinson-White syndrome with septal accessory pathway.,"D002648:Child;D002675:Child, Preschool;D005260:Female;D006329:Heart Conduction System;D006343:Heart Septal Defects;D006346:Heart Septum;D006801:Humans;D007223:Infant;D007231:Infant, Newborn;D008297:Male;D018487:Ventricular Dysfunction, Left;D014927:Wolff-Parkinson-White Syndrome",2010,294
19028709,Successful catheter ablation to accessory atrioventricular pathway as cardiac resynchronization therapy in a patient with dilated cardiomyopathy.,"D001283:Atrioventricular Node;D002304:Cardiac Pacing, Artificial;D002311:Cardiomyopathy, Dilated;D017115:Catheter Ablation;D006333:Heart Failure;D006801:Humans;D008297:Male;D008875:Middle Aged;D016896:Treatment Outcome",2009,295
18256123,Adverse effects of Wolff-Parkinson-White syndrome with right septal or posteroseptal accessory pathways on cardiac function.,"D000293:Adolescent;D017115:Catheter Ablation;D002648:Child;D015331:Cohort Studies;D005260:Female;D006801:Humans;D008297:Male;D012189:Retrospective Studies;D013318:Stroke Volume;D016896:Treatment Outcome;D018487:Ventricular Dysfunction, Left;D054088:Ventricular Septum;D014927:Wolff-Parkinson-White Syndrome",2008,295
17292982,Segmental dyskinesia in Wolff-Parkinson-White syndrome: a possible cause of dilatative cardiomyopathy.,"D001145:Arrhythmias, Cardiac;D002311:Cardiomyopathy, Dilated;D002648:Child;D005500:Follow-Up Studies;D006801:Humans;D007223:Infant;D014927:Wolff-Parkinson-White Syndrome",2008,296
15753115,The effect of cardiac resynchronization on morbidity and mortality in heart failure.,"D000368:Aged;D002304:Cardiac Pacing, Artificial;D003131:Combined Modality Therapy;D005260:Female;D005500:Follow-Up Studies;D006333:Heart Failure;D006760:Hospitalization;D006801:Humans;D008297:Male;D008875:Middle Aged;D009200:Myocardial Contraction;D010138:Pacemaker, Artificial;D013318:Stroke Volume;D016019:Survival Analysis;D018487:Ventricular Dysfunction, Left",2005,52
15679994,Ventricular preexcitation associated with dilated cardiomyopathy: a causal relationship?,"D000293:Adolescent;D002311:Cardiomyopathy, Dilated;D002648:Child;D002675:Child, Preschool;D004562:Electrocardiography;D005260:Female;D005500:Follow-Up Studies;D006801:Humans;D007223:Infant;D008297:Male;D011226:Pre-Excitation Syndromes",2005,297
15152059,Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.,"D000319:Adrenergic beta-Antagonists;D000368:Aged;D000806:Angiotensin-Converting Enzyme Inhibitors;D002908:Chronic Disease;D003131:Combined Modality Therapy;D017147:Defibrillators, Implantable;D004232:Diuretics;D005260:Female;D006333:Heart Failure;D006760:Hospitalization;D006801:Humans;D008297:Male;D010138:Pacemaker, Artificial;D012306:Risk;D013148:Spironolactone;D018487:Ventricular Dysfunction, Left",2004,52
30057745,"A Phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001) and a single compassionate patient treatment (Protocol GALS-C).",ALS;ALS Biomarkers;ALSFRS-R;FVC;neurodegeneration;signaling,2017,298
29540464,The principles that govern transcription factor network functions in stem cells.,D000818:Animals;D002454:Cell Differentiation;D053595:Embryonic Stem Cells;D005786:Gene Expression Regulation;D006801:Humans;D015398:Signal Transduction;D014157:Transcription Factors,2018,299
29470458,"Prevalence of Amyotrophic Lateral Sclerosis - United States, 2014.","D000293:Adolescent;D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000690:Amyotrophic Lateral Sclerosis;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D015995:Prevalence;D012042:Registries;D014481:United States;D055815:Young Adult",2018,300
29376473,It is all about the support - The role of the extracellular matrix in regenerating axon guidance.,D000818:Animals;D000071437:Axon Guidance;D001369:Axons;D005109:Extracellular Matrix;D016695:Glycosyltransferases;D009416:Nerve Regeneration;D010525:Peripheral Nerves;D012583:Schwann Cells,2019,301
29196188,Nervous system development and disease: A focus on trithorax related proteins and chromatin remodelers.,D000818:Animals;D002843:Chromatin;D042002:Chromatin Assembly and Disassembly;D004268:DNA-Binding Proteins;D006801:Humans;D009420:Nervous System;D014157:Transcription Factors;D015533:Transcriptional Activation,2019,228
29155813,Post-guidance signaling by extracellular matrix-associated Slit/Slit-N maintains fasciculation and position of axon tracts in the nerve cord.,"D000818:Animals;D001369:Axons;D004330:Drosophila;D029721:Drosophila Proteins;D005109:Extracellular Matrix;D005207:Fasciculation;D018507:Gene Expression Regulation, Developmental;D020439:Growth Cones;D009419:Nerve Tissue Proteins;D011971:Receptors, Immunologic;D015398:Signal Transduction;D013116:Spinal Cord",2017,302
29154141,Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications.,D000690:Amyotrophic Lateral Sclerosis;D006801:Humans,2017,44
29145629,The Reactome Pathway Knowledgebase.,,2017,303
29132871,The role of TGFβ in wound healing pathologies.,D000818:Animals;D002450:Cell Communication;D006801:Humans;D015398:Signal Transduction;D016212:Transforming Growth Factor beta;D014945:Wound Healing;D014947:Wounds and Injuries,2018,304
29100067,Edaravone: A new drug approved for ALS.,D000690:Amyotrophic Lateral Sclerosis;D000983:Antipyrine;D017277:Drug Approval;D000077553:Edaravone;D018691:Excitatory Amino Acid Antagonists;D006801:Humans;D019782:Riluzole,2017,41
29063562,A Review of Recent Advances in Translational Bioinformatics: Bridges from Biology to Medicine.,D019295:Computational Biology;D057225:Data Mining;D057286:Electronic Health Records;D023281:Genomics;D006801:Humans;D057285:Precision Medicine;D057170:Translational Medical Research,2018,305
29033893,Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement.,amyotrophic lateral sclerosis;animal models;biomarkers;clinical trials;genetic complexity;infrastructural issues,2017,6
28974639,Can injured adult CNS axons regenerate by recapitulating development?,"D000375:Aging;D000818:Animals;D001369:Axons;D002490:Central Nervous System;D008322:Mammals;D008954:Models, Biological;D009416:Nerve Regeneration",2017,299
28812536,eDGAR: a database of Disease-Gene Associations with annotated Relationships among genes.,"D030541:Databases, Genetic;D030342:Genetic Diseases, Inborn;D023281:Genomics;D006801:Humans;D053858:Metabolic Networks and Pathways;D058977:Molecular Sequence Annotation;D060066:Protein Interaction Maps",2018,306
28664100,Integrative approach in the era of failing drug discovery and development.,drug development;integrative;reductionism;systems biology;target-based approach,2014,307
28439461,Quantitative assessment of fibroblast growth factor receptor 1 expression in neurons and glia.,Astrocyte;Cortex;Doublecortin;FGFR1;Fibroblast growth factor;Hippocampus;Hypothalamus tanycyte;Oligodendrocyte;SOX2;SVZ,2017,308
28382000,ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?,amyotrophic lateral sclerosis (ALS);clinical trial;edaravone;masitinib;motor neuron disease;riluzole,2017,5
28343168,Potential skin involvement in ALS: revisiting Charcot's observation - a review of skin abnormalities in ALS.,D008841:Actin Cytoskeleton;D000690:Amyotrophic Lateral Sclerosis;D015415:Biomarkers;D003094:Collagen;D005109:Extracellular Matrix;D006801:Humans;D012867:Skin,2018,309
28334866,C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia.,"D000690:Amyotrophic Lateral Sclerosis;D000818:Animals;D001692:Biological Transport;D000073885:C9orf72 Protein;D019556:COS Cells;D002460:Cell Line;D002522:Cercopithecus aethiops;D042622:DNA Repeat Expansion;D005347:Fibroblasts;D057180:Frontotemporal Dementia;D006801:Humans;D007438:Introns;D009046:Motor Neurons;D009474:Neurons;D016376:Oligonucleotides, Antisense;D010375:Pedigree;D039904:Pluripotent Stem Cells;D011506:Proteins;D020761:rab1 GTP-Binding Proteins",2017,36
28170441,Cerebrospinal fluid from patients with amyotrophic lateral sclerosis inhibits sonic hedgehog function.,D000328:Adult;D000368:Aged;D000690:Amyotrophic Lateral Sclerosis;D016022:Case-Control Studies;D016207:Cytokines;D018450:Disease Progression;D005260:Female;D053823:Hedgehog Proteins;D006801:Humans;D008297:Male;D008875:Middle Aged;D012720:Severity of Illness Index;D015398:Signal Transduction,2017,68
28118852,The SH-SY5Y cell line in Parkinson's disease research: a systematic review.,"D045744:Cell Line, Tumor;D006801:Humans;D009474:Neurons;D010300:Parkinson Disease",2017,33
28070747,Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.,D000328:Adult;D000368:Aged;D000690:Amyotrophic Lateral Sclerosis;D018592:Cross-Over Studies;D003915:Dextromethorphan;D004311:Double-Blind Method;D004338:Drug Combinations;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D011802:Quinidine,2018,182
28069311,Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients.,"D000368:Aged;D000369:Aged, 80 and over;D000690:Amyotrophic Lateral Sclerosis;D001530:Belgium;D015331:Cohort Studies;D005260:Female;D057180:Frontotemporal Dementia;D056726:Genetic Association Studies;D006801:Humans;D008297:Male;D008875:Middle Aged;D024101:Mitochondrial Proteins;D009154:Mutation;D014404:Tubulin",2017,87
27984541,Crosstalk between Notch and Sonic hedgehog signaling in a mouse model of amyotrophic lateral sclerosis.,"D000690:Amyotrophic Lateral Sclerosis;D000818:Animals;D039481:CD11b Antigen;D003959:Diamines;D004195:Disease Models, Animal;D004305:Dose-Response Relationship, Drug;D004791:Enzyme Inhibitors;D005786:Gene Expression Regulation;D053823:Hedgehog Proteins;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D008822:Mice, Transgenic;D009419:Nerve Tissue Proteins;D011506:Proteins;D051880:Receptors, Notch;D015398:Signal Transduction;D013116:Spinal Cord;D013482:Superoxide Dismutase;D013844:Thiazoles;D000075746:Zinc Finger Protein Gli2",2018,218
27899610,MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search.,"D000465:Algorithms;D019295:Computational Biology;D030541:Databases, Genetic;D056726:Genetic Association Studies;D020022:Genetic Predisposition to Disease;D014644:Genetic Variation;D023281:Genomics;D006801:Humans;D058977:Molecular Sequence Annotation;D064878:Web Browser",2017,303
27871848,Sonic hedgehog promotes neurite outgrowth of cortical neurons under oxidative stress: Involving of mitochondria and energy metabolism.,"D000818:Animals;D017209:Apoptosis;D002478:Cells, Cultured;D002540:Cerebral Cortex;D004734:Energy Metabolism;D053823:Hedgehog Proteins;D006861:Hydrogen Peroxide;D008810:Mice, Inbred C57BL;D008928:Mitochondria;D000071446:Neuronal Outgrowth;D009474:Neurons;D018384:Oxidative Stress",2017,310
27694961,Mutations in the HECT domain of NEDD4L lead to AKT-mTOR pathway deregulation and cause periventricular nodular heterotopia.,"D000818:Animals;D002478:Cells, Cultured;D056827:Endosomal Sorting Complexes Required for Transport;D005260:Female;D006801:Humans;D008297:Male;D051379:Mice;D020125:Mutation, Missense;D000075702:Nedd4 Ubiquitin Protein Ligases;D054091:Periventricular Nodular Heterotopia;D000072417:Protein Domains;D051057:Proto-Oncogene Proteins c-akt;D015398:Signal Transduction;D058570:TOR Serine-Threonine Kinases;D025801:Ubiquitin;D044767:Ubiquitin-Protein Ligases",2017,17
27679561,A Case for Microtubule Vulnerability in Amyotrophic Lateral Sclerosis: Altered Dynamics During Disease.,amyotrophic lateral sclerosis;axon transport;dynamics;microtubules,2016,3
27455348,Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis.,D000690:Amyotrophic Lateral Sclerosis;D016022:Case-Control Studies;D015331:Cohort Studies;D020022:Genetic Predisposition to Disease;D055106:Genome-Wide Association Study;D006801:Humans;D051938:Munc18 Proteins;D009154:Mutation;D009185:Myelin Proteins;D009426:Netherlands;D011506:Proteins,2017,17
27328812,A Role for the Chromatin-Remodeling Factor BAZ1A in Neurodevelopment.,"D019943:Amino Acid Substitution;D000818:Animals;D002460:Cell Line;D059472:Exome;D053263:Gene Regulatory Networks;D006801:Humans;D008607:Intellectual Disability;D051379:Mice;D009420:Nervous System;D011401:Promoter Regions, Genetic;D018167:Receptors, Calcitriol;D017422:Sequence Analysis, DNA;D017423:Sequence Analysis, RNA;D055366:Synaptic Potentials;D014018:Tissue Distribution;D014157:Transcription Factors;D060449:Wnt Signaling Pathway",2017,311
26876718,"Translational Bioinformatics: Past, Present, and Future.","D015415:Biomarkers;D035843:Biomedical Research;D019295:Computational Biology;D016208:Databases, Factual;D055106:Genome-Wide Association Study;D023281:Genomics;D006801:Humans;D057285:Precision Medicine",2016,312
26661513,ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization.,"D000818:Animals;D047369:Chromatin Immunoprecipitation;D016208:Databases, Factual;D059014:High-Throughput Nucleotide Sequencing;D006801:Humans;D053858:Metabolic Networks and Pathways;D060066:Protein Interaction Maps;D040901:Proteomics;D015398:Signal Transduction",2016,254
26476454,KEGG as a reference resource for gene and protein annotation.,"D000595:Amino Acid Sequence;D030541:Databases, Genetic;D004352:Drug Resistance, Microbial;D005796:Genes;D016678:Genome;D053858:Metabolic Networks and Pathways;D058977:Molecular Sequence Annotation;D010957:Plasmids;D011506:Proteins;D014780:Viruses",2016,303
26067594,"Notch pathway is activated in cell culture and mouse models of mutant SOD1-related familial amyotrophic lateral sclerosis, with suppression of its activation as an additional mechanism of neuroprotection for lithium and valproate.","D000690:Amyotrophic Lateral Sclerosis;D000818:Animals;D002478:Cells, Cultured;D004195:Disease Models, Animal;D004622:Embryo, Mammalian;D005786:Gene Expression Regulation;D006801:Humans;D018021:Lithium Chloride;D051379:Mice;D008822:Mice, Transgenic;D009046:Motor Neurons;D018696:Neuroprotective Agents;D034741:RNA, Small Interfering;D051880:Receptors, Notch;D015398:Signal Transduction;D013116:Spinal Cord;D013482:Superoxide Dismutase;D014162:Transfection;D014635:Valproic Acid",2016,106
25887539,MeSH ORA framework: R/Bioconductor packages to support MeSH over-representation analysis.,"D000818:Animals;D031204:Caloric Restriction;D019295:Computational Biology;D020869:Gene Expression Profiling;D055106:Genome-Wide Association Study;D006801:Humans;D016247:Information Storage and Retrieval;D046650:Medical Subject Headings;D058977:Molecular Sequence Annotation;D020411:Oligonucleotide Array Sequence Analysis;D011550:Pseudomonas aeruginosa;D039781:PubMed;D051381:Rats;D012984:Software;D018875:Vocabulary, Controlled",2015,313
25883770,Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites.,AP-1;Decoy oligonucleotide;IRF;Motif;NF-kappaB;ODN;Position weight matrix;STAT,2015,314
25877637,DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes.,"D000818:Animals;D000067917:Cloud Computing;D030541:Databases, Genetic;D004195:Disease Models, Animal;D053263:Gene Regulatory Networks;D030342:Genetic Diseases, Inborn;D015894:Genome, Human;D006801:Humans;D020407:Internet;D014584:User-Computer Interface",2015,315
25833344,The neuroprotective agent CNTF decreases neuronal metabolites in the rat striatum: an in vivo multimodal magnetic resonance imaging study.,"D000818:Animals;D001224:Aspartic Acid;D001253:Astrocytes;D020934:Ciliary Neurotrophic Factor;D003342:Corpus Striatum;D018698:Glutamic Acid;D006801:Humans;D008279:Magnetic Resonance Imaging;D008297:Male;D018696:Neuroprotective Agents;D017207:Rats, Sprague-Dawley",2015,108
25753093,The potential of translational bioinformatics approaches for pharmacology research.,"D019295:Computational Biology;D016208:Databases, Factual;D055808:Drug Discovery;D006801:Humans;D017891:Pharmacoepidemiology;D010600:Pharmacology;D057285:Precision Medicine;D057170:Translational Medical Research",2016,316
25677125,DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis.,"D019295:Computational Biology;D030541:Databases, Genetic;D004194:Disease;D063990:Gene Ontology;D006801:Humans;D005810:Multigene Family;D011381:Programming Languages;D012660:Semantics;D012984:Software",2015,317
25348409,Disease Ontology 2015 update: an expanded and updated database of human diseases for linking biomedical knowledge through disease data.,"D064229:Biological Ontologies;D016208:Databases, Factual;D004194:Disease;D030342:Genetic Diseases, Inborn;D006801:Humans;D020407:Internet;D035583:Rare Diseases",2015,303
25316019,Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?,D000690:Amyotrophic Lateral Sclerosis;D006801:Humans;D018696:Neuroprotective Agents;D016032:Randomized Controlled Trials as Topic;D019782:Riluzole;D033581:Stem Cell Transplantation,2015,44
25260700,HTSeq--a Python framework to work with high-throughput sequencing data.,"D005786:Gene Expression Regulation;D015894:Genome, Human;D023281:Genomics;D059014:High-Throughput Nucleotide Sequencing;D006801:Humans;D012984:Software",2015,317
25047909,Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS).,D000690:Amyotrophic Lateral Sclerosis;D006801:Humans;D020782:Matrix Metalloproteinases;D019714:Tissue Inhibitor of Metalloproteinases,2015,123
24316577,"The NHGRI GWAS Catalog, a curated resource of SNP-trait associations.","D030561:Databases, Nucleic Acid;D063990:Gene Ontology;D015894:Genome, Human;D055106:Genome-Wide Association Study;D006801:Humans;D020407:Internet;D059785:Karyotype;D020641:Polymorphism, Single Nucleotide",2014,303
24279194,Management of amyotrophic lateral sclerosis.,D000690:Amyotrophic Lateral Sclerosis;D003952:Diagnostic Imaging;D019468:Disease Management;D006801:Humans,2013,318
24194598,JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles.,"D000818:Animals;D017360:Arabidopsis;D001665:Binding Sites;D017173:Caenorhabditis elegans;D030541:Databases, Genetic;D004331:Drosophila melanogaster;D006801:Humans;D020407:Internet;D051379:Mice;D056510:Position-Specific Scoring Matrices;D050436:Regulatory Elements, Transcriptional;D014157:Transcription Factors",2014,303
23975817,Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology.,"D018929:Cell Culture Techniques;D002454:Cell Differentiation;D045744:Cell Line, Tumor;D015925:Cryopreservation;D006801:Humans;D009446:Neurobiology;D009447:Neuroblastoma",2014,319
23740936,Decreased number of Gemini of coiled bodies and U12 snRNA level in amyotrophic lateral sclerosis.,"D000690:Amyotrophic Lateral Sclerosis;D002478:Cells, Cultured;D004268:DNA-Binding Proteins;D055531:Gemini of Coiled Bodies;D006367:HeLa Cells;D006801:Humans;D009044:Motor Cortex;D009046:Motor Neurons;D012326:RNA Splicing;D012342:RNA, Small Nuclear;D060888:Real-Time Polymerase Chain Reaction;D017411:Ribonucleoproteins, Small Nuclear;D055532:SMN Complex Proteins;D013116:Spinal Cord;D013788:Thalamus",2014,37
23618408,"TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.","D020440:Gene Duplication;D050939:Gene Fusion;D006801:Humans;D016254:Mutagenesis, Insertional;D012680:Sensitivity and Specificity;D016415:Sequence Alignment;D017423:Sequence Analysis, RNA;D012984:Software;D059467:Transcriptome",2015,320
23512712,Systematic dissection of regulatory motifs in 2000 predicted human enhancers using a massively parallel reporter assay.,"D001483:Base Sequence;D001665:Binding Sites;D002477:Cells;D002843:Chromatin;D002874:Chromosome Mapping;D017124:Conserved Sequence;D004742:Enhancer Elements, Genetic;D005786:Gene Expression Regulation;D017930:Genes, Reporter;D015894:Genome, Human;D056945:Hep G2 Cells;D006801:Humans;D059372:Nucleotide Motifs;D011401:Promoter Regions, Genetic;D014158:Transcription, Genetic",2013,321
23497106,Determination of dosage compensation of the mammalian X chromosome by RNA-seq is dependent on analytical approach.,"D000818:Animals;D004303:Dosage Compensation, Genetic;D005260:Female;D020869:Gene Expression Profiling;D015723:Gene Library;D006801:Humans;D051379:Mice;D058977:Molecular Sequence Annotation;D017423:Sequence Analysis, RNA;D013223:Statistics as Topic;D014960:X Chromosome",2014,306
23386971,Robust shifts in S100a9 expression with aging: a novel mechanism for chronic inflammation.,"D000818:Animals;D001483:Base Sequence;D001665:Binding Sites;D040501:Calgranulin A;D040502:Calgranulin B;D002460:Cell Line;D016922:Cellular Senescence;D002908:Chronic Disease;D005260:Female;D020869:Gene Expression Profiling;D053263:Gene Regulatory Networks;D006801:Humans;D007249:Inflammation;D008297:Male;D051379:Mice;D008810:Mice, Inbred C57BL;D011518:Proto-Oncogene Proteins;D012333:RNA, Messenger;D016329:Sp1 Transcription Factor;D015534:Trans-Activators",2013,24
23180794,TFClass: an expandable hierarchical classification of human transcription factors.,"D004268:DNA-Binding Proteins;D030562:Databases, Protein;D006801:Humans;D020407:Internet;D017434:Protein Structure, Tertiary;D016415:Sequence Alignment;D020539:Sequence Analysis, Protein;D014157:Transcription Factors",2013,303
23161678,Gene Ontology annotations and resources.,"D030541:Databases, Genetic;D005796:Genes;D020407:Internet;D058977:Molecular Sequence Annotation;D010802:Phylogeny;D018875:Vocabulary, Controlled",2013,303
22955990,Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors.,"D001482:Base Composition;D001665:Binding Sites;D002460:Cell Line;D042002:Chromatin Assembly and Disassembly;D047369:Chromatin Immunoprecipitation;D016000:Cluster Analysis;D019295:Computational Biology;D003850:Deoxyribonuclease I;D015894:Genome, Human;D059014:High-Throughput Nucleotide Sequencing;D006801:Humans;D020407:Internet;D058977:Molecular Sequence Annotation;D009707:Nucleosomes;D059372:Nucleotide Motifs;D009928:Organ Specificity;D011485:Protein Binding;D014157:Transcription Factors",2013,321
22539670,RNA-SeQC: RNA-seq metrics for quality control and process optimization.,"D020869:Gene Expression Profiling;D015723:Gene Library;D059014:High-Throughput Nucleotide Sequencing;D020407:Internet;D011786:Quality Control;D012313:RNA;D012335:RNA, Ribosomal;D017423:Sequence Analysis, RNA;D012984:Software",2013,317
22493728,Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis.,"D000690:Amyotrophic Lateral Sclerosis;D000818:Animals;D001369:Axons;D045744:Cell Line, Tumor;D002478:Cells, Cultured;D004268:DNA-Binding Proteins;D005260:Female;D006801:Humans;D007150:Immunohistochemistry;D051379:Mice;D009046:Motor Neurons;D009447:Neuroblastoma;D011487:Protein Conformation;D017510:Protein Folding;D034702:RNA-Binding Protein FUS;D013116:Spinal Cord;D013482:Superoxide Dismutase;D000072105:Superoxide Dismutase-1;D014162:Transfection",2012,68
22419278,Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).,D000367:Age Factors;D000690:Amyotrophic Lateral Sclerosis;D018691:Excitatory Amino Acid Antagonists;D006801:Humans;D008017:Life Expectancy;D018696:Neuroprotective Agents;D016032:Randomized Controlled Trials as Topic;D019782:Riluzole;D014139:Tracheostomy,2012,322
22383036,Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks.,"D018076:DNA, Complementary;D020869:Gene Expression Profiling;D056726:Genetic Association Studies;D023281:Genomics;D017422:Sequence Analysis, DNA;D012984:Software",2012,323
22287627,Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation.,"D000465:Algorithms;D001499:Bayes Theorem;D002294:Carcinoma, Squamous Cell;D020869:Gene Expression Profiling;D014644:Genetic Variation;D059014:High-Throughput Nucleotide Sequencing;D016014:Linear Models;D009062:Mouth Neoplasms;D017423:Sequence Analysis, RNA",2012,303
22114774,The use of multi-target drugs in the treatment of neurodegenerative diseases.,D000818:Animals;D016503:Drug Delivery Systems;D006801:Humans;D019636:Neurodegenerative Diseases;D004364:Pharmaceutical Preparations;D016896:Treatment Outcome,2012,324
21979788,Sonic hedgehog is cytoprotective against oxidative challenge in a cellular model of amyotrophic lateral sclerosis.,D000690:Amyotrophic Lateral Sclerosis;D000818:Animals;D002460:Cell Line;D053823:Hedgehog Proteins;D006801:Humans;D006861:Hydrogen Peroxide;D051379:Mice;D009474:Neurons;D016877:Oxidants;D018384:Oxidative Stress,2013,287
21913094,Isolation and culture of postnatal spinal motoneurons.,D000818:Animals;D002469:Cell Separation;D004210:Dissection;D051379:Mice;D009046:Motor Neurons;D059010:Single-Cell Analysis;D013116:Spinal Cord,2011,319
21728978,Peptide mimetics of neurotrophins and their receptors.,"D000818:Animals;D015195:Drug Design;D006801:Humans;D009414:Nerve Growth Factors;D009422:Nervous System Diseases;D010455:Peptides;D017475:Receptors, Nerve Growth Factor;D015398:Signal Transduction",2012,90
21702733,Keeping up with genetic discoveries in amyotrophic lateral sclerosis: the ALSoD and ALSGene databases.,"D000690:Amyotrophic Lateral Sclerosis;D016208:Databases, Factual;D020022:Genetic Predisposition to Disease;D005838:Genotype;D006801:Humans;D009154:Mutation;D010641:Phenotype;D012984:Software;D014584:User-Computer Interface",2011,325
21576262,CpG islands and the regulation of transcription.,"D000818:Animals;D002843:Chromatin;D018899:CpG Islands;D019175:DNA Methylation;D005786:Gene Expression Regulation;D020868:Gene Silencing;D006801:Humans;D063146:Polycomb-Group Proteins;D011401:Promoter Regions, Genetic;D012097:Repressor Proteins;D024363:Transcription Initiation Site",2011,326
21484822,Onset and spreading patterns of upper and lower motor neuron symptoms in amyotrophic lateral sclerosis.,"D000328:Adult;D000368:Aged;D000369:Aged, 80 and over;D000690:Amyotrophic Lateral Sclerosis;D015331:Cohort Studies;D018450:Disease Progression;D004576:Electromyography;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D016472:Motor Neuron Disease;D009046:Motor Neurons;D018482:Muscle, Skeletal;D012189:Retrospective Studies",2011,327
21037262,"UniPROBE, update 2011: expanded content and search tools in the online database of protein-binding microarray data on protein-DNA interactions.","D000818:Animals;D001665:Binding Sites;D004247:DNA;D004268:DNA-Binding Proteins;D030562:Databases, Protein;D006801:Humans;D020407:Internet;D040081:Protein Array Analysis;D020539:Sequence Analysis, Protein;D012984:Software",2011,303
20848190,Sonic hedgehog protects cortical neurons against oxidative stress.,"D000818:Animals;D017209:Apoptosis;D002540:Cerebral Cortex;D005979:Glutathione Peroxidase;D053823:Hedgehog Proteins;D006861:Hydrogen Peroxide;D008315:Malondialdehyde;D009474:Neurons;D016877:Oxidants;D018384:Oxidative Stress;D019253:Proto-Oncogene Proteins c-bcl-2;D051381:Rats;D017207:Rats, Sprague-Dawley;D015398:Signal Transduction;D013482:Superoxide Dismutase;D051028:bcl-2-Associated X Protein",2011,255
20196867,A scaling normalization method for differential expression analysis of RNA-seq data.,"D001483:Base Sequence;D003198:Computer Simulation;D020869:Gene Expression Profiling;D015723:Gene Library;D015233:Models, Statistical;D012313:RNA",2010,320
19910308,edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.,"D000465:Algorithms;D020869:Gene Expression Profiling;D020411:Oligonucleotide Array Sequence Analysis;D011381:Programming Languages;D012815:Signal Processing, Computer-Assisted;D012984:Software",2010,317
19900953,hPDI: a database of experimental human protein-DNA interactions.,"D004247:DNA;D004268:DNA-Binding Proteins;D030562:Databases, Protein;D006801:Humans;D020411:Oligonucleotide Array Sequence Analysis;D025941:Protein Interaction Mapping;D012984:Software",2010,317
19762894,Motor neuron disease: the bare essentials.,D006801:Humans;D016472:Motor Neuron Disease,2009,161
19505943,The Sequence Alignment/Map format and SAMtools.,"D000465:Algorithms;D001483:Base Sequence;D019295:Computational Biology;D016678:Genome;D023281:Genomics;D008969:Molecular Sequence Data;D016415:Sequence Alignment;D017422:Sequence Analysis, DNA;D012984:Software",2010,317
19222867,'Validation' in genome-scale research.,"D023281:Genomics;D017712:Peer Review, Research;D012106:Research;D054928:Validation Studies as Topic",2009,328
19041780,Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation.,"D000690:Amyotrophic Lateral Sclerosis;D000818:Animals;D000831:Animals, Newborn;D002450:Cell Communication;D018929:Cell Culture Techniques;D002454:Cell Differentiation;D002460:Cell Line;D002470:Cell Survival;D002478:Cells, Cultured;D018920:Coculture Techniques;D053595:Embryonic Stem Cells;D006801:Humans;D051379:Mice;D008822:Mice, Transgenic;D008954:Models, Biological;D008967:Molecular Biology;D009046:Motor Neurons;D009154:Mutation;D009410:Nerve Degeneration;D009457:Neuroglia;D009498:Neurotoxins;D011971:Receptors, Immunologic;D011982:Receptors, Prostaglandin;D013482:Superoxide Dismutase;D000072105:Superoxide Dismutase-1",2009,31
18789909,Motoneuronotrophic factor analog GM6 reduces infarct volume and behavioral deficits following transient ischemia in the mouse.,"D000818:Animals;D017209:Apoptosis;D001522:Behavior, Animal;D001921:Brain;D004797:Enzyme-Linked Immunosorbent Assay;D020287:In Situ Nick-End Labeling;D007249:Inflammation;D002546:Ischemic Attack, Transient;D051379:Mice;D008810:Mice, Inbred C57BL;D009414:Nerve Growth Factors;D055495:Neurogenesis;D018696:Neuroprotective Agents;D010455:Peptides",2009,207
18684739,Non-cell-autonomous effects of Ret deletion in early enteric neurogenesis.,"D000818:Animals;D002454:Cell Differentiation;D002465:Cell Movement;D004064:Digestive System;D004622:Embryo, Mammalian;D017615:Enteric Nervous System;D051379:Mice;D018345:Mice, Knockout;D009432:Neural Crest;D009924:Organ Culture Techniques;D051096:Proto-Oncogene Proteins c-ret;D017384:Sequence Deletion;D013234:Stem Cells;D013997:Time Factors",2008,299
18608099,ALSOD: the Amyotrophic Lateral Sclerosis Online Database.,"D000690:Amyotrophic Lateral Sclerosis;D030541:Databases, Genetic;D006801:Humans;D009154:Mutation;D013482:Superoxide Dismutase;D000072105:Superoxide Dismutase-1",2008,325
18469827,Paul Ehrlich's magic bullet concept: 100 years of progress.,"D000911:Antibodies, Monoclonal;D000970:Antineoplastic Agents;D015195:Drug Design;D005858:Germany;D049673:History, 20th Century;D006801:Humans;D009154:Mutation;D009369:Neoplasms",2008,329
17910947,Identification of twinfilin-2 as a factor involved in neurite outgrowth by RNAi-based screen.,"D000818:Animals;D002352:Carrier Proteins;D045744:Cell Line, Tumor;D005786:Gene Expression Regulation;D006801:Humans;D008840:Microfilament Proteins;D016501:Neurites;D011505:Protein-Tyrosine Kinases;D034622:RNA Interference;D051381:Rats;D014212:Tretinoin",2007,27
17599430,Advances in small molecules promoting neurotrophic function.,"D000690:Amyotrophic Lateral Sclerosis;D000818:Animals;D019208:Brain-Derived Neurotrophic Factor;D003863:Depression;D006801:Humans;D020932:Nerve Growth Factor;D009414:Nerve Growth Factors;D019636:Neurodegenerative Diseases;D009765:Obesity;D010523:Peripheral Nervous System Diseases;D017475:Receptors, Nerve Growth Factor;D015398:Signal Transduction;D013119:Spinal Cord Injuries;D014945:Wound Healing",2007,250
17098774,Using GOstats to test gene lists for GO term association.,"D000465:Algorithms;D003627:Data Interpretation, Statistical;D003628:Database Management Systems;D030562:Databases, Protein;D020869:Gene Expression Profiling;D016247:Information Storage and Retrieval;D009323:Natural Language Processing;D011506:Proteins;D012984:Software;D009626:Terminology as Topic",2007,317
16751280,Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.,"D000818:Animals;D001522:Behavior, Animal;D016923:Cell Death;D003342:Corpus Striatum;D000229:Dependovirus;D004195:Disease Models, Animal;D005260:Female;D018014:Gene Transfer Techniques;D015316:Genetic Therapy;D051097:Glial Cell Line-Derived Neurotrophic Factor Receptors;D051098:Glial Cell Line-Derived Neurotrophic Factors;D006801:Humans;D000071058:Huntingtin Protein;D006816:Huntington Disease;D002479:Inclusion Bodies;D008297:Male;D051379:Mice;D008822:Mice, Transgenic;D009419:Nerve Tissue Proteins;D009474:Neurons;D018696:Neuroprotective Agents;D009687:Nuclear Proteins;D051381:Rats",2006,12
16381825,TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes.,"D000818:Animals;D017360:Arabidopsis;D029681:Arabidopsis Proteins;D001665:Binding Sites;D004247:DNA;D030541:Databases, Genetic;D029721:Drosophila Proteins;D004331:Drosophila melanogaster;D005786:Gene Expression Regulation;D006801:Humans;D020407:Internet;D051379:Mice;D017434:Protein Structure, Tertiary;D051381:Rats;D012045:Regulatory Sequences, Nucleic Acid;D018511:Systems Integration;D014157:Transcription Factors;D014158:Transcription, Genetic;D014584:User-Computer Interface",2006,303
15863030,Cellular signaling by fibroblast growth factor receptors.,"D005346:Fibroblast Growth Factors;D006801:Humans;D017436:Kallmann Syndrome;D008958:Models, Molecular;D009139:Musculoskeletal Abnormalities;D009369:Neoplasms;D020033:Protein Isoforms;D020794:Receptor Protein-Tyrosine Kinases;D017468:Receptors, Fibroblast Growth Factor;D015398:Signal Transduction",2005,330
15670639,"Impairment of glutamate transport and increased vulnerability to oxidative stress in neuroblastoma SH-SY5Y cells expressing a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis.","D027322:Amino Acid Transport System X-AG;D000690:Amyotrophic Lateral Sclerosis;D000975:Antioxidants;D001693:Biological Transport, Active;D001932:Brain Neoplasms;D045744:Cell Line, Tumor;D004587:Electrophoresis, Agar Gel;D027341:Excitatory Amino Acid Transporter 1;D050580:Excitatory Amino Acid Transporter 3;D050491:Glutamate Plasma Membrane Transport Proteins;D018698:Glutamic Acid;D006801:Humans;D007700:Kinetics;D009154:Mutation;D009447:Neuroblastoma;D016877:Oxidants;D018384:Oxidative Stress;D012333:RNA, Messenger;D020133:Reverse Transcriptase Polymerase Chain Reaction;D012964:Sodium;D013482:Superoxide Dismutase;D027981:Symporters",2005,199
14699966,Neurotrophic factors in Huntington's disease.,"D000818:Animals;D001921:Brain;D020934:Ciliary Neurotrophic Factor;D004195:Disease Models, Animal;D018507:Gene Expression Regulation, Developmental;D051100:Glial Cell Line-Derived Neurotrophic Factor;D051097:Glial Cell Line-Derived Neurotrophic Factor Receptors;D006801:Humans;D006816:Huntington Disease;D009414:Nerve Growth Factors;D011518:Proto-Oncogene Proteins;D051096:Proto-Oncogene Proteins c-ret;D020794:Receptor Protein-Tyrosine Kinases;D020801:Receptor, Ciliary Neurotrophic Factor;D017475:Receptors, Nerve Growth Factor",2004,331
12031278,Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease.,"D000818:Animals;D001479:Basal Ganglia;D051100:Glial Cell Line-Derived Neurotrophic Factor;D006801:Humans;D006816:Huntington Disease;D008959:Models, Neurological;D009414:Nerve Growth Factors;D009419:Nerve Tissue Proteins;D009474:Neurons;D018696:Neuroprotective Agents;D009498:Neurotoxins;D017470:Receptors, Glutamate",2002,332
11846609,Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.,"D000465:Algorithms;D001921:Brain;D002460:Cell Line;D018076:DNA, Complementary;D006801:Humans;D016133:Polymerase Chain Reaction;D020133:Reverse Transcriptase Polymerase Chain Reaction;D013997:Time Factors",2002,333
10486171,Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible?,D000818:Animals;D020934:Ciliary Neurotrophic Factor;D003342:Corpus Striatum;D016503:Drug Delivery Systems;D015316:Genetic Therapy;D006801:Humans;D006816:Huntington Disease;D009414:Nerve Growth Factors;D009419:Nerve Tissue Proteins;D009474:Neurons;D018696:Neuroprotective Agents,1999,81
10221902,Notch signaling: cell fate control and signal integration in development.,"D000818:Animals;D017209:Apoptosis;D002450:Cell Communication;D002455:Cell Division;D002467:Cell Nucleus;D006801:Humans;D047908:Intracellular Signaling Peptides and Proteins;D008024:Ligands;D008565:Membrane Proteins;D011956:Receptors, Cell Surface;D051880:Receptors, Notch;D015398:Signal Transduction;D014158:Transcription, Genetic",1999,18
10193591,Amyotrophic lateral sclerosis: Lou Gehrig's disease.,D000690:Amyotrophic Lateral Sclerosis;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged,1999,334
9849796,Collagen abnormalities in the spinal cord from patients with amyotrophic lateral sclerosis.,"D000328:Adult;D000368:Aged;D000690:Amyotrophic Lateral Sclerosis;D001808:Blood Vessels;D002196:Capillaries;D003094:Collagen;D005260:Female;D006801:Humans;D008297:Male;D008854:Microscopy, Electron;D008875:Middle Aged;D009422:Nervous System Diseases;D013116:Spinal Cord",1998,113
9828084,Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration.,"D000818:Animals;D002493:Central Nervous System Diseases;D015195:Drug Design;D006801:Humans;D009410:Nerve Degeneration;D009414:Nerve Growth Factors;D019636:Neurodegenerative Diseases;D018696:Neuroprotective Agents;D010523:Peripheral Nervous System Diseases;D017475:Receptors, Nerve Growth Factor;D015398:Signal Transduction",1998,228
9121555,Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.,"D000818:Animals;D001921:Brain;D002460:Cell Line;D020934:Ciliary Neurotrophic Factor;D003342:Corpus Striatum;D006224:Cricetinae;D004195:Disease Models, Animal;D005347:Fibroblasts;D015316:Genetic Therapy;D006801:Humans;D006816:Huntington Disease;D008252:Macaca fascicularis;D009414:Nerve Growth Factors;D009419:Nerve Tissue Proteins;D010784:Photomicrography;D017378:Quinolinic Acid;D011993:Recombinant Fusion Proteins",1997,13
7612265,Neurotrophic factors and their receptors.,"D000818:Animals;D009414:Nerve Growth Factors;D020794:Receptor Protein-Tyrosine Kinases;D017475:Receptors, Nerve Growth Factor;D018124:Receptors, Tumor Necrosis Factor;D015398:Signal Transduction",1995,335
3346711,Increased dermal collagen density in amyotrophic lateral sclerosis.,"D000690:Amyotrophic Lateral Sclerosis;D003094:Collagen;D005260:Female;D006801:Humans;D008297:Male;D008854:Microscopy, Electron;D008875:Middle Aged;D003668:Pressure Ulcer;D012867:Skin;D013997:Time Factors",1988,113
2089137,Amyotrophic lateral sclerosis: unusually low content of collagen in skin.,D000368:Aged;D000596:Amino Acids;D000690:Amyotrophic Lateral Sclerosis;D003094:Collagen;D005260:Female;D006801:Humans;D008297:Male;D008875:Middle Aged;D009135:Muscular Diseases;D009422:Nervous System Diseases;D012867:Skin,1990,113
1467557,Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons.,"D000110:Acetylcholinesterase;D000818:Animals;D002459:Cell Fusion;D002460:Cell Line;D003584:Cytological Techniques;D003598:Cytoskeletal Proteins;D004594:Electrophysiology;D006824:Hybridization, Genetic;D051379:Mice;D009046:Motor Neurons;D009447:Neuroblastoma;D010275:Parasympathetic Nervous System;D013116:Spinal Cord;D013569:Synapses",1992,336
56680,Letter: Amyotrophic lateral sclerosis and bedsores.,D000690:Amyotrophic Lateral Sclerosis;D006801:Humans;D003668:Pressure Ulcer;D012867:Skin,1976,38
